 
 
 
 
STATUS PAGE  
PROTOCOL 16-223 
 
 
 
 
Closed To New Accrual  
 
 
Closure Effective Date: 11/05/2018  
Reason: Study Accrual Goal Met  
 
 
No new subjects may be enrolled in the study - as described above.  
Any questions regarding this closure should be directed to the  study’s 
Principal Investigator  
Neoadjuvant abiraterone a cetate plus leuprolide with or without apalutamide  
 
Protocol Version Date:  January 3, 2019  
 
DF/HCC Protocol #:  16-223 
 Title:  Phase II randomized study of neoadjuvant and adjuvant abiraterone acetate + a palutamide  
for intermediate -high risk prostate cancer undergoing prostatectomy.  
 Sponsor Investigator :  
Mary -Ellen Taplin, MD  
Associate Professor of Medicine  
Dana- Farber Cancer Institute  
Lank Center for Genitourinary Oncology  
450 Brookline Avenue  
Boston, MA 02215  
Telephone: 617- 582-7221 
Fax: 617- 632-6328                                                                
mtaplin@partners.org
 
  Coordinating Center  and Sponsor :  
Dana- Farber Cancer Institute  
450 Brookline  Avenue  
Boston, MA 02215  
 Drug & Funding Support:  
Janssen Scientific Affairs, LLC  
 IND #: 130502  
IND Sponsor:  Mary -Ellen Taplin, MD  
 Study Agents:  
Abiraterone acetate supplied by Janssen Scientific Affairs, LLC  
Apalutamide  supplied by Janssen Scientific Affairs, LLC  
Leuprolide (Commercial  Supply ) 
Prednisone (Commercial  Supply ) 
       
    
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  ABBREVIATIONS  
 
Adrenocorticotropic hormone – ACTH  
Adverse event – AE  
Alanine transaminase – ALT   
American Society of Clinical Oncology  – ASCO    
ANC – Absolute neutrophil count  
Androgen deprivation therapy – ADT  
Androgen Receptor – AR  
Apparent diffusion coefficient – ADC  
Area under the concentration -time curve – AUC  
Aspartate transaminase –  AST   
Canadian Urologic Oncology Group – CU OG  
Cancer and Leukemia Group B – CALGB  
Cancer Therapy Evaluation Program  – CTEP  
Case Report Form – CRF  Castration -resistant prostate cancer – CRPC 
Center for Molecular Oncologic Pathologies – CMOP  
Circulating Tumor Cells – CTCs  
Code of Federal Regulati ons – CFR  
Common Terminology Criteria for Adverse Events – CTCAE  
Computed tomography  – CT  
Dana Farber Cancer Institute – DFCI  
Dana- Farber /Harvard Cancer Center – DF/HCC  
Dana-Farber/Partners Cancer Care – DF/PCC  
Data Safety and Monitoring Committee – DSMC  Dynamic contrast -enhanced – DCE  
Dehydroepiandrosterone – DHEA  
Dehydroepiandrosterone -sulfate – DHEA -S  
Dihydrotestosterone – DHT  Disease- free survival – DFS  
Eastern Cooperative Oncology Group – ECOG  
Echocar diogram – ECHO  
Electrocardiogram – EKG   Food and Drug Administration – FDA  
Good Clinical Practice – GCP  
Hazard ratio – HR  
Health Insurance Portability and Accountability Act  – HIPAA  
Immunohistochemistry –  IHC  
IND – Investigation new drug  
Institution al Review Board – IRB  
International Normalized  Ratio – INR  
Liquid Chromatography Mass Spectrometery/Mass Spectrometery – LCMS/MS  
Liver function test – LFT 
Luteinizing hormone -releasing hormone – LHRH  
Magnetic Resonance Imaging – MRI  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  Multiparametric Magnetic Resonance Imaging – mpMRI  
Maximum plasma concentration – C max   
Minimal Residual Disease – MRD  
National Cancer Institute – NCI  
National Surgical Adjuvant Breast and Bowel Project – NSABP   
New York Heart Association – NYHA  Office for Data Quality –  ODQ  
Office for Human Research Studies – OHRS  Overall survival – OS  
Pathologic complete response – pCR  Principal Investigator – PI  
Progression free survival – PFS  Prostate specific antigen – PSA  
Partial Prothrombin Time – PT T 
Radical Prostatectomy – RP  
Residual cancer burden –  RCB  
Response Evaluation Criteria In Solid Tumors  – RECIST  
Serious adverse event – SAE  
Skeletal related event – SRE  
Sponsor Investigator – SI  
Time to PSA Progression – TTPP  
Upper limit of normal – ULN  
WBC – White blood cell count     
                    
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  Schema:  
 
 
 
 
 
 
 

Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  TABLE OF CONTENTS  
1. OBJECTIVES  .................................................................................................................................................... 1 
1.1 Study Design  .................................................................................................................................................... 1 
1.2 Primary Objectives  .......................................................................................................................................... 1 
1.3 Secondary Objectives  ...................................................................................................................................... 1 
1.4 Correlative Objectives  ..................................................................................................................................... 2 
2. BACKGROUND  ................................................................................................................................................ 3 
2.1 Study Diseas e .................................................................................................................................................. 3 
2.2 Rationale  ......................................................................................................................................................... 4 
2.3 Study Agent(s)  ................................................................................................................................................. 9 
3. PARTICIPANT SELECTION  ........................................................................................................................ 19 
3.1 Eligibility Criteria  ......................................................................................................................................... 19 
3.2 Exclusion Criteria  ......................................................................................................................................... 21 
3.3 Inclusion of Women, Minorities and Other Underrepresented Populations  ................................................. 23 
4. REGISTRATION PROCEDURES  ................................................................................................................ 24 
4.1 General Guidelines for DF/HCC Institutions  ............................................................................................... 24 
4.2 Registration Process for DF/HCC Institutions  ............................................................................................. 24 
4.3 General Guidelines for Other Participating Institutions  ............................................................................... 24 
4.4 Registration Process for Other Participating Institutions  ............................................................................. 24 
5. TREATMENT PLAN  ...................................................................................................................................... 26 
5.1 Treatment Summary and Randomization ...................................................................................................... 26 
5.2 Pre-treatment Criteria  ................................................................................................................................... 27 
5.3 Agent Administration  ..................................................................................................................................... 28 
5.4 General Concomitant Medications and Supportive Care Guidelines  ........................................................... 30 
5.5 Duration of Therapy  ...................................................................................................................................... 33 
5.6 Duration of Follow -Up .................................................................................................................................. 34 
5.7 Criteria for Removal from Study  ................................................................................................................... 34 
6. EXPECTED TOXICITIES AND DOSING DELAYS/DOSE MODIFICATIONS  .................................... 36 
6.1 Anticipated Toxicities  .................................................................................................................................... 36 
6.2 Toxicity Management  .................................................................................................................................... 38 
6.3 Dose Modifications/Delays  ........................................................................................................................... 43 
7. DRUG FORMULATION AND ADMINISTRATION  ................................................................................. 44 
7.1 Apalutamide  .................................................................................................................................................. 44 
7.2 Abirater one acetate  ....................................................................................................................................... 45 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  Pharmacy Storage Requirements  ............................................................................................................................. 46 
7.3 Prednisone  ..................................................................................................................................................... 47 
There are no s pecific instructions for handling prednisone.  .................................................................................. 47 
7.4 Leuprolide  ..................................................................................................................................................... 48 
8. CORRELATIVE STUDIES  ............................................................................................................................ 49 
8.1 Correlative Studies Background .................................................................................................................... 49 
8.2 Correlative Studies Methodologies  ............................................................................................................... 51 
9. STUDY CALENDAR  ...................................................................................................................................... 55 
10. MEASUREMENT OF EFFECT ..................................................................................................................... 61 
10.1 Primary Variable  ........................................................................................................................................... 61 
10.2 Secondary Variables  ..................................................................................................................................... 61 
11. ADVERSE EVENT REPORTING REQUIREMENTS  ............................................................................... 63 
11.1 Overview  ....................................................................................................................................................... 63 
11.2 Management of Safety Data  .......................................................................................................................... 63 
11.3 Definitions  ..................................................................................................................................................... 63 
11.4 Expectedness  ................................................................................................................................................. 66 
11.5 Unlisted (Unexpected) AE/Reference Safety Information  ............................................................................. 66 
11.6 Special Reporting Situations  ......................................................................................................................... 67 
11.7 Pregnancy  ..................................................................................................................................................... 67 
11.8 Maintenance of Safety Information  ............................................................................................................... 67 
11.9 Procedures for Reporting Safety Data and Product Quality Complaints (PQCs) for Janssen Medicinal 
Products to Janssen  ................................................................................................................................................ 68 
11.10  Reporting Procedures for Reporting Safety Data and Product Quality Complaints (PQCs) for Non- Janssen 
Medicinal Products  ................................................................................................................................................. 69 
11.11  Transmission Methods  ................................................................................................................................... 69 
11.12  Reconciliation of SAEs  .................................................................................................................................. 70 
11.13  Final Study Report  ........................................................................................................................................ 70 
11.14  Procedures for AE and SAE Recording and Reporting  ................................................................................. 70 
11.15  Reporting Requirements  ................................................................................................................................ 70 
11.16  Reporting to the Study Sponsor -Investigator  .................................................................................................  71 
11.17  Reporting to the IRB  ...................................................................................................................................... 72 
11.18  Reporting to the FDA  .................................................................................................................................... 72 
11.19  Reporting to Hospital Risk Management ....................................................................................................... 72 
11.20  Monitoring of AEs and Period of Observation .............................................................................................. 72 
12. DATA AND SAFETY MONITORING  .......................................................................................................... 73 
12.1 Data Reporting  .............................................................................................................................................. 73 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  12.2 Safety Meetings  ............................................................................................................................................. 74 
12.3 Monitoring  ..................................................................................................................................................... 74 
13. REGULATORY CONSIDERATIONS  .......................................................................................................... 76 
13.1 Protocol Review and Amendments  ................................................................................................................ 76 
13.2 Informed Consent  .......................................................................................................................................... 76 
13.3 Ethics and GCP  ............................................................................................................................................. 76 
13.4 Study Documentation  .................................................................................................................................... 77 
13.5 Records Retention  ......................................................................................................................................... 77 
13.6 Multi- Center Guidelines  ................................................................................................................................ 77 
14. STATISTICAL CONSIDERATIONS  ............................................................................................................ 79 
14.1 Study Design and Sample Size  ....................................................................................................................... 79 
14.2 Primary Endpoint and Methods of Analysis:  ................................................................................................ 79 
14.3 Secondary Endpoint(s) and Methods of Analysis:  ......................................................................................... 80 
14.4 Correlative Endpoint(s) and Methods of Analysis:  ....................................................................................... 81 
14.5 Sample Size and Accrual Rate  ....................................................................................................................... 83 
For a sample size of 120 participants, we expect a total of 15 months to complete the accrual at a rate 8 
participants/month.  ................................................................................................................................................. 83 
14.6 Study monitoring  ........................................................................................................................................... 83 
15. PUBLICATION PLAN  .................................................................................................................................... 84 
16. REFERENCES  ................................................................................................................................................. 85 
17. APPENDICES  .................................................................................................................................................. 93 
17.1 APPENDIX A: Performance Status Criteria  .................................................................................................  93 
17.2 APPENDIX B: Required Forms at Registration  ........................................................................................... 93 
17.3 APPENDIX C: Patient’s Pill Diary  .............................................................................................................. 93 
17.4 APPENDIX D: Representative Medications that May Predispose to Seizures  ............................................. 93 
17.5 APPENDIX E: Intra -operative and Peri -operative RP Complications Questionnaires  ............................... 93 
17.6 APPENDIX F: Post -Operative Complications (Clavian Classification)  ...................................................... 93 
17.7 APPENDIX G: The Expanded Prostate Cancer Index Composite Questionnaire (EPIC -26 +)  ................... 93 
17.8 APPENDIX H: Family History Questionnaire  .............................................................................................. 93 
17.9 APPENDIX I: Mul ti-Center Data and Safety Monitoring Plan .................................................................... 93 
1.0 INTRODUCTION  .......................................................................................................................................... 113 
1.1 Purpose  ....................................................................................................................................................... 113 
1.2 Multi- Center  Data and Safety Monitoring Plan Definitions  ....................................................................... 113 
2.0 GENERAL ROLES AND RESPONSIBILITIES  ....................................................................................... 114 
2.1 DF/HCC Sponsor  ........................................................................................................................................ 114 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  2.2 Coor dinating Center  ................................................................................................................................... 115 
2.3 DF/HCC Office for Data Quality (ODQ)  .................................................................................................... 115 
2.4 Participating Institution  .............................................................................................................................. 115 
3.0 DF/HCC REQUIREMENTS FOR MULTI -CENTER PROTOCOLS  ..................................................... 116 
3.1 Protocol Distribution  .................................................................................................................................. 116 
3.2 Protocol Revisions and Closures ................................................................................................................. 116 
3.3 Informed Consent Requirements  ................................................................................................................. 117 
3.4 IRB Documentation  ..................................................................................................................................... 117 
3.5 IRB Re -Approval  ......................................................................................................................................... 117 
3.6 Participant Confidentiality and Authorization Statement  ........................................................................... 117 
3.7 DF/HCC Multi- Center Protocol Registration Policy  .................................................................................. 118 
3.7.1  Participant Registration and Randomization  .............................................................................................. 118 
3.7.2  Initiation of Therapy  .................................................................................................................................... 119 
3.7.3  Eligibility Exceptions  .................................................................................................................................. 119 
3.7.4  Verification of Registration, Dose Levels, and Arm Designation  ................................................................ 119 
3.8 DF/HCC Protocol Case Number ................................................................................................................. 119 
3.9 Protocol Deviations, Exceptions and Violations  ......................................................................................... 120 
3.9.1  Definitions  ................................................................................................................................................... 120 
3.9.2  Reporting Procedures .................................................................................................................................. 120 
3.10 Safety Assessments and Toxicity Monitoring............................................................................................... 121 
3.10.1  Guidelines for Reporting Serious Adverse Events  ............................................................................. 121 
3.10.2  Guidelines for Processing IND Safety Reports  .................................................................................. 121 
3.11 Data Management  ....................................................................................................................................... 121 
3.11.1  Data Forms Review  ........................................................................................................................... 121 
4.0 REQUISITIONING INVESTIGATONAL DRUG  ..................................................................................... 122 
5.0 MONITORING: QUALITY CONTROL  .................................................................................................... 122 
5.1 Ongoing Monitoring of Protocol Compliance  ............................................................................................. 122 
5.2 Evaluation of Participating Institution Performance  .................................................................................. 123 
5.2.1  Monitoring Reports  ..................................................................................................................................... 123 
6.0 AUDITING: QUALITY ASSURANCE  ....................................................................................................... 123 
6.1 DF/HCC Sponsored Trials  .......................................................................................................................... 124 
6.2 DF/HCC Internal Audits  ............................................................................................................................. 124 
6.3 Audit Notification  ........................................................................................................................................ 124 
6.4 Audit Reports  ............................................................................................................................................... 124 
6.4.1  Corrective Actions  ....................................................................................................................................... 124 
Neoadjuvant abiraterone a cetate plus leuprolide with or without apalutamide  
 
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
 
1 1. OBJECTIVES  
1.1 Study  Desig n 
 
This is a multicenter, phase II, prospective, randomized trial designed to investigate the 
efficacy of neoadjuvant and adjuvant abiraterone  acetate + apalutamide  for men with 
intermediate -high risk prostate cancer who are candidates for RP. The study includes 
two parts. In part 1, patients will be randomized in 1:1 ratio to receive 6 months of abiraterone acetate, apalutamide , leuprolide and prednisone (Arm 1A) versus 6 months 
of abiraterone acetate, leuprolide and prednisone (Arm 1B) followed by RP, stratified 
by risk factor  (intermediate versus high- risk). High -risk factors will be defined as a 
Gleason score ≥ 8, PSA > 20 ng/dL, or T3 disease on MRI.  In part 2 (post -RP), 
patients will be randomized in 1:1 ratio to receive  an additional 12 months of 
abiraterone acetate, apalutamide , leuprolide and prednisone (Arm 2A) or observation 
(Arm 2B) stratified by type of neoadjuvant therapy and pathological T -stage ( < pT3 
versus ≥ pT3)  after RP but before cycle 7 day 1  following neoadjuvant therapy . There 
will be an early stopping rule for Part 2 should a high rate of patients refuse to participate or drop out early while receiving adjuvant therapy (<6 months).  
 
1.2 Primary Objectives  
Part 1:   
• To determine whether combination  of abiraterone acetate +  apalutamide 
improves frequency of achieving a pCR or MRD (defined as residual tumor in RP specimen measuring ≤ 5 mm) at RP  as compared with abiraterone acetate 
alone, in men treated with neoadjuvant leuprolide and prednisone  prior to RP .  
 
Part 2:  
• To determine whether the use of adjuvant abiraterone  acetate +  apalutamide  + 
prednisone  following RP improves biochemical progression free survival (bPFS)  
at 3 years po st-RP as compared with no adjuvant treatment . 
1.3 Secondary Objectives  
   Part 1:  
• To evaluate the frequency of achieving a pCR at RP following therapy with Arm 1A compared to Arm 1B.  
 
• To evaluate the frequency of achieving favorable RCB (defined as the 33
rd 
percentile of the RCB index which is calculated as the tumor volume x 
cellularity) at RP following therapy with Arm 1A compared to Arm 1B.  
 
• To evaluate the frequency of presen ting cribriform or intraductal carcinoma at 
RP following therapy with Arm 1A compared to Arm 1B.   
 
• To evaluate the frequency of positive surgical margins, extracapsular extension, 
positive seminal vesicles, and positive lymph nodes at time of RP following 
treatment with Arm 1A compared to Arm 1B.  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
2  
• To determine changes in PS A (median nadir value, percentage of participants 
with PSA < 0.2 ng/mL, proportion of participants with achieving 50% and 90% 
decrease in PSA, time to PSA nadir)  from baseline to prior to RP with Arm 1A 
compared to Arm 1B.  
 
• To assess intra -operative and post-operative complications following RP between 
treatment arms (1A and 1B).  
   Part 2:  
• To determine the effect of treatment on freedom from biochemical failure at 2- , 
3-, and 5- years  post -RP between Arms 2A and 2B among patients who achieve 
testosterone recovery (defined as a testosterone > 2 00 ng/dL).  
 
• To determine the effect of treatment on (or freedom from ) further prostate cancer 
therapy (to include adjuvant or salvage radiation therapy, ADT, or other therapies) at 2-, 3-, and 5 -years post -RP between Arms 2A and 2B.  
 
• To assess the safety and tolerability of each treatment arm.  
 
• To assess quality of life parameters over time between treatment arm 2A and  
observation arm  2B.  
 
1.4 Correlative Objectives  
• To assess time to testosterone  recovery, body -mass inde x, lipids, and 
cardiovascular events for treatment Arms 2A and 2B . 
 
• To assess changes in serum hormone  levels ( DHEA, androstenedione, 
testosterone, DHT, androsterone, progesterone, pregnenolone, deoxycorticosterone, cortisol, DHEA -S) by mass spectroscopy from pretreatment 
to during treatment to prior to  RP and to post -RP between treatment Arms 1A and 
1B and Arms 2A and 2B.  
 
• To correlate serum hormone levels from pretreatment to during treatment and to prior to RP with pathologic response at RP.  
 
• To compa re serum abiraterone acetate and apalutamide  levels to tissue abiraterone 
and apalutamide  levels and serum and hormone levels with pCR + minimum 
residual disease.  
 
• To co mpare prostate androgen levels by mass spectroscopy in the RP specimens 
between treatm ent Arms 1A and 1B.  
 
• To compare the expression of the AR and proteins involved in the androgen synthesis, apoptosis, WNT signaling, and PTEN -PI3K -AKT pathways by IHC 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
3 and expression analysis  in the RP specimens between treatment A rms 1A and 1B 
and between patients with MRD compared to those without MRD .   
 
• To assess changes in circulating tumor DNA from pretreatment to during 
treatment to prior to RP and to post -RP between Arms 2A and 2B.   
 
• To assess changes in the whole exome and whole transcriptome by hig h 
throughput parallel sequencing technologies  in evaluable samples from RP 
between treatment A rms 1A and 1B . 
 
• To assess proportion of patients with downstaging on second multi -parametric 
prostate MRI  compared to baseline MRI  between Arms 1A and 1B.  
 
• To correlate imaging T stage at second multi- parametric prostate MRI with 
pathologic T stage in all patients and by treatment arm.  
 
• To determine if multi- parametric prostate MRI can be used to predict pathologic 
response (defined as pCR, MRD, and RCB) foll owing neoadjuvant hormone 
therapy.  
 
• To assess the prevalence of germline mutations in homologous recombination genes in all enrolled patients.  
 
• To correlate homologous recombination gene germline mutation status with pathologic response (defined as pCR, MRD, and RCB). 
 
• To evaluate family history of cancers in the study population and  correlate family 
cancer history with  germline mutation status . 
  
2. BACKGROUND  
2.1 Study Disease  
 
Prostate cancer is the most common cancer in men in the United States, with a life  time 
risk of 16%, and the second leading cause of cancer death in this population.
4 Despite 
ongoing efforts, outcomes in high- risk patients undergoing RP  have not significantly 
improved with time , likely related to systemic micrometastatic disease not adequately 
addressed at the time of local treatment .5-7 Following RP  upwards of 50% of patients 
with high -risk disease will experience a biochemical recurrence at 5 years.7 In a 
retrospective analysis of 379 men who developed a biochemical recurrence after RP , 
approximately 80- 90% of patients with high- risk prostate  cancer died f rom their 
disease.8 Consequently, new treatment strategies, including multimodality therapy, are 
needed to improve outcomes in hi gh-risk patients.  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
4 2.2 Rationale  
 
Treatment of patients with high -risk disease presents two therapeutic challenges: the 
need for local control of the primary disease site and need for systemic control of 
microscopic metastatic disease.  Neoadjuvant and adjuvant therapy is an approach which 
can potentially maximize survival outcomes in patients with localized disease. This approach is under investigation and provides an opportunity to assess pathologic and biologic activity of novel treatments.  
 The paradigm of ne oadjuvant systemic therapy is widely accepted in the treatment of 
patients with localized high -risk breast cancer and other solid tumor malignancies.  The 
National Surgical Adjuvant Breast and Bowel Project ( NSABP ) Protocol B -18 was 
designed to d etermine wh ether four cycles of doxorubicin + cyclophosphamide 
administered preoperatively improved breast cancer  disease -free survival  (DFS) and 
overall survival  (OS) compared with treatment administered postoperatively. At a 
median follow -up of 16 years, there were no statistically significant differences in DFS 
and OS between the two groups, however, there were trends in favor of preoperative chemotherapy for DFS and OS in women less than 50 years old.
9 A meta -analysis of 
nine randomized studies, including a total of 3,946 women, demonstrated that neoadjuvant cytotoxic therapy was equivalent to adjuvant cytotox ic therapy in terms of 
survival and overall disease progression.
10 Few studies have evaluated pCR rates to 
hormonal therapy and theses are on the order of approximately 10% in breast cancer. The metrics for neoadjuvant hormonal therapy studies focus on ORR, breast conservation, PFS and OS as endpoints.  Additionally, neoadjuvant cytotoxic  therapy is 
routinely utilized in the treatment of bladder
11,12, esophageal8,13,14, and rectal  cancer11. 
 
A central tenant of neoadjuvant therapy is that local tumor response correlates with long-term outcomes such as DFS  and OS. For breast cancer, pCR  is a significant 
predictor of improved clinical outcomes  and has been adopted as the primary endpoint 
for neoadjuvant trials . In a review  of 6,377 breast cancer patients from seven 
randomized trials receiving neoadjuvant anthracycline -taxane- based chemotherapy, 
pCR was asso ciated with significantly superior DFS and a trend towards improved 
OS.
15 Residual disease after neoadjuvant treatment includes a broad range of actual 
response s from near pCR to frank resistance. Symmans and colleagues developed a 
method to measure residual disease in breast cancer by combining histopathologic components of residual disease (cellularity, overall diameter, number and extent of nodal involvement) i nto a numerical index of RCB.
16 Favorable RCB was defined as the 
40th percentile of the RCB index values which was used as the cutoff point to separate favorable RCB (including pCR and minimal residual disease) from moderate or extensive residual disease.  In a pathologic review of 382 patients treated in two 
different cohorts, RCB was calculated as a continuous i ndex for prediction of distant 
relapse- free survival in multivariate Cox regression analysis.
16 They determined that 
RBC was independently prognostic in a multivariate  model.  
 Historically, the development of new drugs in the early disease setting has been predicated on a demonstration of improved overall survival. In 2014, the FDA  drafted a 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
5 guidance act, which uses pCR to the neoadjuvant treatment of high- risk early breast 
cancer as an endpoint  to support accelerated approval of new drugs. Pertuzumab was 
the first  drug which was  granted the FDA’s accelerated approval in the neoadjuvant  
setting. The approval was based primarily on results from  the NEOSPHERE study , a 
phase II neoadjuvant study  using pertuzumab in HER2- positive early stage breast 
cancer .1 
 
ADT  is the ma instay of first- line systemic therapy for patients with metastatic prostate 
cancer. However, clinical trials of ADT in the neoadjuvant stetting prior to RP have 
been disappointing. Table 1 provides a review of clinical trials of neoadjuvant ADT  
prior to RP .17-28  
 
Table 1. Trials of neoadjuvant ADT.  
 
Trial  Patients  Clinical 
Stage  Regimen  Outcomes  
(Neoadj uvant ADT + RP vs. RP alone)  Median 
Follow Up 
(Years)  Positive Surgical 
Margin Rate  pCR Rate  PFS  OS  
Dalkin et al 
(1996) 17  56 T1c-T2b G x 3 mo  18% vs. 14%  NR NR NR  
Labrie et al 
(1997) 18 161 T2-T3 L + F x 3 
mo  7.8% vs. 33.8%a 
 6.7% vs. 
0% NR NR  
Fair et al 
(1999) 19 140 T1-T3 L + F x 3 
mo  19% vs. 37%a NR No 
difference  NR 2.9 
Van Der 
Kwast et al 
(1999) 20 47 T1-T3 L + F x 3 
mo vs. L + 
F x 6 mo  27.8% (3 mo) vs. 
9.1% (6 mo)a 
 0 (3 mo)  
vs. 9% (6 
mo) NR NR  
Schulman et 
al (2000) 21 402 T2-T3 
 G + F x 3 
mo  13% vs. 37% T2a 
42% vs. 61% T3  NR 74% vs. 
67% No 
difference  4 
Gleave et al 
(2001) 22 547 T1b-T2 
 L + F x 3 
mo vs. L + 
F x 8 mo  23% (3 mo) vs. 
12% (8 mo)a 
 5.1% (3 
mo) vs. 
9.3% (8 
mo) NR NR  
Soloway et al 
(2002) 25 303 T2b 
 L + F x 3 
mo  18% vs. 48%a NR 64.8% vs. 
67.6%  NR 5 
Selli et al 
(2002) 24 431 T2-T3 
 G + B  x 3 
mo vs. G + 
B x 6 mo  27.9% vs. 53.1% 
(3 mo)a 
29.7% vs. 53.1% 
(6 mo)a NR NR NR  
Aus et al 
(2002) 23 126 T1b-T3a 
 T x 3 mo  23.6% vs. 45.5%a  NR 49.8% vs. 
51.5%  No 
difference  6.85 
Klotz et al 
(2003) 26 213 T1b-T2 
 T x 3 mo  28% vs. 65%a 0% vs. 0%  60.2% vs. 
68.2%  
30.5% 
vs.18.8%a 
for PSA > 
20 ng/ml  88.4% vs. 
93.9%  6 
Prezioso et al 
(2004) 27 167 T1a-T2b  L + C x 3 
mo  39% vs. 60%a NR NR NR  
Yee et al 
(2009) 28 148 T1b-T3 G + F x 3 
mo  19% vs. 38%a NR 80% vs. 
78% NR 8  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
6 a Denotes statistical significance.  
ADT = androgen deprivation therapy; pCR = pathologic complete response = PFS = progression free 
survival; OS = overall survival; RP = radical prostatectomy; G = gosereline ; mo = months; NR = not 
recorded; L = leuprolide; F = flutamide; B = bicalutamide; T = triptorelin; C = cyproterone.  
 
The concept of utilizing neoadjuvant ADT prior to RP  emerged in an attempt to 
improve the rate of organ -confined disease. Labrie and colleagues18 were among the 
first to show improvement in pathologic outcomes with a randomized, prospective trial using leuprolide and flutamide for three months prior to RP  compared to RP alone. The 
study showed that neoadjuvant combination ADT decreased positive surgical margins from 33.8% to 7.8% and resulted in down staging in 54% in the neoadjuvant arm. In 
addition, pCRs were found in six RP specimens (6.7%). The authors postulated that 
longer duration of neoadjuvant ADT would potentially increase the degree of benefit.  
 
Subsequently treatment durations ranging from three to eight months were 
evaluated.
20,22,24 The Canadian Urologic Oncology Group ( CUOG ) conducted the 
largest randomized trial evaluating neoadjuvant ADT prior to RP.22  In this study, 547 
men with cT1b- T2 were randomly assigned to treatment w ith leuprolide and flutamide 
for three or eight months before RP. Compared to the three month group, the eight month group had lower preoperative PSA (0.052 versus 0.133 ug/L, p=0.0141), lower 
positive surgical margin rate (12% versus 23%, p=0.0106), and higher rate of organ -
confined disease (80% versus 68%, p=0.0019).  The pCR rate was higher in the eight month group compared to the three month group, though this was not statistically significant (9.3% versus 5.1%, p=0.0711). There have been no reports of improvement in biochemical relapse rates or other clinical outcomes with longer ADT from this trial.  
 A meta -analysis of 10 studies of neoadjuvant ADT prior to RP  showed that neoadjuvant 
therapy had a beneficial and statistically significant impact in lowering the pathologic T stage, increasing the organ -confined rate, lowering the positive surgical margin rate, and 
decreasing the number of pathologic N1 cases.
29 The effect on positive surgical margins 
and organ- confined rates was significantly better with eight months of neoadjuvant 
treatment as compared to only three months of treatment. Four trials included information about the pCR rate.
18,20,22,26 The bene ficial effects in pathologic outcomes, 
including pCR rate, did not translate to improved DFS or OS. The DFS at five years, defined either as biochemical or clinical progression, remained unchanged between the treatment and control groups. Only one trial found local recurrence rates to be decreased, but this was only in a subset of patients with T2 disease.
21 In the three 
studies which evaluated OS with mean follow -up periods of 4, 6, and 7 years, the meta -
analysis found no significant difference in OS and no assessments with longer follow -
up are available.21,23,26   
 The discordance between the improvement in immediate pathologic endpoints and the lack of benefit in DFS or  OS is likely multi- factorial in nature. This is likely 
multifactorial given that these trials included heterogeneous patients populations (including patients who did not have high- risk disease), various treatment regimens 
(including an LHRH agonist, an antiandrogen, or combination of both), various durations of therap y (with most durations lasting three  months), and limited sample size 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
7 to detect realistic differences between treatment arms. Additionally, this could be 
related to minimal efficacy  standard A DT and more maximal suppression of the 
androgen axis is necessary to observe a therapeutic effect.  
 Additionally, i n prostate cancer, neoadjuvant therapy changes  the morphology of the 
residual , rendering the Gleason score of the post -therapy specimen inadequate. A study 
of 115 patients with high -risk prostate cancer who had preoperative therapy with 
androgen ablation alone or in combination with chemotherapy evaluated morphologic patterns in the RP specimens that may be helpful in assessing prognosis.
30 Based on 
hierarchical clustering analysis, three morphologically distinct groups were identified. On multivariate analysis, the presence of cribriform or intraductal spread morphology 
were strong predictors of biochemical relapse.  
 
With regard to adjuvant therapy, there are only limited data about the role of adjuvant 
hormone therapy without radiation therapy after RP. ECOG (ECOG3886) evaluated 
immediate versus deferred ADT in men with node -positive prostate cancer.
31 Between 
1988 and 1993, 98 men who underwent a radical prostatectomy and pelvic lymphadenectomy and found to have microscopic lymph node metastases were randomized to receive immediate lifel ong ADT or to be observed and receive ADT on 
symptomatic recurrence or detection of distant metastatic disease. At a median follow -
up of 11.9 years, the men assigned to the immediate ADT  arm had a significant 
improvement OS  (hazard ratio [HR] 1.84, 95% confidence interval [CI] 1.01–3.35, P 5 
.04), prostate cancer –specific survival (HR 4.09, CI  1.76–9.49, P 5 .0004), and 
progression- free survival  (HR 3.42, CI 1.96–5.98, P<.0001). In this study, patients in 
the observation arm were initiated on ADT only  after  the development of symptomatic 
recurrence or detectable metastatic disease and not at the time of biochemical 
recurrence, which can occur at a median of 8 years  before the onset of radiologic 
evidence of metastatic disease.
32  
 A separate retrospective observational study using Surveillance, Epidemiology, and End Results (SEER) –Medicare data was done to evaluate the impact of adjuvant ADT for 
patients who have node -positive prostate cancer in the contemporary era of 
postoperative  PSA surveillance to detect biochemical recurrence.
33 Wong and 
colleagues used the SEER -Medicare database to construct a cohort of men with lymph 
node – positive disease who had undergone RP between 1991 and 1999 and classified 
them as receiving adjuvant ADT (within 120 days of RP) or not receiving a djuvant 
ADT (subsequent ADT initiated >120 days from surgery or no ADT). Among the 731 men identified, 209 had received ADT within 120 days of R P. After adjusting for 
potential confounders of receiving adjuvant ADT (ie, tumor characteristics, extent of nodal disease, demographics, receipt of radiotherapy), there was no statistically significant difference in the OS between the adjuvant ADT and non- ADT group (HR 
0.97, 95% CI 0.71–1.27). Additionally, there was no statistically significant survival difference when various definitions of adjuvant ADT (90, 150, 180, and 365 days) were tested. One important limitation of this study is that the indication for ADT (adjuvant versus  salvage) was not available through the database.  
 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
8 In the SWOG (Southwest Oncology Group) S9921 trial, 983 men with high- risk 
prostate cancer (extraprostatic extension, positive nodes, positive margin Gleason 7 or 
Gleason grade >7) received adjuvant therapy with ADT (goserelin and bicalutamide for 2 years) alone or in combination with 6 cyc les of mitoxantrone chemotherapy after a 
prostatectomy.
34 For the 481 men who received ADT only, the estimated 5 -year 
biochemical failure -free survival was 92.5% (95% CI 90–95) and the 5 -year OS was 
95.9% (95% CI 93.9–97.9). This trial was closed to accrual in January 2007 after 3 cases of acute myelogenous leukemia were reported in the mitoxantrone t reatment arm. 
The final analysis of the primary end point of OS comparing the 2 arms for this trial has not been reported; however, the results seen in the ADT -only arm make a compelling 
argument to counsel patients with high- risk prostate cancer about adj uvant ADT after a 
RP. This study represents the largest prospective cohort of patients with high- risk 
prostate cancer receiving adjuvant ADT and showed favorable results. 
 
Though prior clinical trials of ADT in the neoadjuvant and adjuvant setting have not proved effective, promising results of a number of rationally -designed next generation 
hormone therapies in patients with metastatic disease are providing rational for use in early disease stages in an attempt to improve survival in high -risk patients with 
localized prostate cancer.    
We evaluated abiraterone  acetate in a phase II neoadjuvant trial in patients with 
intermediate and high -risk prostate cancer.
3 Fifty -eight patients were randomized to 
treatment with AA (1000 mg PO daily) + leupr olide + prednisone (5 mg PO daily) or 
leuprolide alone for 12 weeks. After 12 weeks, patients underwent prostate biopsy. 
Subsequently all patients received an additional 12 weeks of combination AA (1000 mg PO daily) + leuprolide + prednisone (5 mg PO daily ). After 24 weeks, patients 
underwent RP. This study demonstrated that the pathologic pCR and near pCR rate 
(defined as tumor measuring < 5 mm) was 14% in the overall cohort and was 24% in patients treated with abiraterone acetate for 24 weeks and  4% in th ose treated with 
leuprolide alone followed by 12 weeks of combination therapy (p=0.089). PSA measurements did not reflect pathologic outcomes in patients in both arms of the trial. Though 86% of all patients had a nadir PSA ≤ 0.2 ng/mL at 24 weeks, 54% had pathologic T3 disease. Longer follow -up is needed to evaluate the effect of this therapy 
on long term cancer control. 
  
We completed accrual and are analyzing a randomized phase II trial evaluating  
neoadjuvant enzalutamide  alone versus enzalutamide, dutas teride, and leuprolide in 
men with localized intermediate and high -risk prostate cancer .
35 The primary endpoint 
of this trial is pCR and near pCR rate. Prostate cancer tissue from baseline biopsies and 
from RP  specimens will be available for correlative assessment of mechanisms of 
castration resistance including selective changes in t he AR and AR associated genes.   
Apalutamide  is a novel second- generation anti -androgen, with a similar mechanism of 
action to enz aluta mide  that binds directly to the ligand -binding domain of the AR, 
impairing nuclear translocation and DNA binding. It has not been investigated in the 
neoadjuvant setting.  
 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
9 Though this data is promising, there is an opportunity for further improvement of 
pathologic outcomes. In preclinical models of human castration -resistant prostate cancer 
(CRPC)  xenografts, treatment with abiraterone acetate resulted in increased expression 
of full -length AR, which can lead to AR sensitization to lower levels of andr ogens. 
Additionally, treatment was associated with increased expression of CYP17 and other key enzymes mediating conversion of adrenal androgen intermediates to testosterone, suggesting de novo  steroidogenesis within the tumor microenvironment. This data 
highlights the rationale  for combination abirate rone acetate with a potent antiandrogen.  
 We propose to evaluate the efficacy of neoadjuvant abiraterone acetate + apalutamide  + 
prednisone  + leuprolide compared to abirate rone acetate + prednisone + leuprolid e 
followed by RP and subsequent adjuvant therapy abiraterone aceta te + apalutamide  + 
prednisone  + leuprolide compared to no further adjuvant treatment in patient with 
intermediate to high -risk prostate cancer. The primary objective will be analysis of pCR 
+ minimal residual disease (MRD, defined as residual tumor in RP specimen measuring ≤ 5 mm) in RP specimens following neoadjuvant therapy as well as of freedom from biochemical recurrence post -RP. 
2.3 Study Agent(s)  
2.3.1 Abiraterone acetate  
2.3.2 Abiraterone acetate (17 -(3-pyridyl)  androsta -5,16- dien-3β-ol) is a 
rationally designed, inhibitor of  CYP17 . Key design features of this 
compound include the 3 -pyridyl  substitute , resulting in more potent 
inhibition of CYP17, and 16,17- double bond , which is essential for 
irreversible inhibition of CYP17.
36,37 CYP17 is a key enzyme in 
cortisol synthesis via its 17α -hydroxylase activity and plays a 
central role in androgen biosynthesis via its 17,20 -lyase activity  
(Figure 1) .38 Abiraterone acetate is a potent inhibitor with an 
apparent inhibition constant of 0.5 nM.37  
 
 
 Figure 1.  The pro -drug abiraterone acetate is c onverted to abiraterone after 
absorption.   

Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
10 Abiraterone acetate is the 3 -acetylated analog and  pro-drug of abiraterone  
(given poor bioavailability)  suitable for oral administration  (Figure 2). 
Abiraterone acetate is rapidly  deacetylated and  converted  to the active form  
abiraterone. Abiraterone is metabolized by CYP3A4 and is an inhibitor of 
CYP2D6.39 
 
 
 Figure 2. The steroid biosynthesis pathway. Abiraterone inhibits 17α -hydroxylase 
(crossed in red) which results in re duction of serum cortisol and consequent 
increase in adrenocorticotropic  hormone ( ACTH ) that drives the steroid 
biosynthesis pathway. Abiraterone also inhibits 17,20- lyase (crossed in red) 
resulting in significant suppression of DHEA, androstenedione, and testosterone. DHEA- S. Dehydroepiandrosterone ( DHEA) ; sehydroepiandrosterone -sulfate 
(DHEA- S); sihydrotestosterone ( DHT ); sulfotransferase  (ST); steroid sulfatase  
(STS) .  
 
Rationale  for Using Abiraterone Acetate in Prostate Cancer  
Ketoconazole, a weak and nonspecific CYP17 inhibitor, is commonly used in clinical practice. Ketoconazole, an imidazole antifungal agent, inhibits several enzymes in the steroid biosynthe sis pathway including desmolase and 11β -
hydroxylase, in addition to C YP17.
40 When administered at a dose of 400 mg 
three times daily, ket oconazole reduced testosterone,  androstenedione and 
DHEA.41 
 Numerous phase II studies have demonstrated  that treatment with ketoconazole 
resulted in PSA response rate s (defined as a ≥ 50% decrease in PSA levels from 
baseline) ranging from 40 -62% with median duration of response lasting between 
3.3-7 months.
42 In the  Cancer and Leukemia Group B  (CALGB ) 9583 phase III 
trial comparing androgen withdrawal to androgen withdrawal plus ketoconazole, response rates were 11 and 27%, respectively (p=0.02) , however there was no 
difference in OS  between the two groups , which may reflect 82% crossover rate .
43  
 Treatment with ketoconazole has been limited by toxicity. In the phase III 
CALGB trial, grade 3 and 4 toxicity was reported in 21% of patients and 

Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
11 comprised primarily fatigue, and hepatic, neurologic or respiratory issues. Other 
limitations include multiple drug interactions that limit its use in patients with 
comorbidities. Additionally, it requires frequent daily dosing and hydrocortisone 
daily for glucocorticoid replacement.  
 The development of a therapy with more potent and selective inhibition of CYP17, once daily administration, limited drug -drug interactions, that lacks a 
requirement  for concomitant corticosteroids would represent a significant 
advance ment in the management of CRPC and  desirable alter ative to  therapy with  
ketoconazole.  
 
Clinical Data with Abiraterone Acetate  
Abiraterone acetate has been tested in patients in phase I, II and III trials. Below we will summarize the results of these trials with a focus  on safety and efficacy 
(Table 2 ).  
 Table 2 . Summary of clinical trials o f Abiraterone Acetate.  
 
Study  Patient  Drug  Efficacy  Toxicity  
Phase 1  
Attard et al (2008)
44 21 
Chemo -naive  
Keto -naive  
(non-
metastatic 
and 
metastatic ) AA 250-
2000 mg 
daily, fasting, 
5 dose 
escalations  Increased ACTH, 
upstream steroids; 
decreased 
testosterone, 
downstream 
androgenic steroids; 
PSA decline to 
≥30%, 50%, and 90% 
were 66%, 57%, and 
29%, respectively; 
Median TTPP  69 to ≥ 
578 days; 62% partial 
RECIST response  Hypertension 
(29%), 
hypokalemia 
(48%), lower- limb 
edema (5%);  No 
grade 3 or 4 
toxicities; 
Precipitation of 
migraine and 
asthma, 1 patient 
each, both of 
whom required 
dexamethasone  
Phase I  
Ryan et al (2010)
45 33  
Chemo -naive  
Keto -naive 
(14) (non-
metastatic 
and 
metastatic)  AA 250-
1000 mg 
daily, fed and 
fasting 
cohorts, 4 
dose 
escalations  Decreased 
testosterone, 
downstream, 
androgenic steroids; 
PSA decline ≥50% at 
week 12 in 55% 
(47% vs. 64% prior 
keto vs. no keto); 
Median TTPP  234 
days (283 vs. 230 
days prior keto vs. no 
keto)  Hypertension 
(36%), 
hypokalemia 
(24%), peripheral 
edema (24%) , 
fatigue (67%), 
headache (33%), 
nausea (33%), 
diarrhea (30%); 
Grad e 3 
hypertension 
(12%), grade 3/4 
hypokalemia ( 9%) 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
12 Phase II  
Attard et al 
(2009)46  42  
Chemo -naive  
(non-
metastatic 
and 
metastatic)  AA 1000 mg 
daily, fasting  PSA decline ≥50% 
observed in 67% 
(≥90% observed in 
19%); Median TTPP 
225 days; 38% partial 
RECIST response;  
CTC declined to 
<5/7.5 mL in 59%; 
33% from phase I/II 
had reversal of 
resistance with 
dexamethasone  Hypertension 
(40%), 
hypokalemia (8%), 
fluid overload 
(31%); M anaged 
with eplerenone 
except in 3 
patients who 
required 
dexam ethasone   
Phase II  
Danila et al  
(2010)47 58  
Chemo -
treated  
Keto -naive 
(27) 
(metastatic 
only)  AA 1000 mg 
daily  
(fasting) + 
prednisone 5 
mg twice 
daily  PSA decline to 
≥30%, 50%, and 90% 
were 47%, 36%, and 
16%, respectively  
(PSA decline ≥50%  
26% vs. 45% prior 
keto vs. no keto) ; 
Median TTPP 169 
days (99 vs. 198 prior 
keto vs. no keto) ; 
18% partial RECIST 
response; CTC 
declined <5/7.5 mL 
in 34%  Hypertension 
(4%), hypokalemia 
(5%), p eripheral 
edema (9%) , 
abnormal LFTs 
(15%); No grade 
3/4 hypertension, 
hypokalemia, 
peripheral edema; 
No use of 
eplerenone  
Phase II  
Reid et al (2010)
48 47  
Chemo -
treated  
(metastatic)  AA 1000 mg 
daily, fasting PSA decline to 
≥30%, 50%, and 90% 
were 68%, 51%, and 
15%, respectively; 
Median TTPP 169 
days; 27% partial 
RECIST respon se; 
CTC declined <5/7.5 
mL in 45%  Hypokalemia 
(55%), 
hypertension 
(17%), fluid 
retention (25% ); 
Grade 3 
hypokalemia (2%)  
  
 
Phase III  
de Bono et al 
(2011)49 1195  
Chemo -
treated  
(metastatic 
only)   AA 1000 mg 
daily  versus 
placebo  
(fasting) + 
prednisone 5 
mg twice 
daily  AA-prednisone vs. 
placebo -prednisone 
median OS 14.8 vs. 
10.9 months 
(p<0.001), TTPP 10.2 
vs. 6.6 months 
(p<0.001), PFS 5.6 
vs. 3.6 months 
(p<0.001), PSA AA-prednisone vs. 
placebo -
prednisone 
hypertension 10% 
vs. 8%, 
hypokalemia 17% 
vs. 8%, fluid 
retention 31% vs. 
22% 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
13 response rate 29% vs. 
6% (p<0.001)  
Phase III  
Ryan et al 
(2012)50 1088  
Chemo -naive  
(metastatic 
only)  AA 1000 mg 
daily versus 
placebo 
(fasting) + 
prednisone 5 
mg twice 
daily  (2:1) AA-prednisone vs. 
placebo -prednisone 
median OS NR vs. 
27.2 months 
(p=0.01) , PFS 16.5 
vs. 8.3 months 
(p<0.001), median 
time-to-opiate use 
NR vs. 23.7 months 
(p<0.001), median 
time to initiation of 
cytotoxic 
chemotherapy 25.2 
vs. 16.8 months 
(p<0.001), median 
time to decline in 
performance status  
12.3 vs. 10.9 months 
(p=0.005), median 
TTPP 11.1 vs. 5.6 
months (p<0.001)  AA-prednisone vs. 
placebo -
prednisone 
hypertension 22% 
vs. 13%, 
hypokalemia 17% 
vs. 13%, fluid 
retention 28% vs. 
24%, increased 
ALT 12% vs . 5%, 
increased AST 
11% vs. 5%, 
cardiac disorder 
19% vs. 16%  
AA = abiraterone acetate; keto = ketoconazole; chemo = chemotherapy; ACTH = 
adrenocorticotropic hormone; PSA = prostate specific antigen, TTPP = time- to-PSA progression; 
CTC = circulating tumor cells; LTs = liver function tests; OS = overall survival; PFS = progression- free survival ; ALT = alanine transaminase; AST = aspartate transaminase.  
 
Early phase I studies showed good bioavailability at doses of greater than 200 mg, 
a half -life of approximately 28 hours, and significant increased absorption with 
food.51 The initial studies included men who were not on LHRH  agonist. In this 
population, a compensatory surge in luteinizing hormone led to an increase in testosterone by day 4 of treatment with abiraterone acetate in some men, suggesting the need for abiraterone acetate to be given concomitantly with 
suppressed testicular function.  A Phase I/II study evaluated abiraterone acetate in chemotherapy -naive men with 
CRPC resistant to multiple prior hormone therapies.
44,46 The phase I study (n=21) 
evaluated once, daily, continuous abiraterone acetate, which escalated throug h 
five doses (250- 2,000 mg) in three -patient cohorts . In this study, abiraterone 
acetate was well tolerated. There were no treatment related grade 3 and grade 4 toxicities. Hypertension, hypokalemia, and lower -limb edema was observed in 
29%, 48% , and 5%  patients , respectively. These side effects were controlled with 
eplerenone, a selective mineralocorticoid receptor antagonist . Abiraterone acetate 
was associated with increased levels of ACTH (5 -fold) and steroids upstream of 
CYP17 (10- 40 fold)  with suppression of serum testosterone (<1 ng/dl), 
downstre am and rogenic steroids, and estradiol in all patients. Declines in PSA 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
14 ≥30%, 50%, and 90% were observed in 14 (66%), 12 (57%), and 6 (29%) 
patients, respectively and lasted between 69 to ≥ 578 days. Five (62%) of eight 
patients with measurable disease at b aseline had confirmed partial response by 
Response Evaluation Criteria In Solid Tumors ( RECIST ). The addition of 
dexamethasone 0.5 mg/d resulted in salvage of 4/15 patients who had PSA progression.  
 The phase II expansion of this study  included 42 patient s.
46 A decline in PSA of 
≥50% was observed in 67% of patients and declines of ≥90% were observed in 
19% of patients. The median time -to-PSA progression ( TTPP ) was 225 days. Of 
the 24 patients with measurable disease, 38% experienced partial response by 
RECIST. Decreased in circulat ing tumor cell ( CTC)  counts were documented 
(decline to <5/7.5 mL in 59% of patients). In an exploratory analysis of all 54 
patients in the phase I/II trial, addition of dexamethasone at PSA progression 
reversed resistance in 33% of patients. In long term follow up, after all patients 
were discontinued from therapy with abiraterone acetate, 38/42 (90%) patients experienced signs of mineralocorticoid excess including hypertension, hypokalemia, and peripheral edema. This was effectively treated with eplerenon e 
without exogenous glucocorticoids in 35/38 (92%) patients. Only 3/38 (5%) patients required administration of exogenous glucocorticoids (dexamethasone 0.5 mg daily). The median time to initiation of eplerenone was 28 days.  
 Two phase II studies in post -docetaxel CRPC patients have also been 
conducted.
47,48 PSA declines of ≥50% occurred in 22/58 (36%) and 24/47 (51%) 
patients, respectively, with the median TTPP of 169 days for both studies. Partial responses were seen in 4/22 (18%) and 8/30 (27%) patients with RECIST -
evaluable target lesions, respectively.  
 The efficacy of abiraterone acetate was demonstrated in a phase III trial in which 1,195 men previously treated with docetaxel were randomly assigned to abiraterone acetate plus prednisone or placebo plus prednisone.
49 The primary end 
point was OS. After a median follow -up of 12.8 months, abiraterone acetate  
significantly increased OS  (median 14.8 versus 10.9 months, p<0.0001), TTPP 
(10.2 versus 6.6 months, p<0.0001), radiographic PFS (5.6 versus 3.6 months, 
p<0.001), and PSA response rate (29% versus 6%, p<0.001) compared with placebo plus prednisone. The effect of abiraterone acetate and prednisone on OS 
was consistent across all subgroups.  
 The most common adverse event was fatigue which occurred at a similar frequency in the two treatment groups. Other common AEs  including back pain 
(30%  in the abiraterone acetate group and 33% in the placebo group). Nausea 
(30% and 32%, respectively ), constipation (26% and 31%), bone pain (25% and 
28%), and arthralgia (27% and 23%). Most of these events were grade 1 or 2. Urinary tract infection was more frequent in the abiraterone acetate group (12% 
vs. 7% in the placebo group, p=0.02) and were primarily grade 1 or 2 events. AEs resulting in treatment discontinuation occurred with similar frequency in the 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
15 abiraterone acetate and placebo groups (19% and 23%, respectively, p=0.09) . AEs 
associated with elevated mineralocorticoid levels, cardiac disorders, and liver 
function test (LFT)  abnormalities were more common in the abiraterone acetate 
group than in the placebo group (55% vs. 43%, p<0.001). The incidence of fluid retention and edema was higher in the abiraterone acetate group (31% vs. 22% in 
the placebo group). Hypokalemia occurr ed in a higher proportion of patients in 
the abiraterone acetate group (17% vs. 8%, in the placebo group, p<0.001). 
Cardiac events (primarily grade 1 or 2) occurred at a higher rate in the abiraterone acetate group than in the placebo group (13% vs. 11%, p= -.14), but this difference 
was not significant. The most frequently  reported cardiac events tachycardia and 
atrial fibrillation. A grade 4 elevation in LFTs early on the study led to a protocol amendment to specifying more frequent monitoring of LFTs. Ove rall however, 
abnormalities in LFTs occurred at a similar frequency in the abiraterone acetate 
and placebo groups. A lower proportion of patients in the abiraterone acetate group than in the placebo group had an AE that resulted in death (12% vs. 15%). Based on this trial, abiraterone acetate was approved by the FDA  in April 2011 
for the treatment of patients with metastatic CRPC following docetaxel.
49  
 
A randomized, phase III study evaluated  abiraterone acetate in chemotherapy -
naive patients with metastatic CRPC. In this double -blind study, 1,088 patients 
were randomly assigned to treatment with abiraterone acetate plus prednisone or 
placebo plus prednisone. The co- primary end points  were radiographic PFS and 
OS. The study was unblinded after a planned interim analysis that was preformed 
after 43% of the expected deaths had occurred. The trial showed that treatment 
with abiraterone acetate plus prednisone produced a statistically significant 
improvement in radiographic PFS ( 16.5 vs. 8.3 months, p<0.001) and a strong 
trend for increased OS ( not reached  vs. 27.2 months, Hazard Ratio (HR)  0.75, 
95% CI 0.61 -0.93, p=0.01) over placebo plus prednisone. Abiraterone acetate 
decreased the risk of decline in performance status score (time to decline 12.3 vs. 10.9 months, p=0.005), increased the median time to initiation of cytotoxic 
chemotherapy  (25.2 vs. 16.8 months, p<0.001), delay in time to opiate use for 
cancer -related pain ( not reached  vs. 23.7 months, p<0.001), and median TTPP  
(11.1 vs. 5.6 months, p<0.001).  
Grade 3 or 4 AEs were reported in 48% of patients in the abiraterone acetate group and 42% of the placebo group, serious AEs were reported in 33% and 26% of patients, AEs resulting in death were reported in 4% and 2% of patients, respectively. Common AEs  included fatigue (39% vs. 34%), back pain (32% vs. 
32%), arthralgia (28% vs. 24%), nausea (22% vs. 22%), constipation (23% vs. 19%), hot flush (22% vs. 18%), diarrhea (22% vs. 18%), bone pain (20% vs. 19%), muscle spasm (14% vs. 20%), pain in extremity (17% vs. 16%), and cough (17% vs. 14%). Grade 3 or 4 hepatotoxicity (elevated LFTs) occurred in 8% of 
patient in the abiraterone acetate group and 3% in the placebo group. AEs 
classified as cardiac disorders were reported  in 19% of patient in the abiraterone 
acetate group and 16% in the placebo group. Hypertension (22% vs. 13%), 
hypokalemia (17% vs. 13%), and fluid retention or edema (28% vs. 24%), were 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
16 mostly grade 1 or 2 events. Based on the results of this trial, i n December 2012, 
the FDA expanded the indication for abiraterone acetate for the treatment of 
patients with chemotherapy -naive metastatic CRPC .  
 Pharmacokinetics of Abiraterone Acetate  
Pharmacokinetics were evaluated in two phase I trials and are detailed in table 2.
44,45 In the Attard et al study, a plateau of endocrine effects was reported at 
doses >750 mg, and 1000 mg was selected a s the dose for phase II evaluation. 
There were significant variations in the area under the curve ( AUC ) and 
maximum plasma concentration ( Cmax) among patients. When administered with 
food high in fat content, drug exposure increased 4.4 fold compared to fa sting. 
There was no significant increase in C max, but absorption was significantly 
extended after food. In the Ryan et al study, C max was achieved within 1.5- 5 
hours.45 Less than proportional increased in both C max and AUC were observed 
across dose levels in fed and fasted patients.  
     Table 3 . Abiraterone Acetate Pharmacokinetics Parameters.  
Parameter  Abiraterone Acetate  
Absorption  Systemic absorption (C max and AUC) increases with 
increasing fat content of meals. The AUC was approximately 5 -fold higher when administered with a 
low-fat meal, and approximately 10 -fold higher when 
administered with a high -fat meal. Exposure ( area under 
the curve) of abiraterone acetate increases up to 10 fold 
when abiraterone acetate is taken with meals. Abiraterone Cmax and AUC0 -∞ (exposure) were 
increased up to 17-  and 10- fold higher, respectively, 
when a single dose of abiraterone acetate w as 
administered with a meal compared to a fasted state.   
Abiraterone AUC0 –∞ was approximately 7- fold or 1.6-
fold higher, respectively, when a single dose of abiraterone acetate was administered 2 hours after or 1 hour before a medium fat meal (25% fat, 491 calories)  
compared to overnight fasting.  Systemic exposures of abiraterone in patients with metastatic CRPC, after repeated dosing of abiraterone acetate were similar when abiraterone acetate was taken with low -fat meals 
for 7 days and increased approximately 2 -fold when 
taken with high- fat meals for 7 days compared to when 
taken at least 2 hours after a meal and at least 1 hour before a meal for 7 days .  Due to normal variation and 
composition of meals, no food should be consumed for at least 2 h ours before the dose of abiraterone acetate 
and for at least one hour after the dose.  
Metabolism  Following oral administration, abiraterone acetate is 
hydrolyzed to abiraterone (active metabolite) through 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
17 esterases and not CYP.  The 2 main circulating 
metabolites are abiraterone sulphate (inactive; formed 
via SULT2A1) and N -oxide abiraterone sulphate 
(inactive; formed via CYP3A4 and SULT2A1).  
Elimination  88% recovered in feces and 5% in urine (55% as 
unchanged abiraterone acetate , 22% as abiraterone).  
Half-life Mean terminal t1/2= 12 ±5 hours.  
Protein 
Binding  Highly protein bound (>99%); it is not a substrate for 
but is an inhibitor of P -glycoprotein.  
For detailed information regarding potential drug interactions, refer to section 5. 4. 
2.3.3 Apalutamide  (JNJ-56021927)   
2.3.4 Apalutamide  is synthetic biaryl thiohydantoin compound. It is a 
novel second- generation  antiandrogen that binds direct ly to the 
ligand- binding domain of the AR, impairing nuclear translocation 
and DNA binding.  Apalutamide  is approved by the FDA for the 
treatment of non -metastatic castration resistant prostate cancer, 
however in this study apalutamide is still considered investigational in this trial setting.  It is currently under investigation as a single agent in a Phase  I/II study of patients with metastatic CRPC.
52  
  
Rational e for U sing Apalutamide  in Prostate Cancer  
First generation antiandrogens, including bicalutamide, nilutamide, and 
flutamide, are reversible inhibitors of the AR and have a se veral -fold lower 
affinity to the AR compared with androgens. These agents have been used in the management of advanced prostate cancer for decades. Addition of an 
antiandrogen at the time of CRPC has been shown to lower PSA by 50% or 
more in approximately one -quarter of patients.
30,53,54 There is no data 
supporting the superiority of one antiandrogen over another, however 
nilutamide has been shown to induce PSA declines in men who have developed resistance to A R inhibition with flutamide or bicalutamide.
55  
 
It was first noted in the early 1990s that disease progression, despite the combination of an LHRH agonist and an antiandrogen, could be stopped and reversed simply through discontinuation of the antiandrogen. Stopping the 
antiandrogen i n men with a rising PSA, termed antiandrogen withdrawal, can 
result in PSA declines in between 10- 20% of men.
43 Further work 
demonstrated that in the setting of AR overexpression or mutation, 
conventional antiandrogens have the potential to exhibit paradoxical partial 
agonist activity, promoting prostate cancer progression.52 Thus, more potent 
antagonists lacking agonist activity are necessary.  
 Enzalutamide, formerly known as MDV3100, is a rationally -designed second 
generation AR inhibitor which functions by blocking several steps in the AR 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
18 signaling cascade. Enzalutamide competitively binds the AR with great 
potency. Additionally, enzalutamide inhibits nuclear translocation of activated 
AR and inhibits the association of activated AR with DNA.56 It has been 
tested in two placeb o-controlled, randomized phase III  studies (AFFIRM and 
PREVAIL) to evaluate the efficacy and safety of in patient s with advanced 
prostate cancer. The AFFIRM study evaluated the safety and efficacy of 
enzal utamide in 1,199 patients with CRPC after chemotherapy with 
docetaxel.57 Patients  were randomized in a 2:1 ratio to receive oral 
enzalutamide at a dose of 160 mg per day or placebo. The primary endpoint 
was OS . The study was stopped after a planned interim analysis at the time of 
520 deaths. The median OS was 18.4 months in the enzalut amide group 
versus 13.6 months in the placebo group (HR 0.63, 95% CI 0.53 -0.75, 
p<0.001). The superiority of enzalutamide over placebo was shown with 
respect to all secondary endpoints: ≥ 50% PSA reduction (54% vs. 2%, 
p<0.001), soft -tissue response rate (2 9% vs. 4%, p<0.001), the quality -of-life 
response rate (43% vs. 18%, p<0.001), time to PSA progression (8.3 vs. 3.0 
months, p<0.001), time to first skeletal -related event (SRE)  (16.7 vs. 13.3 
months, p<0.001). The PREVAIL trial is a double -blinded, randomi zed, 
placebo -controlled trial is investigating the effectiveness of enzalutamide in 
patients with metastatic CRPC who have not yet received chemotherapy. The 
primary endpoints are OS and PFS.  T he study was stopped after a planned 
interim analysis showed a  benefit of the active treatment. The rate of 
radiographic PFS at 12 months was 65% among patients treated with 
enzalutamide, as compared with 14% among patients receiving placebo (81% 
risk reduction; hazard ratio in the enzalutamide group, 0.19; 95% confi dence 
interval [CI], 0.15 to 0.23; P<0.001). Based on this data, enzalutamide was 
approved for treatment of metastatic CRPC prior to chemotherapy.  
 Clinical Data of Apalutamide  
Apalutamide  is currently under investigation as a single agent in a Phase I/II 
study of patients with metastatic CRPC. In the phase I  trial, wh ich was 
presented at the 2010 Genitourinary  Cancers Symposium , patients with 
metastatic CRPC received apalutamide  orally on a  continuous daily dosing 
schedule. In the phase 1, 7 doses (30- 300 mg) were tested in a standard 3 x 3 
dose escalation design. Twenty -four patients were treated. The most common 
grade 1 -2 treatment related AEs  were fatigue (38%), nausea (29%), and pain 
(24%). There was only one treatment -related grade 3 AE  (abdominal pain) at 
300 mg, likely related to higher pill burden. The pharmacokinetics were linear 
and dose -dependent. Twelve patients (55%) had ≥ 50% PSA declines. Based 
on preclinical assessment of maxi mum efficacious dose, pharmacokinetics , 
and promising activity across all doses, 240 mg was selected as the 
recommended phase II dose.  
 Results of the Phase II portion of this multicenter trial were presented at the 2013 Genitourinary  Cancers Symposium. A ctivity of apalutamide  was tested 
in three populations (high- risk non- metastatic CRPC, treatment naive 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
19 metastatic CRPC, metastatic CRPC progressive aft er treatment with 
abiraterone acetate ). All patients received treatment with apalutamide  240 
mg/day. The primary endpoint was PSA response rate at 12 weeks according 
to the PCWG2 criteria. Twenty -five patients were enrolled on the treatment 
naive arm and 21 patients were enrolled in the post abiraterone acetate cohort. 
Of patients with metastatic disease, to date, 15 patients had discontinued the study. The most common treatment related AEs  were fatigue (30%), 
abdominal pain (24%), nausea (22%), and diarrhea (17%). There was only one treatment -related grade 3 AE of abdominal pain. At 12 weeks, the PSA 
response  was 88% (treatment naive) and 29% (post abiraterone  acetate) . 
Forty -seven patients were enrolled with non- metastatic CRPC. At a median 
treatment duration of 20 weeks, three patients discontinued the study. The most common treatment- related AEs  were fatigu e (30%), diarrhea (28%), 
nausea (17%), rash (13%), and abdominal pain (11%), the incidence of grade 3 AE was 6.4% and no seizures have been observed. The 12- week PSA 
response was 91% at the time to PSA progression has not been reached.  
 A phase III clinical trial evaluating apalutamide  against placebo in a high- risk, 
non-metastatic castration -resistant prostate cancer population is currently 
ongoing (SPARTAN).  The primary outcome measure is metastasis -free 
survival.  Secondary outcome measures include ove rall survival, time to 
symptomatic progression, time to initiation of cytotoxic chemotherapy, progression free survival, time to metastasis, change in quality of life questionnaire scores, AEs, and plasma concentrations of apalutamide  and 
metabolites ARN00 0308 and ARN 000066.  Of the participants treated to date 
on the experimental abiraterone acetate treatment arm, the most common grade 3 -4 laboratory abnormalities were low phosphorous (7.2%), low 
potassium (5.3), and high AST (2.1%).  The most common laboratory AEs of any grade were high triglycerides (62.5%), high AST (30.6%), low potassium  
(28.3%), and low phosphorous (23.8%).  Any grade of laboratory AEs in the 394 participants on the placebo arm were high triglycerides (53%), high AST (36.3%), low pota ssium (19.8%), and low phosphorous (15.7%).  The most 
common non- laboratory grade 3 -4 AEs in the experimental, abiraterone 
acetate plus prednisone arm were joint swelling/discomfort (4.2%)  and 
muscle discomfort (3.0%).  Grade 3- 4 urinary tract infection w as in 2.1% of 
participants treated with abiraterone acetate and prednisone.  
 
3.  PARTICIPANT  SELECTION  
The inclusion and exclusion criteria for enrolling subjects in this study are described in the following sections. If there is a question about the inclusion or exclusion criteria, the treating investigator should consult with the sponsor investigator  before enrolling the 
subject in the study.  
3.1 Eligibility Criteria  
 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
20 Participants must meet the following criteria on screening examination to be eligible to 
participate in the study : 
3.1.1 Male ≥ 18 years of age.  
3.1.2 Histologically confirmed adenocarcinoma of the prostate  without 
histological variants  comprising > 50% of the sample as determined 
by academic center central review  (including neuroendocrine 
differentiation, small cell, sarcomatoid, ductal adeno carcinoma, 
squamous or transitional cell carcinoma).  
3.1.3 Must have 3  core biopsies involved with cancer. Prostate biopsy 
must be within seven  months from screening.  Less than 3 core 
biopsies is allowed if the patient has >1cm or T3 disease on MRI.  
3.1.4 Patients must have the following features:  
• Gleason ≥ 4+3=7 OR  
• Gleason 3+4=7 AND at l east one of the following: PSA 
> 20 ng/ mL, or T3 disease  (as determined by MRI) .  
3.1.5 No evidence of metastatic disease as determined by radionuclide bone scans and CT/MRI. Lymph nodes must be less than 20  mm in 
the short (transverse) axis.  
3.1.6 Participa nts must be candidates for RP and considered surgically 
resectable by urologic evaluation.  
3.1.7 ECOG (Appendix A) performance status 0 to 1.  
3.1.8 Participants must have normal organ and marrow function as defined below:  
• Hemoglobin ≥  9.0 g/dL  
• ANC ≥ 1,500/mcL  
• Platel ets ≥ 100,000/mcL , independent of 
transfusions/growth factors within 3 months of treatment start 
• Serum potassium ≥ 3.5 mmol/L  
• Serum total bilirubin ≤ 1.5  x ULN  (except in subjects 
with Gilbert’s syndrome who have a total bilirubin > 1.5 x ULN, measure dir ect and indirect bilirubin and if 
direct bilirubin is ≤ 2 x ULN, subject may be eligible)  
• AST, ALT ≤ 2.5 x ULN   
• Serum albumin ≥  3.0 g/dL  
• Serum creatinine < 2.0 x ULN  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
21 • INR ≤  1.5 ULN unless on warfarin therapy (investigator 
would need to determine if safe for participant to stop 
warfarin prior to surgery and warfarin therapy  
• PTT ≤ 60 
3.1.9 Agrees  to use a condom (even men with vasectomies) and another 
effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug. Must also agree not 
to donate sperm during the study and for 3 months after receiving the last dose of study drug.  
3.1.10  Medications known to lower the seizure threshold  must be 
discontinued or substituted prior to st udy treatment . 
3.1.11  Have signed an informed consent document indicating that the subjects understands the purpose of and procedures required for the study and are willing to participate in the study.  
3.1.12  Be willing/able to adhere to the prohibitions and restriction s 
specified in this protocol.  
3.1.13  Able to swallow the study drug whole as a tablet.  
3.1.14  Willing to take abiraterone acetate on an empty stomach; no food 
should be consumed at least two hours before and for at least one hour after the dose abiraterone  acetate is taken. 
3.2 Exclusion Criteria  
 
Participants who exhibit any of the following conditions at screening will not be eligible for admission into the study.  
3.2.1 Prior hormone therapy for prostate cancer including orchiectomy, antiandrogens (including first -generation ant iandrogens, 
enzalutamide, apalutamide  and others), CYP17 inhibitors 
(including abiraterone, TAK -700, galeterone, ketoconazole, and 
others), estrogens, Luteinizing Hormone Releasing Hormone (LHRH ) agonist/antagonists. Prior therapy with 5α -reducta se 
inhibit ors is allowed.  LHRH therapy allowed if begun within 5 
weeks of day 1. Up to 30 days of bicalutamide is allowed if it is 
stopped two weeks prior to day 1.  
3.2.2 Prior chemotherapy, radiation therapy  for the treatment of prostate 
cancer , or immunotherapy for prostate cancer.  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
22 3.2.3 Prior systemic treat ment with an azole drug within two  weeks of 
start of treatment. Please refer to section 5.4.  
3.2.4 Hypogonadism or severe androgen deficiency as defined by 
screening serum testosterone < 200 ng/dL.  Patients who have a low 
screening testosterone due to prior ADT  (per 3.2.1)  will still be 
allowed to enroll on study if they do not have a known history of hypogonadism or severe androgen deficiency. 
3.2.5 Clinically significant cardiovascular disease  within 6 months of 
study treatment  including:  
• Severe or unstable angina;  
• Myocardial infarction;  
• Symptomatic congestive heart failure;  
• New York Heart Association (NYHA class II -IV heart   
failure)  
• Arterial or venous thromboembolic events  (such as 
pulmonary embolism cerebrovascular  accident inc luding 
transient ischemic attacks); 
• History of clinically significant ventricular arrhythmias (e.g. ventricular tachycardia, ventricular fibrillation, torsades de pointes);  
• Prolonged corrected QT interval by the Fridericia correction formula (QTcF) on scre ening EKG > 470 
msec;  
• History of Mobitz II second degree or third degree heart 
block without a permanent pacemaker in place;  
• Uncontrolled hypertension (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg). Participants with a history of hypertension are allowed 
provided blood pressure is controlled by anti -
hypertensive therapy.  
3.2.6 History of seizure or any condition or concurrent medication that may predispose to seizure (including but not limited to prior stroke, transient ischemic attack, loss of consciousness within one year 
prior to randomization, brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect).  
3.2.7 History of allergic reactions attributed to compounds of similar chemical or biologic composition to apalutamide, abiraterone acetate, or other study drugs. 
3.2.8 Severe hepatic impairment (Child -Pugh Class C).  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
23 3.2.9 Active infection (such as human immunodeficiency virus (HIV) or 
viral hepatitis) or other medical condition that would make 
corticosteroid use contraindicated. 
3.2.10  History of pituitary or adrenal dysfunct ion. 
3.2.11  Gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug.  
3.2.12  Pre-existing condition that warrants long -term corticosteroid us e 
greater than the equivalent of 10 mg prednisone daily . Physiologic 
replacement  is permitted. Topical, i ntra-articular steroids or inhaled 
corticosteroids are permitted.   
3.2.13  Concomitant use of medications that may alter pharmacokinetics of abiraterone or  apalutamide  
3.2.14  Individuals with a history of another malignancy a re not eligible if 
the cancer is under active treatment or the cancer can be seen on radiology scans or if they are off cancer treatment but in the opinion of their oncologist have a high risk of relapse within 5 years.  
3.2.15  Major surgery or radiation therapy within 4 weeks from start of 
treatment.  
3.2.16  Any condition that in the opinion of the investigator would preclude participation in this study.  
3.3 Inclusion of Women, Minorities and Other Underrepresented Populations  
 Every effort will be made to include men from minority populations. The  enrollment of 
minority men will reflect the proportion of minority participants  at the sites 
participating in the trial.  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
24 4. REGISTRATION PROCEDURES  
4.1 General Guidelines for DF/HCC Institutions  
 
Institutions will register eligible participants in the Clinical Trials Management System (CTMS) OnCore. Registrations must occur prior to the initiation of protocol therapy. Any participant not registered to the protocol before protocol therapy begins will be considered ineligible and regis tration will be denied.  
 An investigator will confirm eligibility criteria and a member of the study team will complete the protocol -specific eligibility checklist.  
 Following registration, participants may begin protocol therapy. Issues that would cause treatment delays should be discussed with the Sponsor -Investigator, Dr. Mary -Ellen Taplin . If a 
participant does not receive protocol therapy following registration, the participant’s registration on the study must be canceled. Registration cancellations mu st be made in OnCore as soon as 
possible.  
4.2 Registration Process  for DF/HCC Institutions  
 
DF/HCC Standard Operating Procedure for Human Subject Research Titled Subject Protocol Registration (SOP #: REGIST -101) must be followed.   
4.3 General Guidelines for Other Participating Institutions  
 
Eligible participants will be entered on study centrally at the Dana -Farber Cancer 
Institute ( DFCI ) by the Study Coordinator. All sites must  call the Study Coordinator to 
verify treatment av ailability. The required forms will be provided to all participating 
institutions by the DFCI Study Coordinat or.  
 
Following registration, participants should be gin protocol treatment within 7  days  or as 
soon as possible. Issues that would cause treatment delays should be discussed with the 
PI. If a participant does not receive protocol therapy following registration , the 
participant’s registration on the study must be canceled . The Study Coordinator should 
be notified of cancellations  as soon as possible. 
 
4.4 Registration  Process for Other Participating Institutions  
 
To register a participant, the documents listed in Section 3.7.1 of Appendix I  should be 
completed by the research nurse or data manager and faxed (617- 632-6220) or e -mailed 
to the DFCI Clinical Research Manager and Clinical Research Coordinator.  
 
The research nurse or data manager at the participating site will then call  the Clinic al 
Research Manager or email the DFCI Study Coordinator to verify eligibility. To 
complete the registration process, the Coordinator will  follow DF/HCC Standard 
Operating Procedures for Human Subject Research titled Subject Protocol Registration 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
25 (SOP #: RE GIST -101) and register the participant on the protocol.  The coordinator 
will fax or e -mail the participant study number and treatment arm to the participating 
site.  The coordinator will also call the research nurse or data manager at the 
participating site and verbally confirm registration.   
 
Note : Registration and randomization with ODQ can only be conducted during the 
business hours of 8am – 5pm Eastern Standard Time  Monday -  Friday. Same day 
treatment registrations will only be accepted with prior notice and discussion with the DF/HCC Lead Institution.  
 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
26 5. TREATMENT PLAN  
5.1 Treatment Summary and Randomization  
 
5.1.1 In Part 1, e ligible patients  will be randomized in 1:1 ratio to receive 
6 cycles of neoadjuvant treatment with  either : 
• abiraterone acetate,  apalutamide , leuprolide and 
prednisone (Arm 1A) , OR  
• abiraterone acetate, leuprolide and prednisone (Arm 
1B).  
 
Randomization will be  stratified by risk factor: Intermediate (Gleason 4+3) vs. 
high risk (Gleason>7, or PSA>20, or T3 disease). During Part 1, a cycle will be 
defined as 28 days  (+/- 2 days) . Following neoadjuvant treatment as designated in 
each of the above arms, patients will undergo RP . 
 
5.1.2 In Part 2 (post -RP), patients will be re -randomized in 1:1 ratio to 
receive either:  
• an add itional 12 months of a biraterone acetate, 
apalutamide , leuprolide and prednisone (Arm 2A) , OR  
• observation (Arm 2B).  
• Patients who do not get randomized to part 2 will follow the 2B arm.  
 
Randomization will be stratified by type of neoadjuvant therapy and pathological T-stage ( < pT3 versus ≥ pT3 ) after RP but before cycle 7 day 1
  following 
neoadjuvant therapy . Patients will be randomized regardless of post -operative 
PSA. Adjuvant or salvage radiation therapy will be allowed at the discretion of 
the treati ng investigator. Patients do not need to re -meet eligibility criteria at re -
randomization to Part 2 of the study. There will be an early stopping rule for Part 2 should a high rate of patients refuse to participate or drop out early while 
receiving adjuvant therapy (<6 months).  
 
Participants may enter the study with no more than one month of an LHRH agonist 
treatment prior to cycle 1/day 1 . 
 Expected toxicities and potential risks as well as dose modifications are described in Section 6 (Expected Toxicities and Dosing Delays/Dose Modifications). No investigational or commercial agents or therapies other than those described below may be admini stered with 
the intent to treat the participant’s malignancy.  
     
 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
27  
 Table 4. Treatment Plan . 
Treatment Description  
Agent1 Pre-medications; 
Precautions  Dose  Route  Schedule  Cycle 
Length  
Abiraterone 
acetate No food should be 
consumed for at least two hours before the 
dose and for at least 
one hour aft er the dose  1000 mg  
(four 250 mg tablets)   Orally  Once daily  
28 days  
(+/-2 
days) 
during 
Part 1; 
28 days 
(+/- 14 
days 
during 
Part 2)  
 Apalutamide  Can be taken with or 
without food  240 mg 
(four 60 
mg tablets)  Orally  Once daily  
 
   Prednisone  For patients receiving 
abiraterone alone; t ake 
with food   5 mg  Orally  Once daily  
For patients receiving 
both abiraterone and apalutamide; take with 
food 5 mg  Orally  Twice daily  
Leuprolide  None  22.5 mg 
every three months  Intramuscular  Every three 
months  
1. Abiraterone acetate should not be dosed with apalutamide . Apalutamide  and prednisone can be 
taken together with food. Abiraterone  acetate, apalutamide and prednisone will be prescribed 
by prescription in an unblinded fashion and taken by the participant on an outpatient basis. Leuprolide will be administered intramuscularly by a health care professional.  
 
5.2 Pre-treatment Criteria  
5.2.1 For C ycle 1, Day 1 , the following parameters must be met:  
• WBC ≥ 3,000/mcL  
• ANC  ≥ 1,500/mcL  
• Serum potassium ≥ 3.5 mmol/L (patients on exogenous potassium supplementation will require weekly monitoring of potassium levels for one month)  
• AST/ALT ≤ 2 .5 x ULN  
• Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN) (except in subjects with Gilbert’s syndrome who have a total bilirubin > 1.5 x ULN, measure direct and indirect bilirubin and if direct bilirubin is ≤ 2 x ULN, subject may be eligible)  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
28 • Systolic blood pressure ≤  160 mmHg or diastolic blood pressure  < 90 
mmHg  
 
If these parameters are not met, the participant can be evaluated on a weekly basis. Hypertension and hypokalemia should be treated as appropriate.  
 For subsequent cycles, refer to dose modifications as outlined in Section 6.  
5.3 Agent Administration   
5.3.1 Abiraterone acetate  
- Administration: Patient s will be treated with 1,000 mg orally once daily  
of abiraterone acetate prior to RP . Treatment can  continue for 6 cycles 
(+/- 2 days) . Following RP, patients randomized to further adjuvant 
therapy will continue abiraterone acetate with apalutamide  for another 
12 cycles. However, therapy will be held on the day of RP and will resume on  the cycle 7/day 1 visit.  
- Patie nts who are not randomized to further adjuvant therapy will 
administer their last dose of abiraterone acetate on the day prior to RP . 
- Dosing: 1,000 mg orally taken once daily as four 250 mg tablets. Possible dose modifications are outlined in Section 6.  
- Oral Doses: Abiraterone acetate must be taken on an empty stomach. No 
food should be consumed for at least two hours before the dose of 
abiraterone acetate is taken and for at l east one hour after the dose of  
abiraterone acetate is taken. If a dose is skipped, missed or vomited, it 
should not be taken (or retaken if vomited) on the day of the missed dose 
but dosing should be resumed the following day. Doses should be taken 
no later than 12 hours after the scheduled time for dosing. Doses should 
not be crushed, chewed or dissolved.  They should be taken whole.  
Participants will be asked to record actual dosing in a drug diary  
(Appendix C ). There is no specified order of administration of the study 
drugs prescribed in this protocol .  
5.3.2 Apalutamide  
- Administratio n: Patients will be treated with 240 mg orally once daily  of 
apalutamide . Treatment can  continue for 6 cycles (+/- 2 days). 
Following RP, patients randomized to further adjuvant therapy will 
continue apalutamide  with abiraterone acetate for another 12 cycl es. 
However, therapy will be held on the day of RP and will resume on the cycle 7/day 1 visit.  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
29 - Patients who are not randomized to further adjuvant therapy will 
administer their last dose of apalutamide on the day prior to RP.  
 - Dosing: 240 mg orally taken once daily as four 60  mg tablets . Possible 
dose modifications are outlined in Section 6.  
 - Oral Doses:  Apalutamide  can be taken with or without food. If a dose is 
skipped, missed or vomited, it should not be taken (or retaken if vomited) on the day of the missed dose but dosing should be resumed the following day. Doses should be taken no later than 12 hours after the scheduled time for dosing. Doses should not be crushed, chewed or dissolved.  They should be taken whole.  Participants will be asked to record actual dosing in a drug diary  (Appendix C ). There is no specified 
order of administration of the study drugs prescribed in this protocol. 
5.3.3 Prednisone  
 5.3.3.1 Patients taking Abiraterone Only  
- Administration: Patients will be treated with prednisone 5 mg orally once daily. Following RP, patients randomized to further adjuvant therapy with abiraterone acetate and apalutamide will take prednisone 5 
mg twice daily, starting at cycle 7/day 1 visit (for a total of 12 cycles) . 
Prednisone in Par t 1 of the study may be stopped the day prior to RP, 
(same day abiraterone is stopped), or may be tapered at the discretion of the treating investigator. The treating physician or surgeon may administer a higher dose of corticosteroids if there are signs or symptoms of adrenal insufficiency, or concerns for adrenal insufficiency.  
- Dosing: Prednisone 5 mg orally once daily taken as one 5 mg tablet. It is recommended that prednisone be taken in the morning. Dose reduction 
is not allowed.  
- Oral Doses: Prednisone should be taken once daily  with food. If a dose 
is missed  for greater than 12 hours, that dose should not be taken, and if 
the dose is missed for less than 12 hours, it should be taken prior to the next scheduled dose if possible. Vomited doses should not be re -taken . 
Doses should not be  crushed, chewed or dissolved. Tablets  should be 
taken whole.  Patients  will be asked to record actual dosing in a drug 
diary  (Appendix C) . There is no specified order of administration of the 
study drugs prescribed in t his protocol. 
 
5.3.3.2 Patients taking  apalutamide  in combination with Abiraterone  on 
Arm 1A and Arm 2A  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
30 - Administration: Patients will be treated with prednisone 5 mg orally 
twice  daily. Following RP, patients randomized to further adjuvant 
therapy with abi raterone acetate and  apalutamide  will take prednisone 5 
mg twice daily, starting at cycle 7/day 1 visit (for a total of 12 cycles).  
Prednisone in Part 1 of the study may be stopped the day prior to RP (same day abiraterone and apalutamide stopped), or may be tapered at the discretion of the treating investigator. The treating physician or surgeon may administer a higher dose of corticosteroids if there are signs or symptoms of adrenal insufficiency, or concerns for adrenal insufficiency.  
- In Part 1A and 2A, if apalutamide  is permanently discontinued due to 
toxicity, patients taking abiraterone alone should take prednisone once daily.  
- In Part 1A and 2A, if abiraterone is permanently discontinued due to toxicity, patients may take apalutamide  without prednisone.   
- Dosing: Prednisone 5 mg orally twice  daily. It is recommended that 
prednisone be taken with food. Dose red uction is not allowed.  
- Oral Doses: Prednisone should be taken with food twice per day at approximate ly 10-12 hour  intervals. If a dose is missed for greater than 
12 hours, that dose should not be taken, and if the dose is missed for less than 12 hours, it should be taken prior to the next scheduled dose if 
possible. Vomited doses should not be re -taken.  Doses should not be 
crushed, chewed or dissolved. Tablets should be taken whole.  Participants will be asked to record actual dosing in a drug diary  
(Appendix C) . There is no specified order of administration of the study 
drugs prescribed in this protocol.  
- If patients are 80% compliant with their prednisone dosing, missed doses do no need to be reported to the IRB as violations. 
5.3.4 Leuprolide  
- Administration: Participants  may enter the study with no more than one 
month of LHRH agonist /antagonist treatment with or without an anti -
androgen  prior to cycle 1/day 1. Treatment will be administered 
intramuscularly by a health care professi onal. Leuprolide will be 
administered as two 3 -month injections or four 3- month injections 
during Part 2A. Treatment with degareli x or goserelin as a substitute to 
leuprolide is permissible.  
- Dosing: 22.5 mg intramuscularly every three months. 
5.4 General Concomitant Medications and Supportive Care Guidelines  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
31  
General Concomitant Medications  
Medications taken within 14 days prior to the  first dose of study treatment will be 
documented. Medications taken after the first dose of study medication and until 30 days following the last dose of study treatment will be documented as well. Prior and concomitant medications include all vitamins, h erbal remedies, over -the-counter, and 
prescription medications.  
 The following medications are prohibited within two weeks  of start of treatment  
(unless otherwise indicated below) and throughout the time on study:  
 
• Androgens (testosterone, DHT), estrogens, or progestational agents  
• 5α-reductase inhibitors  
• Azole medications  
• Spironolactone  
• Diethylstilbestrol, saw palmetto or other preparations thought to have 
endocrine effects on the prostate  
 Potential Drug Interactions with Abiraterone Abiraterone is an inhibitor of the hepatic drug metabolizing enzyme CYP2D6. In a 
CYP2D6 drug -drug interaction trial the C
max and AUC of dextromethorphan (CYP2D6 
substrate) were increased 2.8 and 2.9 fold, respectively, when dextromethorphan 30 mg was given with a biraterone 1000 mg daily and prednisone 5 mg twice daily.
58 The 
AUC for dextrorphan, the active metabolite of dextromethorphan, increased approximately 1.3 fold. Avoid co- administration of a biraterone with substrates of 
CYP2D6 with a narrow therapeutic index (i.e. thioridazine).   In a CYP2C8 drug- drug interaction trial in healthy subjects, the AUC of pioglitazone 
(CYP2C8 substrate) was increased by 46% when pioglitazone was given together with 
a single dose of 1,000 mg abiraterone acetate. Therefore, patients should be monitored 
closely for signs of toxicity related to a CYP2C8 substrate with a narrow therapeutic index if used concomitantly with abiraterone . 
Based on in vitro data, abiraterone is a substrate if CYP3A4. The effect s of strong 
CYP3A4 inhibitors (i.e. ketoconazole, itraconazole, clarithromycin, atazanavir, nefazodone, saquinavir, telithromycin, ritonavir, indinavir, nelfinavir, rifapentine, and phenobarbital) on the ph armacokinetics of a biraterone have not been evaluated in vivo . 
In vitro, studies with human hepatic microsomes showed that abiraterone is a strong inhibitor of CYP1A2 and CYP2D6 and CYP2C8 and a moderate inhibitor of CYP2C9, CYP2C19, and CYP3A4/5.  
In a clinical study to determine the eff ects of abiraterone 1000 mg daily plus 
prednisone 5 mg twice daily on a single 1000 mg dose of the CYP1A2 substrate 
theophylline, no increase in systemic exposure of theophylline was observed.  
 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
32 In vitro, abiraterone and its major metabolites were shown to inhibit the hepatic uptake 
transporter OATP1B1. There are no clinical data available to confirm transporter 
based interaction. 
 Concomitant use of medications that may alter pharmacokinetics of abiraterone acetate or apalutamide  will not be allowed on this study. Specifically, strong CYP3A4 
inducers (see Table 5) that decrease the exposure of abiraterone will not be allowed .  
 Table 5. Strong CYP3A4 Inducers and Inhibitors . 
Strong CYP3A4 Inducers  Strong CYP3A4 Inhibitors  
Aminoglutethimide  Itraconazole  
Bexarotene  Clarithromycin  
Bosentan  Erythromycin  
Carbamazepine  Diltiazem  
Dexamethasone  Verapamil  
Efavirenz  Delavirdine  
Fosphenytoin  Atazanavir  
Griseofulvin  Indinavir  
Modafinil  Nefazodone  
Nafcillin  Nelfinavir  
Nevirapine  Ritonavir  
Oxcarbazepine  Saquinavir  
Phenobarbital  Telithromycin  
Phenytoin  Voriconazole  
Primidone  Grapefruit juice (or grapefruits)  
Rifabutin   
Rifampin   
Rifapentine   
St. John's wort   
 
 Potential Drug Interactions with Apalutamide  
Prohibited Medications : 
As a class effect, androgen receptor antagonists have been associated with seizures due to an off -target mechanism of action (GABA
A inhibition). To date, one patient 
receiving apalutamide  has experienced seizures, however, in preclinical experiments, 
at very high doses, dogs treated with apalutamide  had tremors and generalized 
seizures. Patients will be closely monitored for seizures, but as a precautionary measure, the following drugs known to decrease the seizure threshold and/or cause seizure will be prohibited while on study:  
• Aminophylline, theophylline  
• Atypical anti- psychotic drugs: cloza pine, olanzapine, ziprasidone  
• Bupropion  
• Lithium 
• Meperidine (Demerol) and pethidine  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
33 • Phenothiazine anti -psychotic drugs: chlorpromazine, mesoridazine, 
thioridazine  
• Tricyclic and tetracyclic anti -depressants: amitriptyline, desipramine,  
doxepine, imipramine, maprotiline, mirtazapine (Remeron)  
 
See Appendix D for a more comprehensive representative list of medications that may predispose to seizures.  
 
 
The potential for drug- drug interactions with apalutamide and warfarin (Coumadin) is 
unknown at present. If a subject is taking warfarin, reassess INR as clinically indicated and adjuvant the dose of warfar in accordingly.  
 Restricted Medications:  
Apalutamide  is metabolized primarily by human CYP3A4, thus co- administration with 
strong inhibitors or inducers of CYP3A4 must be avoided.  Apalutamide  may also 
induce CYP3A4; therefore, apalutamide  should not be t aken in conjunction with 
CYP3A4 substrates that have a narrow therapeutic index. The CYP3A4 inhibitors and inducers listed in Table 5 should be avoided.    
 If at any time an investigator suspects a drug -drug interaction, the PI , Dr. Mary -Ellen 
Taplin should be contact ed at 617- 582-7221 or paged at 617- 632-3353 (beeper 41225).  
5.5 Duration of Therapy  
 
Treatment on study will be for 6 cycles (28 days +/ - 2 days) of neoadjuvant therapy  
followed by 12 months of adjuvant therapy . In the absence of treatment delays due to 
AEs, treatment may continue  for the duration of the study  until one of the following 
criteria:  
 
• Intercurrent illness that prevents further administration of treatment;   
 
• Unacceptable AEs ; 
 
• Treatment emergent seizur e;  
 
• Participant decided to withdraw from the study ; 
 
• General or specific changes in the participant’s condition render the 
participant unacceptable for further treatment in the opinion of the treated investigator.  
 
Protocol  therapy may be held for up to six  weeks in the event of an AE and the 
participant may  be restarted on therapy when the toxicity has resolved to ≤ grade 1, In 
the event of therapy being held for more than six weeks, it is recommended that the participant come off protocol , however the t reating physician may obtain permission  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
34 to continue on the protocol with permission of the PI, Dr. Mary -Ellen Taplin, if the 
treating physician feels it is in the participant’s best interest.  
5.6 Duration of Follow -Up 
 
Participants randomized to adjuvant ther apy as designated by Arm 2A  will be followed 
every 3 months  (+/- 28 days ) following completion of the 12 cycles of adjuvant therapy 
for years  2-3. After year 3  post -RP, follow -up will take place every 6 months (+/ - 28 
days) for up to 5 years post -RP. Long -term follow -up assessments in years 4 -5 may be 
done locally and information may be collected via medical record review.  Whenever 
long-term follow -up PSA blood draws are done at the research clinic  conducting the 
study , the research team should collec t ctDNA samples.  
 
Participants randomized to no adjuvant therapy as designated by Arm 2B  will be 
followed every 3 months (+/ - 28 days ) during years 1 -3 post -RP.  After 3 years post -RP,  
follow -up will take place every 6 months (+/ - 28 days ) for up to 5 yea rs post -RP. Long -
term follow -up assessments in years 4 -5 may be done locally and information may be 
collected via medical record review.   Whenever long -term follow -up PSA blood draws 
are done at the research clinic conducting the study, the research team s hould collect 
ctDNA samples.  
 Participants who do not get randomized to part 2 will follow the 2B arm.  
 Participants removed from study for unacceptable AEs will be followed until resolution or stabilization of the AEs.  
5.7 Criteria for Removal from Study 
 
Participants will be removed from study when any of the  criteria are met:  
 
• Intercurrent illness that prevents further administration of treatment;   
 
• Unacceptable AEs;  
 
• Treatment emergent seizure;  
 
• Participant decided to withdraw from the study ; 
 
• General or  specific changes in the participant’s condition render the 
participant unacceptable for further treatment in the opinion of the treated investigator ;  
 
• Participants Lost to Follow -up; 
 
• Death.  
 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
35 The reason for study removal and the date the participant was removed must be 
documented in the study -specific Case Report Form (CRF) . Alternative care options 
will be discussed with the participant.  
 Participants will be removed from treatment at the time of unacceptable AEs  but will 
remain on study (i.e. enrolled on the protocol) until resolution or stabilization of any AEs.  
 In the event of unusual or life -threatening complications, participating investigators 
must immediately notify the PI, Dr. Mary -Ellen Taplin, at 617- 582-7221 or page 617-
632-3352 (beeper 41225).  
 
 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
36 6. EXPECTED TOXICITIES AND DOSING DELAYS/DOSE MODIFICATIONS  
 
It should be noted that we do not anticipate any excess toxicity as there are no overlapping 
toxicities and no apparent drug -drug interactions (either pharmacokinetics or combined 
inhibition of enzymes in t he androgen signaling cascade) between abiraterone acetate, 
apalutamide , prednisone, and leuprolide.  
 
Anticipated toxicities e re detailed below. Toxicity assessments will be done using the 
Cancer Therapy Evaluation Program ( CTEP ) Active Version of the National Cancer 
Institute ( NCI)  Common Terminology Criteria for Adverse Events ( CTCA E) (version 4) 
which is identified and located on the CTEP websit e at: 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm .  
 If possible, symptoms should be managed symptomatically. In the case of toxicity, appropriate medical treatment should be used (including anti -emetics, anti -diarrheals, etc.).   
 All AEs  experienced by participants will be collected from the time of the first dose of study 
treatment, through the study and until the final study visit. Pa rticipants continuing to 
experience toxicity at the off study visit may be contacted for additional assessments until the toxicity has resolved or is deemed irreversible.  
6.1 Anticipated Toxicities  
 
A list of the AEs  and potential risks associated with the age nts administered in this 
study appear below and will determine whether dose delays and modifications will be 
made or whether the event requires expedited reporting in addition  to routine 
reporting.  
6.1.1 AEs for Apalutamide  
Apalutamide  has been associated with grade 1 -2 AEs up to a dose of 240 mg by 
mouth when administrated as a single agent in a phase I/II study. Anticipated 
AEs from preliminary results of this study include fatigue,  nausea, skin rash, 
changes in thyroid function, tast e alterations, decreased appetite, itching, 
vomiting, dizziness, falls, insomnia, increase in blood cholesterol, increase in 
blood triglycerides, fractures , constipation, diarrhea, hot flashes  and rarely, 
seizures . Reported grade 3 toxicity was abdominal pain, likely related to pill 
burden.  
6.1.2 AEs for Abiraterone  
 
Hypertension, Hypokalemia, F atigue  and Fluid Retention  
Abiraterone may cause hypertension, hypokalemia, fatigue  and fluid retention 
as a consequence of increased mineralocorticoid levels resulting  from CYP17 
inhibition. In a phase III  randomized clinical trial,  grade 3 to 4 hypertension 
occurred in 1.3% of patients, grade 3 to 4 hypokalemia in 5.3% of patients,  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
37 grade 3 or 4 fatigue in 2.2% of patients  and grade 3 to 4 edema in 1.9% of 
patients treated with abiraterone.  
 
Co-administration of a corticosteroid suppresses ACTH drive, resulting in a 
reduction in the incidence and severity of these  adverse reactions. In this trial 
5 mg daily of steroids will be used. The safety of abirat erone in patients with 
left ventricular  ejection fraction < 50% or NYHA Class III or IV  heart failure 
(in the COU- AA-301 study ) or NYHA Class II to IV heart failure (in the  
COU- AA-302 study ) was not  established because these patients were 
excluded from the se randomized  clinical trials.  
 Adrenocortical Insufficiency  
Adrenal insufficiency occurred in the two randomized clinical studies in 0.5% of patients taking abiraterone and in 0.2% of patients taking placebo. 
Adrenocortical  insufficiency was reported in patients receiving abiraterone in 
combination with  prednisone, following interruption of daily steroids and/or 
with concurrent  infection or stress. Symptoms and signs of adrenocortical 
insufficiency may be masked by adverse  reactions associated with 
mineral ocorticoid excess seen in patients treated with  abiraterone.  
 Hepatotoxicity  
In the two randomized clinical trials, grade 3 or 4 ALT or AST increases (at  
least 5X ULN) were reported in 4% of patients who received abiraterone, typically  during the first three months after starting treatment. Patients whose 
baseline ALT or  AST were elevated were more likely to experience liver test 
elevation than those  beginning with normal values. Treatment discontinuation 
due to liver enzyme  increases occurred in 1% of p atients taking abiraterone. 
No deaths clearly related to  abiraterone were reported due to hepatotoxicity 
events.  
 For guidance on management of side symptoms of mineralocorticoid excess , 
symptoms related to androgen deprivation, or  other toxicities please contact 
the PI, Dr. Mary -Ellen Taplin at 617- 582-7221 or page 617- 632-3352 (beeper 
41225).  
See current package insert for abiraterone acetate (Zytiga) for additional  
information on abiraterone (http://www.zytiga.com/).  
6.1.3 AEs for Prednisone  
A daily dose of 5-10 mg of prednisone is below the daily physiologic steroid 
dose and thus it is not expected that prednisone will cause significant side 
effects.  
Potential side effects of prednisone are listed below:  
Cardiovascular:  Congestive heart failure, hypertension. 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
38 Central nervous system:  Emotional instability, headache, intracranial pressure 
increased, psychic derangements (including euphoria, insomnia, mood swings, 
personality changes, severe depression), seizure, vertigo.  
Dermatologic:  Bruising, facial erythema , petechiae, thin fragile skin, urticaria, 
wound healing impaired.  
Endocrine and metabolic:  Adrenocortical and pituitary unresponsiveness (in 
times of stress), carbohydrate intolerance, Cushing’s syndrome, dia betes 
mellitus, fluid retention , hypokalemic alkalosis, hypothyroidism enhanced, 
menstrual irregularities, negative nitrogen balance due to protein catabolism, potassium loss, sodium retention. Gastrointestinal:  Abdominal distension, pancreatitis, peptic ulcer (with 
possible perforation and hemorrhage), ulcerative esophagitis . 
Hepatic:  ALT increased, AST increased, alkaline phosphatase increased . 
Neuromuscular and skeletal:  Aseptic necrosis of femoral and humeral  heads, 
muscle mass loss, muscle weakness, osteoporosis, pathologic fracture of long bones, st eroid myopathy, tendon rupture , vertebral compression fractures . 
Ocular:  Exophthalmos, glaucoma, intraocular pressure increased, posterior 
subcapsular cataracts . 
Other:  Allergic reactions, anaphylactic reactions, diaphoresis, hypersen sitivity 
reactions, infections . 
6.1.4 Close monitoring of blood sugars is recommended in diabetic patients.  Close monitoring for infections is also recommended.  It is 
recommended the prednis one never be stopped suddenly. Gradual 
tapering of the dose and/or schedule of prednisone is recommended when discontinuing therapy. Monitoring for signs and symptoms of 
adrenal insufficiency during prednisone administration and tapering is recommended.  
6.1.5 AEs for Leuprolide  
Side effects of leuprolide are mainly secondary to intended therapeutic effects of ca strate levels of testosterone. Common AEs include edema, headache, 
depressed mood, fatigue, insomnia, skin reaction at injection site, h ot flashes, 
testicular atrophy, hyperlipidemia , decreased libido, nausea/vomiting , bowel 
function alteration, joint pain, weakness, bone loss, and flu- like symptoms.  
6.2 Toxicity Management  
 
Management of abiraterone and a palutamide  related toxicities are detailed below. 
Patients who have abiraterone treatment related toxicities many continue on 
apalutamide and leuprolide. Patients who have  apalutamide  toxicities may continue on 
abiraterone, prednisone, and leuprolide. If both study drugs are held, a patient will remain on sc hedule for all study assessments.  If a patient requires a dose reduction in 
Part 1 of the study , the dose reduction should also be followed in Part 2, if the patient is 
randomized to part 2A .  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
39 6.2.1 Management of Apalutamide  Related Toxicity  
Apalutamide  is generally well- tolerated  based on phase I/II data. The starting 
dose of  apalutamide  will be 240 mg daily. In the presence of any  apalutamide  
related toxicitie s > grade 2 (NCI CTCAE version 4 ) during treatment with  
apalutamide at the starting dose level , treatment will be held.  Once  toxicity 
improves  to ≤ grade  1, the dose of  apalutamide will be decreased to 180 mg 
daily. Two levels of dose de -escalation are planned for the study. If > grade 2 
toxicity  occurs at dose level -2, apalutamide  will be discontinued. Therapy 
with apalutamide  will be discontinued at first occurrence of seizure of any 
grade or grade 4 neurotoxicity.  
 
Dose Level   Apalutamide  
Starting dose 
level  240 mg orally once daily  
-1 180 mg orally once daily  
-2 120 mg orally once daily  
6.2.2 Management of other toxicities is detailed below.  
• Grade 1 -2 Toxicities : Management per investigator. No study 
treatment dose reduction  indicated .  
• Grade 3 of Higher Toxicities : Hold  apalutamide . When toxicity 
resolves to ≤  grade 1, resume at  first dose m odification level . 
Prophylactic medications should be considered. If toxicity 
recurs, hold study medication and adjust or add medications to 
mitigate the toxicity. When recurrent toxicity has resolved to ≤  
grade 1, resume  apalutamide  at second dose modific ation level . 
If grade 3 toxicity recurs, the patient will be discontinued from 
the study.  
6.2.3 Management of Abiraterone Related Toxicity  
The starting dose of abiraterone will be 1000 mg daily.  For g rade 1 -2 toxicities,  
unless otherwise described below, management per investigator. In the presence 
of any abiraterone related toxicitie s > grade 2 (NCI CTCAE version 4 ) during 
treatment with abiraterone at the starting dose level, treatment with abiraterone 
will be held. When toxicity improves  to ≤ grade  1, the dose of abiraterone will 
be decreased to 750 mg  daily in the subsequent dose level. Two levels of dose 
de-escalation are planned for the study. If > grade 2 toxicity occurs at dose 
level -2, participants will be removed from the protocol . Management of  other 
toxicities is detailed below.  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
40  
  
Dose Level  Abiraterone A cetate  
Starting dose level  1000 mg orally once daily  
-1 750 mg orally once daily  
-2 500 mg orally once daily  
 
6.2.4 Management of Hypertension  
• Grade 1 -2 Hypertension:  
o Management per investigator. No study treatment dose reduction.  
 
•   Grade 3 -4 Hypertension:  
o Hold abiraterone. Adjust or add medications to mitigate the 
toxicity and/or consider the specific mineralocorticoid receptor antagonist, eplerenone. When toxicity resolves to ≤ grade 1, 
resume abiraterone at full dose.  
o If grade 3 toxicity recurs  x 1, hold abiraterone, and adjust or add 
medications to mitigate the toxicity. When toxicity resolves to ≤ grade 1 , resume abiraterone at first dose level red uction (750 mg) .  
o If grade 3 toxicity recurs  x 2, hold abiraterone, and adjust or add 
medications to mitigate the toxicity. When toxicity resolves to ≤ grade 1 , resume abiraterone at second  dose level reduction ( 500 
mg daily).  
o If grade 3 toxicity recurs  x 3 despite optimal medical management 
and two dose level reductions, discontinue abiraterone.  
6.2.5 Management of  Hypokalemia  
• Subjects entering study on exogenous potassium supplementation:  
o Monitor potassium levels weekly for one month to ensure 
appropriate mai ntenance of levels.    
• Grade 1 -2 Hypokalemia : 
o Initiate oral potassium supplementation and/or consider the specific mineralocorticoid receptor antagonist, eplerenone. Once toxicity presents potassium will be monitored weekly until 2 consecutive  values are documented in the normal range.  
• Grade 3 -4 Hypokalemia:  
o Hold abiraterone. Adjust or add medications to mitigate the toxicity and/or consider the specific mineralocorticoid receptor 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
41 antagonist, eplerenone. Once toxicity presents potassium will b e 
monitored at least weekly until 2 consecutive  values are 
documented in the normal range. Once toxicity resolves 
(potassium ≥  3.5 mmol/L ), resume abiraterone at first dose level 
reduction (750 mg)  after discussion with PI . Once abiraterone is 
reinitiated potassium, should be monitored at least weekly for the 
first two weeks and then every 2 weeks for 4 weeks, and then monthly.  
o If grade 3 toxicity recurs, hold abiraterone, and adjust or add medications to mitigate the toxicity. Once toxicity presents , 
potas sium will be monitored at least weekly until 2 consecutive  
values are documented in the normal range. When toxicity resolves to ≤ grade 1 , resume abiraterone at second dose level reduction 
(500 mg daily)  after discussion with PI . Once abiraterone is 
reinitiated , potassium should be monitored at least weekly for the 
first two weeks and then every two weeks for four  weeks, and then 
monthly.  
o If grade 3 toxicity recurs despite optimal medical management and two dose level reductions, discontinue abiraterone.  
6.2.6 Management of LFT abnormalities  
• Grade 1 LFT Abnormalities ( increase in AST or ALT from ULN to 3.0 x 
ULN; increase in total bilirubin from ULN to 1.5 x ULN):  
o The frequency of LFT monitoring should be increased, if the investigator judges that the laborator y abnormalities are potentially 
related to abiraterone. No abiraterone dose reduction is required.  
• Grade 2 LFT Abnormalities ( increase in AST or ALT > 3.0 – 5 x ULN; 
increase in total bilirubin from > 1.5 – 3 x ULN):  
o The frequency of LFT monitoring should be increased  to ≥ once a 
week, if the i nvestigator judges that the laboratory abnormalities 
are potentially related to abiraterone. No abiraterone dose 
reduction is required.  
• Grade 3 LFT Abnormalities ( increase in AST or ALT to > 5 x ULN  – 20.0 
x ULN ; increase in total bilirubin to > 3 x ULN  – 10.0 x ULN ):  
o Hold  abiraterone and all other concomitant medications that are 
potentially hepatotoxic. Frequent laboratory evaluations (at least once weekly) should be conducted until the LF Ts return to baseline 
value or grade 1 . Hold until return to baseline of AST or ALT ≤ 
2.5 x ULN and total bilirubin ≤ 1.5 x ULN. If abiraterone resumption is considered for  subjects who have experienced g rade 
3 increases in AST, ALT, or bilirubin, and the PI agrees, resume abiraterone with th e first dose level reduction (750 mg) when grade 
3 toxicities resolve to g rade 1 or baseline. For participants who 
resume treatment, monitor LFTs at a minimum of every 2 weeks for 3 months and monthly thereafter.  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
42 o If grade 3 increases in AST, ALT, or bilirubin recur after the first 
dose reduction hold abiraterone and all other concomitant 
medications that are potentially hepatotoxic. Frequent laboratory evaluations should be conducted (at minimum weekly) until the LFTs return to baseline value or grade 1 . If abiraterone resumption 
is considered for par ticipants who have experienced g rade 3 
increases in AST, ALT, or bilirubin with the first dose reduction, and the PI agrees, resume abiraterone with the second dose level reduction (500 mg) when AS T, ALT, or bilirubi n returns to 
baseline value or g rade 1. For participants  who resume abiraterone , 
monitor LFTs at a minimum of every 2 weeks for 3 months and monthly thereafter.  
• Grade 4 LFT Abnormalities ( increase in AST or ALT to >  20 x ULN; 
increase in  total bilirubin to > 10 x ULN):  
o Participants must discontinue abiraterone immediate ly and will not 
be re- challenged. They should be followed until resolution of LFT 
abnormalities to ≤  grade 1 or baseline.  
• Concurrent elevation of AST/ALT > 3x ULN with bil irubin >2x ULN 
(unless the concurrent elevation is related to biliary obstruction or other causes unrelated to study treatment)  
o Discontinue abiraterone acetate. No change or consider tapering prednisone if abiraterone acetate discontinued.  
6.2.7 Rash Management  
• Dose modifications for rash are allowed only for apalutamide and are 
summarized in below table.  
• If the skin rash has any component of desquamation, mucosal 
involvement, or pustules, stop dosing with apalutamide, refer to 
dermatologist for evaluation, and a skin biopsy is  recommended (in 
addition to the interventions listed in below Table)  
• If the skin rash is Grade 3 or higher, asking the subject to consent to documentation by a photograph and further evaluation by a dermatologist should also be considered. 
  
Severity  Intervention  
Grade 1  • Continue apalutamide at current dose  
• Initiate dermatological treatmenta 
o Topical steroid cream AND  
o Oral Antihistamines  
• Monitor for change in severitya 
Grade 2 (or symptomatic 
Grade 1)b • Hold apalutamide for up to 28 days         
•  Initiate dermatological treatmenta 
o Topical steroid cream AND  
o Oral Antihistamines  
• Monitor for change in severitya 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
43 o If rash or related symptoms improve, reinitiate 
apalutamide when rash is Grade≤1. Consider dose 
reduction at a 1 dose level reduction.  
Grade ≥3d • Hold apalutamide for up to 28 days  
• Initiate dermatological treatmenta 
o Topical steroid cream AND  
o Oral Antihistamines AND  
o Consider short course of oral steroids  
• Reassess after 2 weeks (by site staff), and if the rash is the 
same or has worsened, initiate oral steroids (if not already 
done) and refer the subject to a dermatologist  
o Reinitiate apalutamide at a 1 dose level reductionc 
when rash is Grade≤1.  
o If the dose reduction will lead to a dose less than 
120mg, the study drug must be stopped 
(disco ntinued)  
• If after 28 days, rash has not resolved to Grade≤1, contact 
Janssen to discuss further management and possible 
discontinuation of study drug.  
  
Note: Rash may be graded differently according to the type of rash and associated symptoms. 
For example, maculo -papular rash is graded by body surface area covered and not severity of the 
rash. Please consult NCI -CTCAE Version 4.03 for specific grading criteria for other types of 
rash.  
a Obtain bacterial/viral cultures if infection is suspected  
b Subject presents with other rash related symptoms such as pruritus, stinging, or burning 
c If a subject previously started oral corticosteroids, continue for at least 1 week after 
resumption of reduced dose of apalutamide. If the proposed total oral steroid use will exceed 28 days, contact Janssen.  
d If there is blistering or mucosal involvement, stop apalutamide dosing immediately and 
contact Janssen  
6.3 Dose Modifications/Delays  
 Instructions on management (including dose modifications and delays) of treatment 
related toxicitie s > grade 2 (NCI CTCAE version 4) are detailed in section 6.2 . 
Instruction s on management of abiraterone  treatment related toxicities including  
hypertension, hypokalemia , and LFT abnormalities  are detailed in section 6.2 .  
 There are no d ose modifications for leuprolide and prednisone .  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
44 7. DRUG FORMULATION AND ADMINISTRATION  
7.1 Apalutamide  
7.1.1 Description  
Name:  Apalutamide  
Chemical Classification: Non -steroidal anti- androgen  
Chemical Name: (4 -[7-(6-cyano -5-trifluoromethylpyridin -3-yl)-8-oxo-6-
thioxo-5,7-diazaspiro[3.4]oct -5-yl]-2-fluoro -N-methylbenzamide)  
Molecular Formula: C 21H15F4N5O2S 
Molecular Weight: 477.44 
Appearance: White to off -white powder  
7.1.2 Form  
The tablet formulation of apalutamide  is an immediate release oral tablet 
containing 60- mg of drug substance, with a non- functional green film coat. 
Each 60 -mg tablet contains the following inactive ingredients: hydroxypropyl 
methylcellulose acetate succinate (HPMC -AS), colloidal anhydrous si lica, 
croscarmellose sodium, microcrystalline cellulose, silicified microcrystalline cellulose, and magnesium stearate. Commercially available Opadry® coating powder is used for the film coating, which is comprised of polyvinyl alcohol (partially hydrolyze d), titanium dioxide, polyethylene glycol, talc, and 
colorants iron oxide yellow and iron oxide black (E172).  
7.1.3 Storage and Stability  
Apalutamide  tablets (60 -mg) are packaged in 120- count, 160 cc high- density 
polyethylene (HDPE) bottles with child -resistant closure (CRC) and include 
desiccant. For clinical  formulation -specific and batch -specific storage 
instructions, see the packaging labels.   At the clinical site and at the patient’s 
home, the study drug should be stored at room temperature and protected fro m 
heat and should not  be frozen . Participants should be advised to keep all 
medications out of the reach and out of sight of children. 
7.1.4 Compatibility  
We do not anticipate any excess toxicity combining apalutamide  with 
abiraterone as there are no overlappin g toxicities and no apparent drug -drug 
interactions (either pharmacokinetic or combined inhibition of enzymes in the any of the adrenal steroid synthesis pathways).  
7.1.5 Handling  
There are no specific instructions for handling apalutamide . Study treatment 
must  only be dispensed by a pharmacist or medically qualified staff. Study 
treatment is to be dispensed only to participants enrolled in this study. Once the study treatment is prepared for a participant, it can only be administered to that participant.  
7.1.6 Availability  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
45 Apalutamide  tablets will be provided to each site. Partici pants will be 
provided with a 30- day supply to allow for visits to occur every 28 days with 
a ± 2 day window. Information presented on the labels for investigative 
product will comply with applicable local regulations. Site pharmacist will dispense the study treatment to each participant in accordance with this protocol under the guidelines of the site’s dispensation standard operating procedure.  
7.1.7 Ordering  
Apalutamide  is to be ordered direct ly from Janssen Scientific Affairs, LLC . 
 
7.1.8 Accountability  
Accountability for study treatment is the responsibility of the investigator. The study site must maintain accurate records demonstrating dates and amount of apalutamide received, to whom dispensed ( participant by participant 
accounting), and accounts of any study treatment accidentally or deliberately destroyed. At the end of the study, reconciliation must be made between the amount of study treatment supplied, dispensed, and subsequently destroyed. At 
the time of delivery of study treatment to the site, the investigator, designee, or pharmacist (where appropriate) will confirm that the supplies for the study have 
been received. Th e following information will be confirmed: lot numbers, 
quantities ship ped/delivered, and date of receipt.  
7.1.9 Destruction and Return  
Drug should be destroyed at the site  per each research pharmacy’s drug  
destruction policy . Destruction will be documented in the Drug Accountability 
Record Form.  
7.2 Abiraterone acetate  
 
Refer to the package insert for abiraterone acetate information . 
7.2.1 Description  
The chemical nomenclature of abiraterone acetate  (3β)- 17-(3-pyridinyl) 
androsta -5,16- dien-3-yl acetate Its empirical formula is C26H33NO2 and it 
has a molecular weight of 391.55. Once absorbed after oral administration, abiraterone acetate is rapidly deacetylated and converted to the active form abiraterone.   
 
7.2.2 Form  
Abiraterone acetate 250- mg tablets are ov al, white to off -white and contain 
abiraterone acetate  and compendial (USP/NF/EP) grade lactose monohydrate,  
microcrystalline cellulose, croscarmellose sodium, povidone, sodium lauryl  
sulfate, magnesium stearate, colloidal silicon dioxide, and purified wat er, in  
descending order of concentration (the water is removed during tabletting).  
7.2.3 Storage and Stability  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
46 Pharmacy Storage Requirements  
The study treatment must be stored in a secure area and administered only 
to participants entered into the clinical study  in accordance with the 
conditions specified in this protocol. Bottles of study treatment should be stored at a room temperature between 15º -30º C with the cap kept on tightly 
and should not be refrigerated. Additional information is provided in the abirat erone acetate Investigator’s Brochure.  
 Storage Requirements for the Participant  
Bottles of study treatment should be stored at room temperature with the cap kept on tightly and should not be refrigerated. Participants should be advised to keep all medications out of the reach and out of sight of children.  
7.2.4 Compatibility  
We do not anticipate any excess toxicity combining apalutamide , abiraterone 
acetate, prednisone and leuprolide . There are no overlapping toxicities and no 
apparent drug -drug interactions (either pharmacokinetic or combined 
inhibition of enzymes in the any of the adrenal steroid synthesis pathways).  
7.2.5 Handling  
Study treatme nt must only be dispensed by a pharmacist or medically 
qualified staff. Study treatment is to be dispensed only to participants enrolled in this study. Once the study treatment is prepared for a participant, it can only be administered to that participant.  
 
7.2.6 Pregnancy  
Abiraterone may cau se fetal harm when administered to a pregnant woman.  
Abiraterone is contraindicated in women who are or may become pregnant. Women who are pregnant or who may be pregnant should wear gloves if they need to touch abiraterone acetate tablets. This medicine may cause harm to the unborn child if taken by women who are pregnant. It should not be taken by women who are breast -feeding.  If abiraterone is used during pregnancy, or if 
the participant becomes pregnant while taking this drug, the participant should be apprised of the potential hazard to the fetus. Study staff and caregivers should be notified of this information, to ensure the appropriate precautions are taken.  
7.2.7 Availability  
Abiraterone acetate tablets will be provided to each site. Participants will b e 
provided with a 30- day supply to allow for visits to occur every 28 days with 
a ± 2- day window. Information presented on the labels for investigative 
product will comply with applicable local regulations. Site pharmacist will dispense the study treatment  to each participant in accordance with this 
protocol under the guidelines of the site’s dispensation standard operating procedure. The agent is supplied and will be provided free -of-charge.   
7.2.8 Ordering  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
47 Abiraterone acetate is to be ordered directly from Jans sen Scientific Affairs, 
LLC . 
7.2.9 Accountability  
Accountability for study treatment is the responsibility of the investigator.  
 
The study site must maintain accurate records demonstrating dates and 
amount of abiraterone acetate received, to whom dispensed (par ticipant by 
participant accounting), and accounts of any study treatment accidentally or deliberately destroyed. At the end of the study, reconciliation must be made between the amount of study treatment supplied, dispensed, and subsequently destroyed.  
 At the time of delivery of study treatment to the site, the investigator, 
designee, or pharmacist (where appropriate) will confirm that the supplies for the study have been received. This following information will be confirmed: lot numbers, quantities shipped/delivered, and date of receipt.  
7.2.10  Destruction and Return  
Drug should be destroyed at the site, after the sponsor –investigator approves 
the drug destruction policy at the site. Destruction will be documented in the Drug Accountability  Record Form . 
7.3 Predniso ne 
7.3.1 Description  
Prednisone is a corticosteroid. 
7.3.2 Form  
Prednisone 5- mg tablets are small, white tablets.  
7.3.3 Storage and Stability  
Prednisone will be prescribed by prescription and prescriptions may be filled at a pharmacy chosen by the participant.  
7.3.4 Compatibility  
We do not anticipate any excess toxicity combining apalutamide , abiraterone 
acetate, prednisone and leuprolide . There are no overlapping toxicities and no 
apparent drug -drug interactions (either pharmacokinetic or combined 
inhibition of enzymes in the any  of the adrenal steroid synthesis pathways).  
 
7.3.5 Handling  
 There are no specific instructions for handling prednisone. 
 
7.3.6 Availability  
Prednisone will not be provided by the study and will be prescribed by standard prescriptions.  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
48 7.4 Leuprolide  
7.4.1 Description  
Leupro lide is a LHRH agonist . 
7.4.2 Form  
Leuprolide is a sterile solution administer ed as an intramuscular injection .  
7.4.3 Storage and Stability  
Leuprolide will be stored at the site specific pharmacy .  
7.4.4 Compatibility  
We do not anticipate any excess toxicity combining apalutamide, abiraterone 
acetate, prednisone and leuprolide . There are no overlapping toxicities and no 
apparent drug -drug interactions (either pharmacokinetic or combined inhibition 
of enzymes in the any of the adrenal steroid synthesis pathways).  
7.4.5 Handli ng  
There are no specific instructions for handling leuprolide . 
7.4.6 Availability  
Leuprolide  is commercially available and will be ordered by the institution’s 
pharmacy . 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
49 8. CORRELATIVE  STUDIES  
8.1 Correlative Studies Background  
 
PTEN and the PI3K Pathway  
The PTEN ge ne is a tumor suppressor that encodes a protein phosphatase recurrently 
mutated in cancer. PTEN activity removes a phosphate from phosphoinositides at the plasma membrane and negatively regulates the PI3K –AKT –mTOR. Thus, either loss 
or inactivation of PTEN  genes leads to PI3K pathway activation.  Genomic evidence 
of PTEN loss in prostate cancer through point mutation, deletion, or rearrangement has been observed in at least 50% of metastatic CRPCs. Interestingly, recent studies have demonstrated a relationship for ERG fusions and androgen signaling with PTEN loss, suggesting that PTEN loss and ETS fusions are not mutually exclusive events. Additionally , preclinical models have  demonstrated cross -talk between the PI3K 
pathway and AR signaling axis and regulati on via reciprocal feedback.
53  We 
hypothesize the PTEN loss may be a mechanism of intrinsic resistance to androgen ablation.  Whole Exome and Transcriptome Sequencing  
Considerable evidence now exits that prostate cancer, like all malignancies, is a genomic disease. Understanding the genetic basis of prostate cancer is therefore crucial for the creation of more powerful preventative interventions, diagnostics, and target ed therapies. The prevalence of genomic aberrations in clinically meaningful 
prostate cancer raises the hypothesis that such changes may influence the castration -
resistant phenotype.  
The initial pilot study representing the first whole genome sequencing a nalysis of 
primary human prostate cancer consisted of radical prostatectomy specimens from seven patients with high -risk primary tumors.
59 This analysis showed that several 
tumors contained complex chains of balanced rearrangements that occurred within or adjacent to known cancer genes. Rearrangement breakpoints were enriched near open chromatin, AR, and ERG DNA binding sites in the setting of the ETS gene fusion TMPRSS2 -ERG, but inversely correlated with these regions in tumors lacking ETS 
fusions. Three tumors contained rearrangements that disrupted CADM2 and four harbore d events disrupting either PTEN, a prostate tumor suppressor, or MAG12, a 
PTEN interacting protein.  
To gain insights into the genomic alterations that may underpin lethal prostate cancer, 
we plan to perform whole exome and transcriptome  characterization of prostate tumor 
samples  (obtained from fresh- frozen tissue at pretreatment biopsy and RP)  and their 
matched normal counterparts (from whole blood obtained from the same patient).  For control purposes, blood will be assessed for germline DNA.  This will be 
accomplished by paired -end, massively parallel sequencing of tumor and normal 
DNA using the Illumina platform.  
   
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
50 AR Signaling Axis  and Serum Hormones and Hormone Levels  
Although effective CYP17 inhibition by abiraterone represents a si gnificant advance 
in the treatment of metastatic CRPC, studies of resistance mechanisms to abiraterone 
provide the rational for adding antiandrogen therapy. In vitro, abiraterone  treatment 
increases CYP17 expression, AR expression, and expression of AR spl ice variant . 
Based on preclinical models of enzalutamide resistant cell lines, researchers have identified a novel missense mutation in the AR ligand -binding domain (F876L) that 
confers agonistic activity to enzalutamide . This mutation is hypothesized to drive 
phenotypic resistance. Additionally, in preclinical models splice variant AR expression driven by AR gene rearrangements demonstrated resistance to enzalutamide given activity as independent effectors of the AR transcriptional program. Other postulate d mechanisms of castration resistance  include aberrant AR 
co-regulators leading to altered AR transcriptional activity and cross -talk with 
alternative signaling pathways, including the PI3K/Akt/mTOR and RAS/MAPK pathways .  
 ctDNA  
There is an unmet clinical  need for reliable biomarkers that can be used for early 
detection of cancer recurrence and to guide therapy. Detecting ctDNA in plasma or serum could serve as a ‘liquid biopsy’, which would be useful for numerous diagnostic applications. Use of such a liquid biopsy delivers the possibility of taking repeated blood samples, consequently allowing the changes in ctDNA to be traced during the natural course of the disease or during cancer treatment. The physiological events that lead to the increase of ctDNA d uring cancer development and progression 
are still not well understood. However, analyses of ctDNA will allow for the detection of tumor -related genetic and epigenetic alterations that are relevant to cancer 
development and progression. We and others have previously shown that detection of ctDNA is feasible.
60,61 In a study of 640 patients with various types of cancer, ctDNA 
was identified in >75% of cases. We have thus far been able to detect ctDNA in post RP patients treated on our previously mentioned abiraterone neoadjuvant study.  
 Multiparametric Prosta te MRI  
We previously conduc ted a pilot study to investigate multiparametric MRI as a 
biomarker for predicting response to neoadjuvant hormone therapy with enzalutamide +/- leuprolide + dutasteride for high- risk localized prostate cancer undergoing 
prostate ctomy. From this small pilot study of 8 patients, we demonstrated that at 
baseline, there was a significant difference in mpMRI parameters in areas of tumor versus normal tissue. Following neoadjuvant therapy, t here was no significant change 
in diffusion parameters in response to therapy, but a significant change in parameters derived from dynamic contrast imaging (DCE), which may indicate a decrease in neovascularity and perfusion, but no significant change in cellular density.  Using 
Spearman’s rank correl ation, there was a significant correlation between tumor volume 
on post -treatment MRI ( Apparent diffusion coefficient (ADC), T2 , and Dynamic 
contrast -enhanced ( DCE )) and pathology volume, indicating that multiparametric MRI 
post-therapy may be useful to pr edict tumor volume at prostatectomy . Using Wilcoxon 
means for difference in volumes, there was no significant difference between 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
51 pathology volumes and multiparametric MRI volumes. There was a significant 
moderate- large correlation between quantitative DCE parameters of the post -treatment 
MRI and RCB: mean AUC (Spearman correlation of 0.79, p=0.028) and mean Ktrans (Spearman correlation of 0.76, p=0.037). There was also a strong negative correlation between minimal ADC 500 value in the post -treatment MR and RCB (r= -0.91, 
p=0.0046). Again, this may indicate that multiparemteric MRI indices may be useful for predict ing the RCB at prostatectomy .  
 
Sequencing of Germline DNA for assessment of Aberrations  in Homologous 
Recombination Genes  
Pritchard and colleagues reported on the germline DNA analysis of 692 men with documented metastatic prostate cancer who were unselected for family history of cancer or age at diagnosis. Germline DNA was isolated and multiplex sequencing assays were used t o assess mutations in 20 DNA -repair genes associated with autosomal dominant 
cancer -predisposition syndromes. These genes included: ATM, ATR, BAP1, BARD1, 
BRCA1, BRCA2, BRIP1, cHek2, FAM17A, GEN1, MLH1, MRE11A, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, RAD51D, XRCC2 . A total of 84 germline DNA -repair 
gene mutations that were presumed to be deleterious were identified in 82 men (11.8%); mutations were found in 16 genes, including BRCA2 (37 men [5.3%]), ATM (11 [1.6%]), CHEK2 (10 [1.9% of 534 men with data]), BRC A1 (6 [0.9%]), RAD51D (3 
[0.4%]), and PALB2 (3 [0.4%]). Mutation frequencies did not differ according to whether a family history of prostate cancer was present or according to age at diagnosis. Overall, the frequency of germline mutations in DNA -repair genes among men with 
metastatic prostate cancer significantly exceeded the prevalence of 4.6% among 499 men with localized prostate cancer (P<0.001), including men with high -risk disease.  
 For this work, next -generation targeted sequencing of germline DNA will be performed 
using the Illumina T ruSight Cancer Sequencing Panel 
(http://www.illumina.com/products/trusight_cancer.html). The panel includes 94 genes, 35 of which have been identified as bein g involved in human DNA repair . Libraries will 
be created us ing 50ng germline DNA and sequenced by Illumina MiSeq platform using 
PE150 chemistry, according to the manufacturer’s instructions. To identify genomic variants we will use two independent commonly used standard vari ant calling pipelines 
(GATK and samtools /bcftools ). Bowtie2 aligner will be applied. Alterations will be 
visualized by IGV tool and validated by Sanger Sequencing.  
  
8.2 Correlative Studies Methodologies  
Detailed methodologies regarding sample collection, processing, storing, shipment and analytical  methodologies are detailed in the study laboratory manual. Please refer 
to this document for specific details regarding the specifics of the correlative laboratory procedures.  
    
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
52 PTEN and the PI3K Pathway  
During this study, we will use IHC analysis to assess PTEN expression in 
pretreatment prostate biopsies and RP specimens to determine whether PTEN status (loss or no loss) is associated with pathological response.   IHC will be performed for the following targets on archival prostate biopsies and FFPE RP specimens at Center for Molecular Oncologic Pathologies  (CMOP )/DFCI: 
AR, apoptosis markers, WNT signaling, PTEN -PI3K -AKT pathway, PSA , ERG, and 
Ki67. Scoring systems will be specific to each target scored, and will follow the 
accepted quantitative and qualitative system for each target . 
 Whole Exome and Transcriptome Sequencing  
To gain insights into the genomic alterations that may underpin lethal prostate cancer, we plan to perform whole exome and transcrip tome  characterization of prostate tumor 
samples  (obtained from fresh- frozen tissue at pretreatment biopsy and RP)  and their 
matched normal counterparts (from whole blood obtained from the same patient).  For control purposes, blood will be assessed for ger mline DNA.  This will be 
accomplished by paired -end, massively parallel sequencing of tumor and normal 
DNA using the Illumina platform.  This will be performed at the Broad Institute.  
 Upon completion of 24 weeks of neoadjuvant therapy, participants will undergo RP according to each institution’s policy. The on -treatment samples will be collected on 
the day of operation with the last dose of oral medications for Part 1 taken the day prior to the operation.  Coordination efforts with the interventional radiol ogy and 
pathology teams will vary depending on the institution.  
  Whole Blood for Germline DNA  
Collection  
1. Five (5) mL of blood will be drawn into purple top vacutainers with EDTA. Gently invert tubes 8- 10 times. DO NOT  use heparin as anticoagulant, since the polymer 
will tightly bind downstream PCR enzyme during sequencing.  
2. Immediately transfer the blood into 5 cryovails (1 mL per cryovial) and store in -
80⁰C.   
 Storage  
 Store at - 80ºC  until shipment in batches togethe r with matching tissue specimens.   
 The whole blood should be shipped to CMOP following the RP and preferably with 
 RP tissue.   
 Shipment  
Whole blood and matching tissue specimen should be shipped together to CMOP. 
This specimen will be shipped on dry ic e by express overnight courier. Shipping 
reservations must be made to allow delivery, prior to 2:00 PM next day, delivery on Tuesday through Friday. Call the receiving laboratory the day prior to shipping to confirm plan for receipt. Do not ship on Friday as there is no weekend coverage in the laboratory and the frozen samples should not sit in transit over a weekend.  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
53  
CMOP will receive the “Blood for Germline DNA/RNA” and store it at labeled 
conditions (i.e - 80 ⁰C) ‘as is’ (package intact and unopened), an d will ship this 
package together with RP  tissue specimens to the Broad.  
 
Please see the Study Laboratory Manual for specific instructions.  
 AR Signaling Axis  and Serum Hormones and Hormone Levels  
We hypothesize that following treatment with either treatme nt arm, we will observe 
changes in the AR signaling axis in RP specimens compared to pretreatment biopsy specimens. We will assess the AR axis by assaying serum androgens prior to treatment, during treatment, and prior to RP. Additionally, we will assay tu mor 
androgens from pretreatment biopsy and RP specimens. Additionally, we will perform IHC analysis to include, but not limited to, assessment of the following: AR signaling pathway, steroidogenesis and hormone receptors, DNA repair pathway, PI3K pathways and other  AR and AR -regulated genes (PSA, ERG). 
 Subject samples (including blood and tissue samples) at the time of collection will be handled and procured by a dedicated technician or physician at each study site. Samples processing will be performed by trained technicians or physician at each study site  place by dedicated technicians and physicians. Samples will be processed 
for correlative studies and remaining samples will be stored for future use to include assessment of biological and molecular predi ctive and prognostic biomarkers.
 
Hormone levels assessed will include DHEA, androstenedione, testosterone, DHT, androsterone, progesterone, pregnenolone, deoxycorticosterone, cortisol, and DHEA -
S. 
 Samples will be stored and protected atCMOP .  Multi -center sites will ship samples to 
DFCI on a quarterly or other specified basis as described in the laboratory manual.  Participants will be de -identified by assigning each participant a unique subject ID .  
 Instructions on sample collection and processing are contained in the Laboratory Manual  
 ctDNA  
cfDNA plasma will be drawn into (2) 10mL Streck BCT tubes according to institutional phlebotomy guidelines. Blood collected at DF/HCC sites will be processed in  the Balk lab.  Blood collected at outside sites will be processed in local 
laboratories and then sent to the Balk lab.  Samples will be stored in a - 80°C freezer.  
Plasma for cfDNA will be collected at C1D1, C4D1, Day 170- 179 (+/ - 4 day s) and  q3 
andq6 months following RP.  
 See Study Lab Manual for further instructions regarding specimen and tissue processing.  
 
Multiparametric Prostate MRI  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
54 On this study, we will be performing baseline and post -treatment multiparametric MRI 
and correlating MRI with patholog ic outcomes to determine if this could be a predictor 
of pathologic response to treatment . 
 
Any further future analyses not specified in this protocol or above will be agreed upon by prior approval from Janssen Scientific Affairs, LLC.  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
55 9. STUDY CALENDAR  
 
PART 1  
 
 Pre-Studya Day 1 of Cycle 
1 and Cycle 4 
(+/- 2 days)b  
Every Two 
Weeks for the 
first 3 Cycles  Day 1 of Each Cycle 
(+/- 2 days) Pre-Operative Day 
170-179 (+/ - 14 days)  Day 180  
(+/- 14  days)  
Informed Consent  X      
History and Physicalc X X  X X  
Digital Rectal Examination X   
   
ECOG Performance Status  X X  
X X  
Vital Signsd X X  X X  
Hematologye X X  X X  
Serum Chemistryf X X  X X  
TSHg X X     
Liver Function Testsh X X                                                 
X X X  
Fasting Lipid Panel   X     
Coagulation Factorsi X    X  
EKG X    X  
ECHO or MUGA  X      
Testosterone  X X   X  
Serum Hormonesj  X   X  
Research Samplek  X     
ctDNA  Plasma Sample   X    X  
PSA X X  X X  
Bone Scan  X      
CT or MRI abdomen   X      
Prostate MRI  including 
pelvisl X    X  
Dispense Drugm  X  X   
Administer Leuproliden  X     
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
56 AA and Apalutamide 
Compliance Assessment   X  
X X  
Prior and Concomitant 
Medications X X  
X X  
Adverse Eventso X X  X X  
Prostatectomyp      X 
Request Diagnostic 
Biopsyq X   
   
Quality of Life  and Family  
Questionnairesr  X  
 X  
Randomization  
for Part 2s    
 X  
 a: Baseline evaluations are to be conducted within 30 days prior to registration  with the exception of scans and DREs . Scans  and DREs  may be done within 60 
days prior to registration. All baseline screening should  be done prior to registration.  Note: the treating physician must refer participants to genetic counseling 
within the first year (preferably before RP)  of being on study. This must be documented i n the clinic note and case report forms.  
b: A cycle will be defined as 28 days (+/- 2 days) . Criteria outlined in Section 5.2 must be met prior to treatment on C1D1.  
c: Physical examination should include general description of participant, head, eyes, ea rs, nose, and throat, chest, abdominal, extremities, neurologic, skin, and 
lymph node examination. Any other evaluation is up to the discretion of the practitioner. It will not be considered a violati on if the exam is not described as 
outlined here. Inform ation regarding cardiovascular events to include the following list will be documented pretreatment and prior to RP during Pa rt 1. This 
includes: CAD ( angina, NSTEMI, S TEMI and need for intervention such as stent, CABG) , cardiomyopathy/ heart failure, v alvular heart disease, a rrhythmia 
(defined as need for intervention (cardioversion) or need for new medication), hypertension (defined as need for new medication , peripheral artery disease, 
cerebrovascular disease (d efined by new TIA, CVA )). 
d: Vital signs include upright blood pressure, heart rate, respiratory rate, body temperature, height (baseline only), and we ight.  
e: Hematology testing to include WBC, ANC, hemoglobin, and platelet count.  
f: Serum  or plasma  chemistry to include sodium, potassium, chloride, bicarbonate, BUN, creatinine, glucose, calcium, and magnesium  
g:TSH will be done at screening, day 1 of cycles 1 and 4..  T3 and T4 will be done only if TSH is abnormal at baseline.  
h: Liver function tests to include: albumin, globulin , AST, ALT, alkaline, phosphatase, total bilirubin, and direct bilirubin.  LFTs will be collected every two 
weeks for the first three cycles of treatment and every cycle thereafter. LFTs on day 15 of cycles 1-3 can be completed locally.  Direct bilirubin an d globulin do 
not need to be col lected if labs are done locally or if a participating institution does not collect it.    
i: Coagulation factors to include PT T, PT and INR.  
j: Serum hormones to include DHEA, androstenedione, testosterone, DHT, androsterone, progesterone, pregnenolone, deoxycorticosterone, cortisol, and 
DHEA -S.  
k: Blood for germline DNA. See the Lab Manual for processing instructions. The lab manual is maintained as a separate document.  
l: The baseline MRI will be standard of care; however, the pre -RP MRI will be conducted as research.  The pre -RP MRI is only required for DFCI patients and 
optional for participating site patients .  
m: For Part 1 of the study, participants will be randomize d to treatment with AA + prednisone  + apalutamide + leuprolide or AA + prednisone + leuprolide.  
n: Participants who have started leuprolide within four weeks of cycle 1/day 1 are eligible to enroll. Participants may receive monthly leuprolide.  
o: Adverse events should be collected from the date informed consent is signed until 30 days after discontinuation from the s tudy. SAEs will reported starting 
from the first dose of study drugs.  
p: RP should occur on day 180 (+/ - 14 days). Dosing should c ontinue until 1 day before surgery. Treatment will resume on Cycle 7 Day 1 for Part 2A 
participants.. Preoperative and postoperative evaluation and treatment will be administered as per the instruction of the sur geon.  
q: Tissue from the diagnostic biopsy will be requested (tissue blocks wherever possible; if not possible , 15 unstained slides from each p ositive core sample for a 
total of 45 to be sent to the  central analytical laboratory. See the Lab Manual for processing instructions. Pathology report (inc luding the assessment of the local 
pathologist regarding Gleason score) from diagnostic biopsy must accompany registration materials.   
r: The EPIC -26 with 2 additional questions will be used to evaluate quality of life parameters (see Appendix G).  The Fami ly Questionnaire only needs to be 
completed at C1D1 (see appendix H).  
s: The study team will randomize participants to their Part 2 assignments after RP but before cycle 7 day 1. Participants wil l not need to re -meet eligibility 
criteria prior to Part 2 r andomization. Part 2 will commence within 28 days post -RP (Cycle 7 Day 1).  Participants who do not get randomized to part 2 will 
follow  the 2B arm.   
 
 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
57  
 
PART 2A  
 Year 1 (Adjuvant Treatment)  
(Cycle length 28 days) (+/ - 2 days)  Year s 2-3 (Follow -up) 
 Years 4-5 
(Follow -up)  
 Day 1 of 
Cycle s 7-
18a Cycle 7, 10 , 
13, and 16  Cycle 13 End of 
Treatment ( 1 
year post -RP) Every 3 
Months  
(+/-1 
month)  
2 years p ost-
RP (+/-1 
month) Every 6 
Months  (+/-
1 month)b 
History and Physica lc X X X X X X  
ECOG Performance 
Status  X X X X X X  
Vital Signsd X X X X X X  
Hematologye X X X X    
Serum Chemistryf X X X X    
Liver Function Testsg X X X X   
   
TSHh  X  X    
Fasting Lipid Paneli  X X X X X  
Testosteronej     X X X 
Serum Hormonesk   X X  X  
ctDNAl Plasma 
Sample   X X X X X X 
PSAm X X X X X X X 
Dispense Drugn X X X     
Administer 
Leuprolide  X X     
AA and Apalutamide  
Compliance 
Assessment  X X X X  
  
Prior and 
Concomitant 
Medications X X X X  
  
Adverse Eventso X X X X    
Intra -Operative/Post -
Operative 
Complicationp Xp (Cycle s 7 
and 10 Day 1 
only)  Xp (Cycle s 7 
and 10 Day 1 
only)     
  
Quality of Life 
Questionnairesq    X X  
X  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
58 a: A cycle will be defined as 28 days (+/- 2 days) . During Part 2 of the study, patients randomized to further adjuvant therapy will be seen once 
every cycle for 12 cycles until end of treatment. Cycle 7 Day 1 will take place 28 days (+/- 5 days)  post-RP.  All following visits will depend 
upon when the first visit post -RP occurred . Note: the treating physician must refer participants to genetic counseling within the first year 
(preferably before RP) of being on study. This must be documented in th e clinic note and case report forms.  
b: After completion of adjuvant therapy on Part 2A of the study, all patients will be followed every 3 months (+/ - 1 month) for years 2 -3. Follow 
up will take place every 6 months (+/ - 1 month) during  years 4-5 post-RP. During years 4 -5 post -RP, assessments may be done locally , and 
information may be collected via medical record review. It is recommended that testosterone continue to be checked (q3 cycles) until normalized 
according to institutional range.  
c: Physical examination should include general description of participant, head, eyes, ears, nose, and throat, chest, abdominal,  extremities, 
neurologic, skin, and lymph node examination. Any other evaluation is up to the discretion of the practitioner. It wi ll not be considered a 
violation if the exam is not described as outlined here. Information regarding cardiovascular events to include the following list will be 
documented during Part 2 every 3 months (+/ - 1 month) for 3 years post -RP, and then every 6 months (+/ - 1 month) for up to 5 years post -RP. 
This includes: CAD ( angina, NSTEMI, S TEMI and need for intervention such as stent, CABG) , cardiomyopathy/ heart failure, v alvular heart 
disease , arrhythmia (defined as need for intervention (cardioversion) or need for new medication), hypertension (defined as need for new 
medication ), peripheral artery disease, cerebrovascular disease (d efined by new TIA, CVA ). 
d: Vital signs include upright blood pressure, heart rate, respirator y rate, body temperature, height  (C7D 1 only) , and weight. During the follow up 
period, BMI (weight in Kg/height in m2) will collected every 3 months (+/ - 1 month) 2-3 post -RP and then every 6 months (+/ - 1 month) during 
years 4 -5 post -RP.  
e: Hematology te sting to include WBC, ANC, hemoglobin, and platelet count.  
f: Serum  or plasma  chemistry to include sodium, potassium, chloride, bicarbonate, BUN, creatinine, glucose, calcium, and magnesium.  
g: Liver function tests to include albumin, AST, ALT, alkaline phosphatase, total bilirubin, and direct bilirubin . Direct bilirubin and globulin do 
not need to be collected if labs are done locally or if a participating institution does not collect it.    
h: TSH will be done at Cycle 7 Day 1, Cycle 13 Day 1 and End of  Treatment .  T3 and T4 will be done only if TSH is abnormal at baseline.  
i: A fasting lipid will be collected every 3 cycles  (+/- 2 days) for year 1 and every 6  months  (+/- 1 month) for year s 2-3. Fasting is defined as no 
food or liquids except for water f or 8 hours.  
j: Testosterone will be checked in follow -up every 3 months (+/ - 1 month) for the years 2 -3 post -RP and then every 6 months  (+/- 1 month) for 
years 4 -5 post -RP until recovery to the institutional normal range.  
k: Serum hormones to include DHE A, androstenedione, testosterone, DHT, androsterone, progesterone, pregnenolone, deoxycorticosterone, 
cortisol, and DHEA .-S 
l: ctDNA will be collected at all time points that PSA is collected  during years 1 -3 post -RP. It is recommended that study teams collect ctDNA 
plasma samples from participants whenever long -term follow -up assessments are conducted at the research site during years 4 -5, if possible.  
m: PSA will be collected every cycles (+/ - 2 days) for year 1 and every 3 months (+/ - 1 month) for yea rs 2-3 and th en every 6 months (+/- 1 
month ) for up to 5 years post -RP. 
n: For Part 2 of the study, participants will be randomized to AA + prednisone +  apalutamide + leuprolide versus no further treatment.  
o: Adverse events should be collected from the date informed consent is signed until 30 days after discontinuation from treatment .  
p: Intra -operative and peri -operative (hospital course) complications will be collected via questionnaire (see Appendix E)  at Cycle 7 Day 1 . Post -
operative complications wi ll be captured via the C lavien classification  (Appendix F).  The post -operative complications will be collected at Cycle 
7 Day 1  and Cycle 10 Day 1 post -operatively.  
q: The EPIC -26 with 2 additional questions will be used to evaluate quality of life parameters (see Appendix G).  
 
 
 
 
 
 
 
 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
59  
PART 2B  
 Year 1 ( NO Adjuvant Treatment)  
(Cycle length 28 days) ( every 3 cycles  +/- 2 weeks ) Year s 2-3 (Follow -up) 
Every 3 months (+/- 1 month ) Years 4-5 
(Follow -up)  
 Day 1 of cycle 7, 
10,13, 16 Post-RP a Cycle 13  End of 
Treatment ( 1 
year post -RP)  Every 3 
Months  (+/- 1 
month) 2 years p ost-RP 
(+/- 1 month)  Every 6 
Months  (+/- 1 
month)b  
History and Physicalc X X X X X  
ECOG Performance 
Status  X X X X X  
Vital Signsd X X X X X  
Hematologye X X X    
Serum Chemistryf X X X    
Liver Function Testsg X X X    
Fasting Lipid Panelh X X X X X X 
Testosteronei X X X X X X 
Serum Hormonesj  X X  X  
ctDNA Plasma 
Samplek X X X X X X 
PSAl X X X X X X 
Prior and Concomitant 
Medications X X X    
Adverse Eventsm X X X    
Intra -Operative/Post -
Operative 
Complicationn X (Cycle 7 Day 1 and 
Cycle 10 Day 1 only)     
  
Quality of Life 
Questionnaireso  X X  
X  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
60 a: A cycle will be defined as 28 days (+/- 14 days) . Patients randomized to no further adjuvant treatment will be seen once every 3 months 
beginning at cycle 7. Cycle 7 Day 1 will take place within 28 days (+/ - 5 days)  post-RP.  All following visits will depend upon when the first visit 
was post -RP. Note: the treating physician must refer participants to genetic counseling within the first year (preferably before RP) of being on 
study. This must be documented in the cli nic note and case report forms.  
b: Participants in Part 2B will be followed every 3 cycles  (+/- 2 weeks ) for the first 1 year, every 3 months (+/ - 1 month) for ears 2-3 and then 
every 6 months (+/ - 1 month for up to 5 years  post-RP during which time assess ment may be done  locally and information may be collected via 
medical record review.   It is recommended that testosterone continue to be checked until normalized according to institutional range.  It is also 
recommended that study teams collect c tDNA plasma samples from participants whenever PSA blood tests occur and whenever long -term follow -
up assessments are conducted at the research site, if possible.  
c: Physical examination should include general description of participant, head, eyes, ears, nose, and t hroat, chest, abdominal, extremities, 
neurologic, skin, and lymph node examination. Any other evaluation is up to the discretion of the practitioner. It will not b e considered a violation 
if the exam is not described as outlined here. Information regarding  cardiovascular events to include the following list will be documented during 
Part 2 every 3 cycles (+/ - 2 weeks) for year 1, every 3 months (+/ - 1 month) for years 2-3 and then every 6 months (+/ - 1 month) for up to 5 years 
post-RP. This includes: CAD ( angina, NSTEMI, S TEMI and need for intervention such as stent, CABG) , cardiomyopathy/ heart failure, v alvular 
heart disease , arrhythmia (defined as need for intervention (cardioversion) or need for new medication), hypertension (defined as need for new 
medic ation ), peripheral artery disease, cerebrovascular disease (d efined by new TIA, CVA ). 
d: Vital signs include upright blood pressure, heart rate, respiratory rate, body temperature, height  (C7D1 only) , and weight. During the follow up 
period, BMI (weight in  Kg/height in m2) will collected every 3 cycles (+/ - 2 weeks) for year 1, every 3 months (+/ - 1 month) for years 2- 3 and then 
every 6 months (+/ - 1 month) for up to 5 years post -RP.  
e: Hematology testing to include WBC, ANC, hemoglobin, and platelet count .  
f: Serum  or plasma  chemistry to include sodium, potassium, chloride, bicarbonate, BUN, creatinine, glucose, calcium, and magnesium.  
g: Liver function tests to include albumin, AST, ALT, alkaline phosphatase, total bilirubin, and direct bilirubin.  Direct bilirubin and globulin do 
not need to be collected if labs are done locally or if a participating institution does not collect it.   
h: During Part 2B, fasting lipid will be collected every 3 months  (+/- 2 weeks) for year 1  and every 6 months (+/ - 1 mont h) for years 2 -3. Fasting is 
defined as no food or liquids except for water for 8 hours.  
i: Testosterone will be checked in follow -up every 3 cycles (+/ - 2 weeks) for year 1, every 3 months (+/ - 1 month) for years 2-3 and then every 6 
months (+/ - 1 month)  for up to 5 years post -RP until recovery to the institutional normal range.  
j: Serum hormones to include DHEA, androstenedione, testosterone, DHT, androsterone, progesterone, pregnenolone, deoxycorticosterone, 
cortisol, and DHEA -S. 
k: ctDNA will be colle cted whenever PSA blood draws are being collected during years 1 -3 post -RP.  During years 4 -5 post -RP, when follow -up 
assessments may be done locally, ctDNA is recommended only if follow -up assessments are being conducted at the research clinic conducting the 
study.  
l: PSA will be collected every 3 cycles (+/ - 2 weeks) for year 1, every 3 months (+/ - 1 month) for years 2-3 and then every 6 months (+/ - 1 month) 
for up to 5 years post -RP. 
m: Adverse events should be collected from the date informed consent is signed until 30 days after RP.  
n: Intra -operative and peri -operative (hospital course) complications will be collected via questionnaire (see Appendix E) at Cycle 7 Day 1. Post -
operat ive complications will be captured via the C lavien classification  (Appendix F). The post -operative complications will be collected at Cycle 7 
Day 1 and Cycle 10 Day 1 post -operatively.  
o: The EPIC -26 with 2 additional questions will be used to evaluate quality of life parameters (see Appendix G).  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
61 10. MEASUREMENT OF EFFECT  
 
10.1 Primary Variable  
Pathological Response  (Part 1) : The primary efficacy measure is pathological 
response, defined as achieving   either pCR or  MRD  at RP . pCR is defined as the 
absence of morphologically identifiable carcinoma in the RP specimen. MRD  will be 
defined as residua l tumor in the RP specimen measuring ≤  5 mm. If the tumor is 
multifocal, the size of the largest focus will be used to determine the  size of the 
residual tumor. RP specimens will initially be evaluated by the site pathologist using standard methods. Prostate biopsy specimens will be evaluate d by central pathology 
review at completion of the study.  
 Biochemical Progression Free Surviva l (bPFS) (Part 2) : The primary efficacy 
measure is the rate of 3 -year biochemical progression -free survival (bPFS).  bPFS will 
be defined as the time from the date of randomization to the date of first evidence of disease progression (defined below) or deat h from all causes, censored at the date of 
last disease follow -up 
− Biochemical failure (defined as a serum PSA ≥0.2 ng/mL, which is confirmed by a second determination with a PSA ≥0.2 ng/Ml, according to the 2007 American 
Urological Association Prostate Guidelines ). It is expected that the majority of 
patients will relapse biochemically with a rising PSA.  
− Any new evidence of metastatic disease based on bone or CT/MRI scan.  
− Local recurrence in prostate bed  as demonstrated on CT/MRI scan . 
− Treatment with post -operative radiotherapy for a rising PSA or adjuvant radiation 
initiated more than 6 months following surgery . 
10.2 Secondary Variables  
Pathologic Outcomes : RCB will be calculated as tumor volume x percent cellularity. 
A favorable RCB is defined as the 33rd percentile of the RCB index . Tumor volume 
and percent cellularity will be  evaluated by central pathology  review at completion of 
the study. Cribriform or intraductal spread will be evaluated by central pathology review at the completion of the study. At t he time of RP, pathologic specimens will be 
assessed for positive surgical margins, extracapsular extension, positive seminal vesicles, and positive lymph nodes, which will be determined by each site pathologist.   PSA Kinetics prior to RP : PSA kinetics pr ior to RP include nadir value, achieving 
nadir PSA < 0.2 ng/mL, achieving 50% or  achieving 90% decrease in PSA from 
baseline, and time to PSA nadir.  
 Safety and Tolerability: CTCAE version 4 will be used to characterize toxicity during treatment.  
 Peri-Operative and Post -Operative Complications:  Peri-operative and post -
operative complications will be determined via questionnaires  that will be completed at 
time of surgery, at discharge and in the post -operative  period. The Clavian 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
62 Classification will be use d to determine post -operative complications and will be 
collected at 30 and 90 days post -operatively.  
 
Quality of Life:  The Expanded Prostate Cancer Index Composite ( EPIC -26) with 2 
additional questions will be used to evaluate quality of life parameters . This will be 
completed by the patient pretreatment, prior to RP, and every 3 months for 2 years post-RP. 
 Body- Mass Index, Lipids, and Cardiovascular Events:  Weight, height, fasting lipid 
panel, and cardi ovascular events will be collected.   
 Serum Hormone  Levels : Pregnenolone, progesterone, deoxycorticosterone, cortisol, 
DHEA, DHEA- S, androstenedione, testosterone, DHT , androsterone  will be assessed 
at baseline, during treatment, prior to RP  and post -RP. Hormones will be assayed by 
mass spectroscopy . Additionally, testosterone  levels will be checked by routine 
laboratory at baseline and every 3 months until recovery. Recovery will be defined as a testosterone level > 2 00 ng/dL.  
 Prostate Hormone  Levels:  DHEA, DHEA- S, androstenedione, testosterone, DHT will 
be assayed from pretreatment prostate biopsy and RP specimens by mass spectroscopy.  
 Ki-67 Expression:  Ki-67 expression will be assessed by IHC staining. This will be 
scored on the percentage of cells that display nuclear staining for Ki67.  
 AR and AR- Regulated Gene Expression:  AR and AR -regulated gene (PSA, ERG) 
expression will be assessed by IHC staining. This will be scored based on the percentage of cells staining for the specific protein and the i ntensity of the staining.  
 PTEN Status: PTEN status (loss versus presence) will be assessed by IHC staining via a dichotomous scoring system. Staining will be classified as negative if the intensity was markedly decreased or entirely negative across tumor  cells  (either all cells or  if 
>5% cells are negative/markedly reduced) compared with the surrounding benign glands and/or stroma.  
 ctDNA: Blood will be collected for ctDNA and will be pro cessed in the Balk 
Laboratory. Plasma will be used to extract ctDNA.  DNA will be analyzed using PCR 
and will be compared to genome analysis of residual primary tumor. The PCR will be will be based on patient specific mutations identified from sequencing the primary tumors. Emergence of specific ctDNA alterations will be co rrelated with disease 
progression.  
 Whole Exome and Transcriptome Sequencing:  Whole exome and transcriptome 
sequencing will be performed at the Broad Institute Sequencing platform, which has vast experience in cancer sequencing. Following sequencing, exome  data will be 
analyzed for somatic mutations, insertions and deletions, and copy number alterations using established pipelines at the Broad Institute. Transcriptome data will be analyzed 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
63 for overexpressed genes, chimeric transcripts (possibly indicative of structural genomic 
rearrangements), and alternatively spliced variants. Sequencing information will be analyzed using novel computations algorithms, which have been developed at the Broad Institute.   Quantitative MRI : From T2, ADC and DCE MR sequences, quantitative parameters 
will be extracted from all loci within a lesion. The attributed PI -RADS score from each 
MR sequence and the final overall PI -RADS score (1 -5 scale: 1 -normal, 5 -definite 
cancer) will be recorded for each lesion per ESUR 2012 guideline  
 
11. ADVERSE EVENT REPORTING REQUIREMENTS
 
11.1 Overview  
As the sponsor of the Study, DFCI  and Mary -Ellen Taplin, MD  shall be solely responsible 
for complying, within the required timelines, any safety reporting obligation to competent 
Health Authorities, IRB/ECs and any participating (co or sub) investigators, as defined in applicable laws and regulations.  S afety data includes adverse events, product quality 
complaints (PQCs), and special situations including pregnancies.  
The DFCI  and Mary -Ellen Taplin, MD  will provide safety information  to Janssen  on adverse 
events, special situations including pregnancies and product  quality complaints.  
11.2 Management of Safety Data  
This Study has been designated as an interventional study.  As such, all adverse events 
regardless of causality and special situations excluding those from subjects not exposed to a 
Janssen Medicinal Product  and product quality complaints with or without an adverse event 
as described in this Exhibit will be reported from the time a subject has signed and dated an Informed Consent Form (ICF) until completion of the subject’s last study -related procedure 
(which may include contact for follow -up safety).  Serious adverse events will be reported 
for 30 days after the last dose of study drug.  
 For the purposes of this study, the Janssen medicinal product is:  
  
Apalutamide  (56021927, Apalutamide)  
Abiraterone acetate  
11.3 Definitions  
11.3.1  Adverse Events ( AEs) 
An adverse event  (AE) is any untoward medical occurrence in a clinical study 
subject administered a medicinal (investigational or non- investigational) 
product. An AE  does not necessarily have a causal relationship with the 
treatment. An AE  can therefore be any unfavorable and unintended sign 
(including an abnormal finding), symptom, or disease temporally associated 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
64 with the use of a medicinal (investigational or non - investigational) product, 
whether or not related to that medicinal (investigational or non- investigational) 
product. (Definition per International Conference on Harmonization  [ICH]) 
This includes any occurrence that is new in onset or aggr avated in severit y or 
frequency from the baseline condition, or abnormal results of diagnostic 
procedures, including laboratory test abnormalities. 
 
Adverse Events of Special Interest (AESIs) 
There are no adverse events of special interest identified for apalutamide or abiraterone acetate.  
11.3.2  Individual Case Safety Report (ICSR)  
A valid ICSR must contain the four minimum criteria required to meet regulatory reporting requirements.  
− An identifiable subject (but not disclosing personal information such as the 
subject’s name, init ials or address)  
− An identifiable reporter (investigational site)  
− A Janssen medicinal product  
− An adverse event, outcome, or certain special situations  
 
The minimum information required is:  
− Suspected Janssen medicinal product (doses, indication)  
- Date of therapy (start and end date, if available)  
- Batch or lot number, if available  
- Subject details (subject ID and country)  
- Gender  
- Age at AE onset  
- Reporter ID 
- Adverse event detail (AE verbatim in English), onset date, relatedness, 
causality, action taken, outcom e, (if available)  
- Janssen protocol ID  
11.3.3  Product Quality Complaint (PQC)  
A PQC  is defined as any suspicion of a product defect related to a potential 
quality issue during manufacturing, packaging, release testing, stability monitoring, dose preparation, stora ge or distribution of the product, or 
delivery system.  Not all PQCs involve a subject.  Lot and batch numbers are of high significance and need to be collected whenever available.  
     
 Examples of PQC include but not limited to:  
− Functional Problem: e.g.,  altered delivery rate in a controlled release 
product  
− Physical Defect:  e.g. abnormal odor, broken or crushed tablets/capsules  
− Potential Dosing Device Malfunction: e.g., autoinjector button not working, needle detaching from syringe  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
65 − Suspected Contamination 
− Suspected Counterfeit  
11.3.4  Serious Adverse Event (SAE)  
An SAE based on ICH and EU Guidelines on Pharmacovigilance for 
Medicinal Products for Human Use is any untoward medical occurrence that at 
any dose:  
- Results in death  
- Is life -threatening (The subject was at risk of death at the time of the event. 
It does not refer to an event that hypothetically might have caused death if it were more severe.)  
- Requires inpatient hospitalization or prolongation of existing hospitalization  
- Results in persistent or significan t disability/incapacity  
- Is a congenital anomaly/birth defect  
- Is a suspected transmission of any infectious agent via a medicinal product  
- Is medically important*  
 
*Medical and scientific judgment should be exercised in deciding whether 
expedited reporting is also appropriate in other situations, such as important 
medical events that may not be immediately life threatening or result in death 
or hospitalization but may jeopardize the subject or may require intervention to 
prevent one of the other outcomes lis ted in the definition above. These should 
usually be considered serious
. 
 
NOTE: DEATH FOR ANY REASON SHOULD BE REPORTED AS A 
SERIOUS ADVERSE EVENT.  
Hospitalization  
For reports of hospitalization, it is the sign, symptom or diagnosis which led to the hospit alization that is the serious event for which details must be provided. 
 Any event requiring hospitalization or prolongation of hospitalization that occurs during the study must be reported as a serious adverse event, except hospitalizations for the follow ing: 
• Hospitalizations not intended to treat an acute illness or adverse event (e.g., social reasons such as pending placement in long -term care facility)  
• Surgery or procedure planned before entry into the study. [Note: Hospitalizations that were planned before the start of data collection and where the underlying condition for which the hospitalization was planned has not worsened will not be considered serious adverse events. Any adverse event that results in a prolongation of the originally planned hospitalization is to be reported as a new serious adverse event.]  
 
Life-Threatening Conditions  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
66 The cause of death of a subject in a study within 30- days of the last dose of  
apalutamide  or abiraterone acetate drug, whether or not the event is expected 
or associated with the study drug, is considered a serious adverse event.  
 
Disease progression should not be recorded as an adverse event or serious 
adverse event term; instead, signs and symptoms of clinical sequelae resulting from disease progression/lack o f efficacy will be reported if they fulfill the 
serious adverse event definition.  
11.4 Expectedness  
11.4.1  AEs can be 'Expected' or 'Unexpected.'  
• Expected adverse event  
 
Expected AEs  are those that have been previously identified as resulting 
from administration of the agent. For the purposes of this study, an adverse event is considered expected  when it appears in the current 
adverse event list, the Investigator’s Brochure, the package insert or is included in the informed consent document as a potential risk.   
• Unexpected adverse event  
  
For the purposes of this study, an adverse event is considered unexpected  
when it varies in nature, intensity or frequency from information provided in the current adverse event list, the Investigator’s Brochure, the package insert or when it is not included in the informed consent document as a potential risk.   
11.4.2  Attribution  
Attribution is the relationship between an adverse event or SAE and the study 
treatment. Attribution will be assigned as follows:  
 
• Definite – The AE is clearly related  to the study treatment.  
• Probable – The AE is likely related  to the study treatment.  
• Possible – The AE may be related  to the study treatment.  
• Unlikely -  The AE is doubtfully related to the study treatment.  
• Unrelated - The AE is clearly NOT related  to the study treatment.  
11.5 Unlisted (Unexpected) AE/Reference Safety Information  
 
An AE is cons idered unlisted if the nature or severity is not consistent with the applicable 
product reference safety information. For a medicinal product(s) with a marketing authorization, the expectedness of an adverse event will be determined by whether or not it is listed in the applicable product information.  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
67 For a biraterone acetate, the link to the package insert is   
https://www.zytiga.com/shared/product/zytiga/zytiga -prescribing -information.pdf  
For apalutamide , the expectedness of an adverse event will be determined by whether or 
not it is listed in the Informed Consent Form, which includes the latest risk information  
listed in the Investigator’s Brochure.   
11.6 Special Reporting Situations  
Safety events of interest for a Janssen medicinal product that require expediting 
reporting and/or safety evaluation include, but are not limited to:  
• Drug exposure during pregnancy (ma ternal and paternal)  
• Overdose of a Janssen medicinal product  
• Exposure to a Janssen medicinal product from breastfeeding  
• Suspected abuse/misuse of a Janssen medicinal product  
• Inadvertent or accidental exposure to a Janssen medicinal product  
• For a biraterone acetate only, failure of expected pharmacological action (i.e., lack 
of effect) of a Janssen medicinal product  
• Medication error involving a Janssen medicinal product (with or without patient exposure to the Janssen medicinal product, e.g., name confusion)  
• Suspected transmission of any infectious agent via administration of a medicinal product  
• For a biraterone acetate only, unexpected therapeutic or clinical benefit from use 
of a Janssen medicinal product  
These safety events may not meet the defini tion of an adverse event; however, from 
the standpoint of Janssen , they are treated in the same manner as adverse events. 
Special situations should be recorded on the Adverse Event page of the CRF.  
Any special situation that meets the criteria of a serious  adverse event should be 
recorded on a Serious Adverse Event Report Form and be reported to Janssen  within 
24 hours of becoming aware of the event.  
11.7 Pregnancy  
 
Because the Janssen medicinal product may have an effect on sperm, pregnancies in partners of male subjects exposed to a Janssen medicinal product will be reported by the PI  within 24hours of their knowledge of the event  using the Serious Adverse Event 
Form.  Depending on local legislation this may require prior consent of the partner.  
 Follow -up information regarding the outcome of the pregnancy and any postnatal 
sequelae in the infant will be required.  
11.8 Maintenance of Safety Information  
All safety data sho uld be maintained in a clinical database in a retrievable format. DFCI  
and the PI  shall provide all adverse events, both serious and non- serious, in report 
format. However, in certain circumstances more frequent provision of safety data may 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
68 be necessary, e.g. to fulfill a regulatory request, and as such the data shall be made 
available within a reasonable timeframe at Janssen’s  request.  
11.9 Procedures for Reporting Safety Data and Product Quality Complaints (PQCs) for Janssen Medicinal Products to Janssen  
 
All adverse events and special situations, whether serious or non- serious, related or not 
related, following exposure to a Janssen medicinal product  are to be documented by 
the investigator and recorded in the CRF and in the subject’s source records. Inves tigators 
must record in the CRF their opinion concerning the relationship of the adverse event to a Janssen medicinal product.  
All (serious and non- serious) adverse events reported for a Janssen medicinal product 
should be followed- up in accordance with clinical practice.  
11.9.1  SAEs and Special Reporting Situations  
All serious adverse events that have not resolved by the end of the study, or that have not resolved upon discontinuation of the subject's participation in the study, must be followed until any of the  following occurs:  
• The event resolves  
• The event stabilizes  
• The event returns to baseline, if a baseline value/status is available  
• The event can be attributed to agents other than the study drug or to 
factors unrelated to study conduct  
• It becomes unlikely t hat any additional information can be obtained 
(subject or health care practitioner refusal to provide additional 
information, lost to follow -up after demonstration of due diligence with 
follow -up efforts)  
Participating investigators must report each SAE to the Sponsor Investigator (Dr. Mary -Ellen Taplin) within 24 hours of learning of the occurrence.  In the 
event a participating investigator is not made aware of the SAE immediately (e.g., participant sought treatment elsewhere), the participating investigator is to report the event within 24 hours after learning of it and document the time of his or her first awareness of the AE.  Non DF/HCC sites participating in this research are expected to submit each S AE to its local ethics committee 
according to FDA and local IRB guidelines.   
All follow -up information for serious adverse events that are not resolved at 
the end of the study or by the time of patient withdrawal must be reported directly by the PI , withi n 24 hours becoming aware , to Janssen  using 
Janssen’s  Serious Adverse Event Report  
All available clinical information relevant to the evaluation of a related SAE 
or special situation is required.  
• DFCI  and/or PI  is responsible for ensuring that these cases are 
complete and if not are promptly followed- up. A safety report is not 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
69 considered complete until all clinical details needed to interpret the 
case are received. Reporting of follow -up information should follow 
the same timeline as initial reports.  
• Copies of any and all relevant correspondences with regulatory authorities and ethics committees regarding any and all serious adverse events, irrespective of association with the Janssen Product under study, are to be provided to the COMPANY within 24 hours of 
such report or correspondence being sent to applicable health 
authorities . 
11.9.2  Non-Serious AEs  
All non- serious adverse events should be reported to Janssen  according to the 
timeframe outlined in the Research Fundin g Agreement section entitled 
Reporting of Data.  
 
11.9.3  PQC Reporting 
A PQC may have an impact on the safety and efficacy of the product. Timely, accurate, and complete reporting and analysis of PQC information from studies are crucial for the protection of patients, investigators, and Janssen , 
and are mandated by regulatory  agencies worldwide. Janssen  has established 
procedures in conformity with regulatory requirements worldwide to ensure appropriate reporting of PQC information. Lot and/or Batch #s shall be collected or any reports failure of expected pharmacological actio n (i.e., lack 
of effect). The product should be quarantined immediately and if possible, take a picture.  
 
All initial PQCs involving a Janssen medicinal product under study must be reported to Janssen by the PI  within 24hours after being made aware of the 
event. The Janssen contact will provide additional information/form to be 
completed.  
 If the defect for a Janssen medicinal product under study is combined with either a serious adverse event or non- serious adverse event, the PI  must report 
the PQC to Janssen according to the serious adverse event reporting timelines.  
A sample of the suspected product should be maintained for further investigation if requested by Janssen . 
11.10 Reporting Procedures for Reporting Safety Data and Product Quality Complaints (PQCs) for Non -Janssen Medicinal Products  
 For SAEs, special reporting situations and PQCs following exposure to a non- Janssen 
medicinal product under study, the PI  should notify the appropriate 
regulatory/competent authority or the manufacturer of that medicina l product (in the 
absence of appropriate local legislation) as soon as possible.  
11.11 Transmission Methods  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
70 The following methods are acceptable for transmiss ion of safety information to 
Janssen : 
• Electronically via Janssen SECURE Email service (preferred)  to the Janssen 
IIS-BIO/VIRO -GCO central mailbox < RA-OMPUS -
COBS_Cen_E@its.jnj.com > 
• For business continuity purposes, if SECURE Email is non- functional:  
o Facsimile (fax  – 866.451- 0371), receipt of which is evidenced in a 
successful fax transmission report  
Please use the contact information and process information provided by Janssen .  
 
11.12 Reconciliation of SAEs  
At a minimum, on a quarterly basis and at the end of the Study, Janssen will provide to the 
INSTITUTION and/or SPONSOR  INVESTIGATOR, a listing of all SAE s reported to 
Janssen.  SPONSOR INVESTIGATOR will review this listing and provide any discrepancies to the Janssen. 
Upon request, INSTITUTION and SPONSOR  INVESTIGATOR shall provide Janssen with 
a summary list of all SAEs, and AEs of Special Interest and Sp ecial Reporting Situation 
reports to date, for reconciliation purposes. 
 
11.13 Final Study Report  
The INSTITUTION/ SPONSOR  INVESTIGATOR will prepare a final report including a 
complete and full summary of all adverse events, special situations and pregnancy repor ts 
according to the timeframe outlined in the executed Research Funding Agreement with 
Janssen.  
 
11.14 Procedures for AE and SAE Recording and Reporting  
 
Participating investigators will assess the occurrence of AEs and SAEs at all participant evaluation time points during the study.  
 All AEs and SAEs whether reported by the participant, discovered during questioning, directly observed, or detected by phys ical examination, laboratory test or other means, 
will be recorded in the participant’s medical record and on the appropriate study -
specific case report forms.   The descriptions and grading scales found in the revised NCI CTCAE version 4.0 will be utilize d for AE reporting. All appropriate treatment areas should have access to a 
copy of the CTCAE version 4.0. A copy of the CTCAE version 4.0 can be downloaded from  the CTEP website at: 
 http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
.  
11.15 Reporting R equirements  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
71  
The DF/HCC will serve as the Sponsor of this multi- site trial. E ach participating 
investigator is required to abide by the reporting requirements set by the DF/HCC. The study must be conducted in compliance with Food and Drug Administration (FDA)  
regulations, local safety reporting requirements, and reporting requirements of the  
Sponsor . Each investigative site will be responsible to report SAEs that occur at that 
institution to their respective IRB. It is the responsibility of each participating investigator to report SAEs  to the study sponsor and/or others as described below.  
 
11.16 Reporti ng to the Study Sponsor -Investigator  
11.16.1  SAE Reporting  
 
All SAEs  that occur after the initial dose of study treatment, during 
treatment, or within 30 days of the last dose of treatment must be reported to the DF/HCC Overall PI  on the local institutional SAE fo rm. This 
includes events meeting the criteria outlined in Section 11.1.2, as well as the following:  
 
• Grade 2 (moderate) and  Grade 3 (severe) Events – Only events that 
are unexpected and possibly , probably or definitely related/associated 
with the intervention. 
 • All Grade 4 (life- threatening or disabling) E vents – Unless expected 
AND specifically listed in the protocol  as not requiring reporting.  
 • All Grade 5 (fatal) E vents – When the participant is enrolled and 
actively participating in the trial OR when the event occurs within 30 
days of the last study intervention.  
 
Note : If the participant is in long term follow up, report the death at the 
time of continuing review.  
 
Participating  investigators must report each SAE  to the DF/HCC Overall PI  
within 24 hours of learning of the occurrence. In the event that the participating investigator does not become aware of the SAE  immediately 
(e.g., participant sought treatment elsewhere), the pa rticipating investigator 
is to report the event within 24 hours after learning of it and document the time of his or her first awareness of the AE . Report SAEs  by telephone, 
email or facsimile to:    
  Mary -Ellen Taplin, MD  
  Phone: 617- 582-7221 
  Email: Mary_Taplin@DFCI.harvard.edu
 
  Fax: 617- 632-2165 
 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
72 Within the following 24- 48 hours, the participating investigator must 
provide follow -up information on the SAE . Follow -up information should 
describe wheth er the event has resolved or continues, if and how the event 
was treated, and whether the participant will continue or discontinue study 
participation.  
 If the significant other of a study participant becomes pregnant while the study subject is in the tria l, the pregnancy must be reported within the SAE 
reporting timelines (24 business hours). 
11.16.2  Non-SAE Reporting  
 
Non-SAEs  will be reported to the DF/HCC Overall PI  on the toxicity 
CRFs .   
11.17 Reporting to the IRB  
 Investigative sites within DF/HCC will report all SAEs  directly to the DFCI Office of 
Human Research Studies (OHRS) . 
 
Other investigative sites should report SAEs  to their respective IRB according to the 
local IRB’s policies and procedures in reporting AEs. A copy of the submitted 
institutional SAE form should be forwarded to:  
 
  Mary -Ellen Taplin, MD  
  Phone: 617- 582-7221 
  Email: Mary_Taplin@DFCI.harvard.edu
 
  Fax: 617- 632-2165 
 
The DF/HCC PI  will submit SAE reports from outside institutions to the DFCI OHRS  
according to DFCI IRB  policies and procedures in reporting AEs .  
11.18 Reporting to the FDA  
 
The Overall PI, as study sponsor, will be responsible for all communications with the FDA. The Overall PI will report to the FDA, regardless of the site of occurrence, any serious adverse event that meets the FDA’s criteria for expedited reporting following the reporting requirements and timelines set by the FDA.  
11.19 Reporting to Hospital Risk Managemen t 
 
Participating investigators will report to their local Risk Management office any subject safety reports or sentinel events that require reporting according to institutional policy.  
11.20 Monitoring of AEs  and Period of Observation  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
73  
All AEs , both serious and non- serious, and deaths that are encountered from initiation 
of study intervention, throughout the study, and within 30 days of the last study 
intervention should be followed to their resolution, or until the participating investigator assesses them as sta ble, or the participating investigator determines the 
event to be irreversible, or the participant is lost to follow -up. The presence and 
resolution of AEs and SAEs (with dates) should be documented on the appropriate case report form and recorded in the participant’s medical record to facilitate source data verification.  
 For some SAEs, the study sponsor or designee may follow -up by telephone, fax, and/or 
monitoring visit to obtain additional case details deemed necessary to appropriately evaluate the SAE  report (e.g., hospital discharge summary, consultant report, or 
autopsy report).  
 Participants should be instructed to report any serious post -study event(s) that might 
reasonably be related to participation in this study. Participating investigators should notify the DF/HCC Overall PI  and their respective IRB of any unanticipated death or 
adverse event occurring after a participant has discontinued or terminated study participation that may reasonably be related to the study.   
 
12. DATA AND SAFETY MONITORING  
12.1 Data Reporting  
12.1.1  Method  
 The ODQ will collect, manage, and monitor data for this study.  
12.1.2  Data Submission  
The schedule for completion and submission of CRF  (paper or electronic) to the 
ODQ is as follows:  
 
Form  Submission Timeline  
Eligibility Checklist  Complete prior to registration with ODQ. 
On Study Form  Within 14 days of registration. 
Baseline Assessment Form  Within 14 days of registration. 
Treatment Form  Within 10 days of the last day of the cycle . 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
74 Adverse Event Report Form  Within 10 days of the last day of the cycle. If 
AEs are ongoing at the end of the last cycle, 
continue to submit adverse event reports until resolution or 30 days post -treatment.  
Response Assessment Form  Within 10 days of the completion of the cycle 
required for response evaluation . 
Off Treatment/Off Study 
Form  Within 14 days of completing treatment or 
being taken off study for any reason . 
Follow up/Survival Form  Within 14 days of the protocol defined follow up visit date or call . 
12.2 Safety Meetings  
 
The DF/HCC Data Safety and Monitoring Board (DSM B) will review and monitor 
study progress, toxicity, safety, and other data from this trial. The board is chaired by a medical oncologist from outside of DF/HC C and has external and internal 
representation. Information that raises any questions about participant safety or protocol 
performance will be addressed with the PI , a statistician and study team members. 
Should any major concern arise, the DSMB will offer recommendations regarding whether or not to suspend the tri al.  
 
The DSMB will meet twice a year to review accrual, toxicity, response and reporting 
information. Information to be provided to the DSMB may include: participant accrual treatment regimen information, AEs  and SAEs  reported by category , summary of any 
deaths on study, audit  results, and summary  provided by the study  team. Other  
information (i.e. scans, laboratory values) will be provided upon request.  
12.3 Monitoring  
 
Involvement in this study as a participating investigator implies acceptance of potential audits or inspections, including source data verification, by representatives designated by the DF/HCC Overall PI  or DF/HCC. The purpose of these audits or 
inspections is to examine study -related activities and documents to determine whether 
these activities were conducted and data were recorded, analyzed, and accurately reported in accordance with the protocol, institutional policy, Good Clinical Practice (GCP), and a ny applicable regulatory requirements.  
 
All data will be monitored for timeliness of submission, completeness, and adherence to protocol requirements. Monitoring will begin at the time of participant registration and will continue during protocol performa nce and completion.  
 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
75 To ensure proper oversight of local and external study conduct, on- site and virtual 
monitoring will take place at the beginning of the study and periodically for the 
duration of the clinical trial.  The lead site will host monthly teleconferences with external sites to discuss amendments, SAEs, data, sample processing, and more. 
 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
76 13. REGULATORY CONSIDERATIONS  
13.1 Protocol Review and Amendments  
This protocol, the proposed informed consent and all forms of participant information 
related to the study (e.g., advertis ements used to recruit participants) and any other 
necessary documents must be submitted, reviewed and approved by a properly constituted IRB governing each study location.  
Any changes made to the protocol must be submitted as amendments and must be approved by the IRB prior to implementation. Any changes in study conduct must be reported to the IRB. The DF/HCC Overall PI  will disseminate protocol amendment 
information to all participating investigators.  
All decisions of the IRB concerning the conduct of the study must be made in writing.  
13.2 Informed Consent  
 
All participants must be provided a consent form describing this study and providing sufficient information for participants to make an informed decision about their participation in this study. The form al consent of a participant, using the IRB approved 
consent form, must be obtained before the participant is involved in any study -related 
procedure. The consent form must be signed and dated by the participant or the participant’s legally authorized repre sentative, and by the person obtaining the consent. 
The participant must be given a copy of the signed and dated consent document. The 
original signed copy of the consent document must be retained in the medical record or research file.  
13.3 Ethics and GCP  
This study is to be conducted according to the following considerations, which 
represent good and sound research practice:  
• E6 GCP : Consolidated Guidance  
www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM129515.pdf
  
• US Code of Federal Regulations (CFR)  governing clinical study conduct and 
ethical principles that have their origin in the Declaration of Helsinki  
o Title 21 Part 11 – Electronic Records; Electronic Signatures www.access.gpo.gov/nara/cfr/waisidx_02/21cfr11_02.html
 
o Title 21 Part 50 – Protection of Human Subjects www.access.gpo.gov/nara/cfr/waisidx_02/21cfr50_02.html
  
o Title 21 Part 54 – Financial Disclosure by Clinical Investigators www.access.gpo.gov/nara/cfr/waisidx_02/21cfr54_02.html
  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
77 o Title 21 Part 56 – Institutional Review Boards 
www.access.gpo.gov/nara/cfr/waisidx_02/21cfr56_02.html   
o Title 21 Pa rt 312 – Investigational New Drug Application 
www.access.gpo.gov/nara/cfr/waisidx_02/21cfr312_02.html   
• State laws  
• DF/HCC research policies and procedures        
http://www.dfhcc.harvard.edu/clinical -research -support/clinical -research -unit-
cru/policies -and-procedures/   
It is understood that deviations from the  protocol should be avoided, except when 
necessary to eliminate an immediate hazard to a research participant. In such case, the 
deviation must be reported to the IRB according to the local reporting policy.  
13.4 Study Documentation  
 
The investigator must prepare and maintain adequate and accurate case histories designed to record all observations and other data pertinent to the study for each research participant. This information enables the study to be fully documented and the study data to be subsequently verified.  
 
Original source documents supporting entries in the case report forms include but are not limited to hospital records, clinical charts, laboratory and pharmacy records, recorded data from automated instruments, microfiches, photographic negatives, microfilm or magnetic media, and/or x -rays.  
13.5 Records Retention  
 
All study -related documents must be retained for the maximum period required by 
applicable federal regulations and guidelines or institutional policies.  
13.6 Multi -Center Guidelines  
This protocol will adhere to the policies and requirements of the DF/HCC . The specific 
responsibilities of the DF/HCC Overall PI , Coordinating Center, and Participating 
Institutions  are presented in the DF/HCC  Multi- Center Data and Safety Monitoring 
Plan (see Appendix H ). 
• The DF/HCC Overall PI /Coordinating Center is responsible for distributing all 
IND Action Letters or Safety Reports to all participating institutions for 
submission to their individual IRBs for action as required.  
• Mechanisms will be in place to ensure quality assurance, protocol compliance, and adverse event reporting at each site.  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
78 • Except in very unusual circumstances, each participating institution will order the 
agent(s) directly from the supplier. A participating site may order the agent(s) only after the in itial IRB  approval for the site has been forwarded to  the 
Coordinating Center.  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
79 14. STATISTICAL CONSIDERATIONS  
14.1  Study Design and Sample Size  
 
This is a multicenter, phase II, prospective, randomized trial designed to investigate the efficacy of neoadjuvant and adjuvant abiraterone acetate + apalutamide  for men with 
intermediate -high risk prostate cancer who are candidates for RP. The study includes 
two parts. In part 1, patients will be randomized in 1:1 ratio to receive 6 months of neoadjuvant abiraterone acetate, apalutamide , leuprolide and prednisone (Arm 1A) 
versus 6 months of abiraterone acetate, leuprolide and prednisone (Arm 1B) followed by RP. Randomization will be stratified by disease risk factor (intermediate versus high 
risk). In part 2 (post -RP adjuvant ), patients will be randomized in 1:1 ratio to receive 
additional 12 months of adjuvant abiraterone acetate, apalutamide , leuprolide a nd 
prednisone (Arm 2A) or observation (Arm 2B) stratified by type of neoadjuvant therapy and pathological T -stage (< pT3 versus ≥ pT3). 
 
For part I, t he primary analysis will compare the proportion of patients with pCR or  
MRD ( pCR plus MRD, see section 10.1) at RP following therapy with A rm 1A and 
Arm 1B . We hypothesize that treatment with abiraterone acetate, leuprolide and 
prednisone ( Arm 1B)  will have a pCR plus MRD rate of 15% based on our prior 
experience.
3 We hypothesize that  with the addition of a palutamide  (Arm  1A), the rate of  
pCR plus MRD will increase to  35%. 120 patients will be enrolled and randomized in 
part 1. This sample size provides  81% power to distinguish a pCR  plus MRD rate of 
35% in Arm 1A (N=60) from a rate of  15% in Arm 1B  (N=60), using a chi -square test 
for binomial proportion (one sided a= 0.05) . 
 
For part 2, the primary analysis will compare the rate of bPFS (see section 10.1) at 3 
years after RP between the two arms with and without adjuvant therapy. There is limited data with regard to long term outcomes of use of novel hormonal agents. Based on the institutional experience of patients treated with neoadjuvant abiraterone acetate, 3-year bPFS rate is expected to be approximately 70%. Assuming that 90% of the 
population is able to complete RP and agrees to participa te  the adjuvant part of the 
study, there is 83% power to  distinguish a 3- year bPFS rate of 90% in Arm 2A 
(adjuvant arm: N=54) from a rate of 70% in Arm 2B (observation arm: N=54),  using a chi-square test for binomial proportion (one sided a=0.05).  
14.2 Primary Endpoint and Methods of Analysis:  
 
Part 1: The  number and percent of patients achieving pCR  plus MRD will be 
summarized with two -sided 90% exact binomial CI by treatment arm. All patients wh o 
are randomized in part 1 will be included. The  primary comparison between Arm1A 
and Arm1B  will be conducted usi ng the chi -square test for binomial proportion, with 
one-sided  P value of ≤ 0.05 considered statistically significant. The Cochran- Mantel -
Haens zel test accounting for the stratification factor at randomization  will be 
performed as a sensitivity analysis .  
 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
80 Part 2: At time of final analysis, the 3- year bPFS  rate (SE and two -sided 90% CI) will 
be estimated using the Kaplan -Meier method according to  treatment arm. bPFS is 
defined in section 10.1. All patients who are randomized in part 2 will be included in 
the analysis. If the lower limit of 90% CI (two sided) for the difference in 3-year bPFS  
(estimated from the Kaplan Meier method, as adjuvant treatment arm 2A minus 
observation arm 2B) is greater than 0, we will consider there is a statistically significant difference between the two treatment arms.   This approach to hypothesis testing is used instead of using the observed rate at 3- years 
post-surgery, or instead of comparing the bPFS distribution using logrank test for 
multiple reasons. It is the 3 year timepoint that is of clinical interest. There may be 
censored data prior to 3 years that can be included using a time- to-event endpoint. In 
addition there may be different hazards during the first year (i.e. when one group 
receives active treatment and the other is observed) than in the next 2 -year period and 
may not meet a proportionality assumption. The analysis will include plotting hazard functions over time to assess whether there are different hazards in the first and subsequent year   periods. Proportional hazard assumption will also be asses sed in 
order to estimate hazard ratio from Cox proportional hazards model.   
 It is anticipated that the primary analysis of bPFS will be conducted when the last 
subject enrolled in part 2 has been followed up to 3 years post RP, or has experienced 
biochem ical progression (as defined in section 10.1) , or has been removal from study, 
whichever occurs first.   
14.3 Secondary Endpoint(s) and Methods of Analysis:  
 
Pathological endpoints  (part 1)  
Other pathological analyses  include (1) proportion of participant s wit h pCR at RP, (2) 
proportion of participants with favorable RCB (see section 10.2) at RP, (3) proportion 
of participant s with cribriform or intraductal spread at R P, and (4) proportion of 
participant s with positive surgical margins, extracapsular extension,  positive seminal 
vesicles, and positive lymph nodes at time of RP following therapy with A rm 1A and 
Arm 1B. Number  and percent of participant s with pCR, favorable RCB or presenting 
each of these pathological features as described above will be summarized by arms with a two -sided 90% confidence interval ; comparison between arms will be conducted 
using chi -square test or Fisher’s exact test  as appropriate .  
 
PSA kinetics prior to RP  (part 1)  
PSA kinetics prior to RP include nadir value, achieving nadir PSA < 0.2 ng/mL, achieving 50% or  achieving 90% decrease in PSA from baseline, and time to PSA 
nadir. PSA kinetics will be summarized with descriptive statistics (e.g. median, range, and proportions) and presented by arm  (Arm 1A and 1B) . Comparison between arms 
will be conducted using chi -square test for categorical variables and Wilcoxon rank -
sum test for continuous variables.  
 Safety endpoints  (part 1 and 2)  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
81 Safety analysis will be conducted using the Safety Population defined as any participant 
receiving  one dose of study treatment. All safety endpoints  will be summarized 
according to treatment arm , separately for part 1 (neoadjuvant part) and part 2 (adjuvant 
part) . 
 For toxicity reporting, all adverse events will be graded and analyzed using CTCAE versi on 4. Type of adverse events, intensity  (grading) , and attribution will be provided 
in a listing. The worst grade will be used if any toxicity event is reported multiple times on the same participant. All adverse events resulting in discontinuation, dose modification, and/or dosing interruption, and/or treatment delay of drug will also be 
summarized. All laboratory test results will be classified according to the CTCAE version 4.   Quality of Life (QOL) endpoints  (part 1 and 2)  
The QOL will be measured using the Expanded Prostate Cancer Index Composite 26 (EPIC -26). The questionnaires will be administered at baseline, prior to RP  and every 3 
months for 2 years post RP .  Analysis will be conducted separately for part 1 
(neoadjuvant part) and part 2 (adjuvant part) . 
 
Resulting domain scores for EPIC -26 (urinary incontinence, urinary obstruction, sexual, 
bowel, hormonal/vitality) is on a 0–100 scale, with higher values representing a more favorable health -related QOL. For each treatment group, calculated scores on each 
domain and changes from baseline will be summarized by time  points . The effect of 
treatment will be evaluated using a repeated measures model to incorporate assessments across time into a single analysis , using model contrasts to compare treatment groups at 
selected time  points, prior to RP and 2 years post -RP.  
 Quantitative MRI  
Prostate gland volumes and quantitative indices (T2, ADC DCE metrics) will be compared pre-  and post neoadjuvant therapy (by lesion or by patient) using Wilcoxon 
signed -rank test. Their changes from baseline will be correlated, using Spearman’s rank 
correlation, with (1) pathological RCB index (2) changes in PSA values (3) changes in serum/tissue androgen levels. Comparison of quantitative changes between pathological response groups will be conducted using Wilcoxon rank- sum test or t- test. Logistical 
regression will be conducted to predict pathological response using different mpMRI parameters or their combination. Model performance will be evaluated by the AUC index.  
14.4  Cor relative Endpoint(s) and Methods of Analysis:  
 
              Time to testosterone recovery (part 2)  
The Kaplan -Meier product limit method will be used to estimate the distribution of the 
time from RP until testosterone recovery, or censored at date of last test of testosterone level,  for Arm 2A and 2B . Comparison between treatment arms will be assessed using 
the log rank test.  
 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
82 Serum/Tissue androgen concentrations  (part 1 and part 2)  
Serum androgen concentrations will be measured at multiple timepoints (see section 
10.2) by mass spectroscopy.  Tissue androgens will only be assayed in RP specimens. 
Mean change in serum androgen concentrations from baseline to during neoadjuvant treatment and to prior to RP will be su mmarized for Arm 1A and 1B (part 1). Mean 
change during follow -up post RP will be summarized  for Arm 2A and 2B (Part 2). 
Comparisons  between  arms will be conducted using the ANOVA methods (with log 
transformation as appropriate) or the non -parametric Wilco xon rank- sum test .  
 
IHC staining  (part 1) 
The expression of the AR and proteins involved in the androgen synthesis, apoptosis, WNT signaling, and PTEN -PI3K -AKT pathways  from  the RP  specimens  will be 
assessed by the IHC staining , scored as  percentage of cells staining for the specific 
protein (i.e. categorized as 0, <5, 5- 25, 25- 50, >50% ) and /or the intensity of the 
staining.  These semi -quantitative measurements will be compared between treatment 
arms  (Arm 1A versus 1B) using the Cochran –Armitage test for trend or o ther 
appropriate methods . 
    Whole Exome and Transcriptome Sequencing  (part 1)  
Changes in w hole exome and whole transcriptome between pretreatment prostate 
biopsy and RP specimens  between treatment arms (Arm1A and 1B) will be analyzed 
using nove l computational algorithms developed at the Broad Institute. It is anticipated 
that whole genome sequencing of prostate cancer will be undertaken in about  60% of 
participants (N=72 )  using fresh -frozen tissue at pretreatment biopsy and RP  to study de 
novo or acquired resistance to neoadjuvant therapy  in terms of genomic alterations such 
as base mutations, small insertions/deletions (indels), copy number changes, and structural rearrangements.  
 Gene mutation frequencies and mean ± SD of quantitative gene exp ression profile will be 
summarized pre and post neoadjuvant therapy. For detection of rare gene mutations, with 
72 participants, there are 0.9 8, 0.89  and 0.52  probabilities to observe ≥1 mutation if the 
true underlying mutation rate is 5%, 3% and 1% respec tively. For more prevalent 
mutations, the 90% exact binominal CI width is 0.1 3 and 0.19 with the observed mutation 
rate of 0.1 and 0.3 respectively. To compare pre -post therapy changes in gene expression, 
there is 80% power to detect a 0.3 4 SD mean change between time points with n= 72 
using a paired t -test (two -sided α=0.05). To compare gene expression between groups 
(e.g. treatment arms, pathology response), we will use student t -test for continuous values 
or Fisher’s exact test if the data are summarized as % of patients with up-  or down-
regulated expression.  
 Germline mutations  (Part 1)  
The prevalence of germline mutations in homologous recombination genes will be 
assessed in all enrolled patients.  With N=120, the 90% exact binominal CI width is 0.10~  
0.15 with the observed mutation rate of 0.1~  0.3 respectively. Fisher’s exact test will be 
used to compare pathologic response (such as pCR, MRD, and RCB ) with homologous 
recombination gene germline mutation status as an exploratory analysis . 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
83  
14.5 Sample Size an d Accrual  Rate   
For a sample size of 120 participants, we expect a total of 15 months to complete the accrual 
at a rate 8 participants/month.  
14.6 Study monitoring  
 The DF/HCC  DSMB on a semi -annual basis will review the study for  safety, progress 
toward completion  and the status of case report forms.  Interim analysis of efficacy 
endpoints is not planned. H owever, the following events will be monitored to ensure that the  
study has sufficient statistical power for the analysis of the primary efficacy endpoint in part 2.     Rate of p articipa tion in part 2  
We assum e that 90% of the population agrees to participate  in the adjuvant part of the  study  
(part 2) after completion of RP. The statistical power reduces to 61% if only 50% of subjects are randomized into part 2. Therefore, among the first 40 patients who complete RP, if 21 or more subjects refuse to be randomized into part 2, “ part 2(adjuvant therapy post RP)” of the 
study will be terminated early due to insufficient participation rate.   
 The following table gives the statistical power if various numbers of patients are enrolled in the part 2 under the same design param eters.  
 
% enrolled in part 2  90% 80% 70% 60% 50% 
N per arm  54 48 42 36 30 
Power  83% 79% 74% 68% 61% 
  Treatment compliance in Arm 2A  
We will also monitor the rate of early discontinuation of adjuvant hormone therapy  (defined 
as receiving <6 months of adjuvant therapy in Arm 2A). A mong the first 20  (out of 54, 37% ) 
subject s on the A rm 2A , if 8 or more patients  withdraw therapy within 6 months, “part 2” of 
the study may be terminated early due to low treatment compliance  in part 2. Using this rule, 
the probability that the study may be terminated early is 0.03 if the true early discontinuation rate is 20% and 87%  if the rate is 50%.  
 
 True but unknown rate of early 
discontinuation  
 10% 20% 30% 40% 50% 60% 
Probability of observing 8 or more 
receiving<6month adjuvant therapy in the 
first 20 patients in Arm 2A  <0.1 0.03 0.23 0.58 0.87 0.98 
 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
84 15. PUBLICATION PLAN  
 
The data will be collected by Dr. Taplin  and study team  and analyzed by Dr. Taplin an d the 
statistical team at DFCI . It is anticipated that the results will be made public  within 12 months of 
the end of data collection. A report is planned to be published in a peer -reviewed journal, 
however initial release may be an abstract that meets  the requirements of the International 
Committee of Medical Journal Editors.  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
85 16. REFERENCES  
1. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab 
and trastuzumab in women with locally advanced, inflammatory, or early HER2- positive 
breast cancer (NeoSphere): a randomised multicentre, open -label, phase 2 trial. Lancet 
Oncol. Jan 2012;13(1):25- 32. 
2. Lam ET, Glode LM. Neoadjuvant and adjuvant hormonal and chemotherapy for prostate cancer. Hematol Oncol Clin North Am. Dec 2013;27(6):1189- 1204, viii. 
3. Taplin ME MB, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, et al. Intense androgen -
deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high -risk prostate cancer: Results of a randomized phase II neoadjuvant study. 
Journal of Clinical Oncology. 2014 (In press).  
4. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. Jan -Feb 
2012;62(1):10- 29. 
5. Bastian PJ, Gonzalgo ML, Aronson WJ, et al. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer. Sep 15 2006;107(6):1265- 1272.  
6. Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Frank I, Blute ML. Impact of prostate -specific antigen testing on the clinical and pathological outcomes after radical 
prostatectomy for Gleason 8 -10 cancers. BJU Int. Feb 2008;101(3):299 -304. 
7. Kane CJ, Presti JC,  Jr., Amling CL, et al. Changing nature of high risk patients 
undergoing radical prostatectomy. J Urol. Jan 2007;177(1):113- 117. 
8. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer -specific 
mortality following biochemical recurrence a fter radical prostatectomy. JAMA. Jul 27 
2005;294(4):433- 439. 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
86 9. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National 
Surgical Adjuvant Breast and Bowel Project Protocols B -18 and B -27. J Clin Oncol. Feb 
10 2008;26(5):778- 785. 
10. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta- analysis. J Natl Cancer Inst. Feb 2 2005;97(3):188 -194. 
11. Richards J, Lim AC, Hay CW, et al. Interactions of abiraterone, eplerenone, and prednisolone with wild- type and mutant androgen receptor: a rationale for increasing 
abiraterone exposure or combining with MDV3100. Cancer Res. May 1 2012;72(9):2176- 2182.  
12. Cuzick J, Fisher G, Kattan MW, et al. Long -term outcome among men with 
conserva tively treated localised prostate cancer. Br J Cancer. Nov 6 2006;95(9):1186-
1194. 
13. Monfardini S, Sorio R, Boes GH, Kaye S, Serraino D. Entry and evaluation of elderly 
patients in European Organization for Research and Treatment of Cancer (EORTC) new -
drug-development studies. Cancer. Jul 15 1995;76(2):333- 338. 
14. Lichtman SM. Guidelines for the treatment of elderly cancer patients. Cancer Control. Nov-Dec 2003;10(6):445 -453. 
15. von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. May 20 2012;30(15):1796- 1804.  
16. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. Oct 1 
2007;25(28):4414- 4422.  
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
87 17. Dalkin BL, Ahmann FR, Nagle R, Johnson CS. Randomized study of neoadjuvant 
testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer. J Urol. Apr 1996;155(4):1357- 1360. 
18. Labrie F, Cusan L, Gomez JL, et al. Neoadjuvant hormonal therapy: the Canadian experience. Urology. Mar 1997;49(3A Suppl):56- 64. 
19. Fair WR, Rabbani F, Bastar A, Betancourt J. Neoadjuvant H ormone Therapy Before 
Radical Prostatectomy: Update on the Memorial Sloan -Kettering Cancer Center Trials. 
Mol Urol. 1999;3(3):253- 260. 
20. van der Kwast TH, Tetu B, Candas B, Gomez JL, Cusan L, Labrie F. Prolonged neoadjuvant combined androgen blockade lea ds to a further reduction of prostatic tumor 
volume: three versus six months of endocrine therapy. Urology. Mar 1999;53(3):523-
529. 
21. Schulman CC, Debruyne FM, Forster G, Selvaggi FP, Zlotta AR, Witjes WP. 4- Year 
follow -up results of a European prospecti ve randomized study on neoadjuvant hormonal 
therapy prior to radical prostatectomy in T2 -3N0M0 prostate cancer. European Study 
Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol. Dec 2000;38(6):706- 713. 
22. Gleave ME, Goldenberg SL, Chin JL, et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol. Aug 2001;166(2):500 -506; discussion 506- 507. 
23. Aus G, Abra hamsson PA, Ahlgren G, et al. Three -month neoadjuvant hormonal therapy 
before radical prostatectomy: a 7 -year follow -up of a randomized controlled trial. BJU 
Int. Oct 2002;90(6):561- 566. 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
88 24. Selli C, Montironi R, Bono A, et al. Effects of complete androgen blockade for 12 and 24 
weeks on the pathological stage and resection margin status of prostate cancer. J Clin Pathol. Jul 2002;55(7):508- 513. 
25. Soloway MS, Pareek K, Sharifi R, et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxM o prostate cancer: 5 -year results. J Urol. Jan 
2002;167(1):112- 116. 
26. Klotz LH, Goldenberg SL, Jewett MA, et al. Long -term followup of a randomized trial of 
0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol. Sep 2003;170(3):791- 794. 
27. Prezioso D, Lotti T, Polito M, Montironi R. Neoadjuvant hormone treatment with leuprolide acetate depot 3.75 mg and cyproterone acetate, before radical prostatectomy: a randomized study. Urol Int. 2004;72(3):189- 195. 
28. Yee DS, Lowran ce WT, Eastham JA, Maschino AC, Cronin AM, Rabbani F. Long -term 
follow -up of 3- month neoadjuvant hormone therapy before radical prostatectomy in a 
randomized trial. BJU Int. Jan 2010;105(2):185- 190. 
29. Shelley MD, Kumar S, Wilt T, Staffurth J, Coles B, Ma son MD. A systematic review and 
meta -analysis of randomised trials of neo- adjuvant hormone therapy for localised and 
locally advanced prostate carcinoma. Cancer Treat Rev. Feb 2009;35(1):9- 17. 
30. Efstathiou E, Abrahams NA, Tibbs RF, et al. Morphologic cha racterization of 
preoperatively treated prostate cancer: toward a post -therapy histologic classification. Eur 
Urol. Jun 2010;57(6):1030- 1038. 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
89 31. Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation 
treatment in patients with node -positive prostate cancer after radical prostatectomy and 
pelvic lymphadenectomy. Lancet Oncol. Jun 2006;7(6):472- 479. 
32. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. May 5 1999;281(17):1591- 1597. 
33. Wong YN, Freedland S, Egleston B, Hudes G, Schwartz JS, Armstrong K. Role of androgen deprivation therapy for node -positive prostate cancer. J Clin Oncol. Jan 1 
2009;27(1):100- 105. 
34. Dorff TB , Flaig TW, Tangen CM, et al. Adjuvant androgen deprivation for high- risk 
prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol. May 20 2011;29(15):2040- 2045.  
35. Medivation, Inc. Study of MDV3100 as a neoadjuvant therapy for patients  undergoing 
prostatectomy for localized prostate cancer [ClinicalTrials.gov identifier [STUDY_ID_REMOVED]]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http//www.clinicaltrials.g ov
 [Accessed 2012 Jul 24].  
36. Jarman M, Barrie SE, Llera JM. The 16,17- double bond is needed for irreversible 
inhibition of human cytochrome p45017alpha by abiraterone (17- (3-pyridyl)androsta -5, 
16-dien-3beta -ol) and related steroidal inhibitors. J Med Ch em. Dec 31 
1998;41(27):5375- 5381.  
37. Rowlands MG, Barrie SE, Chan F, et al. Esters of 3- pyridylacetic acid that combine 
potent inhibition of 17 alpha -hydroxylase/C17,20- lyase (cytochrome P45017 alpha) with 
resistance to esterase hydrolysis. J Med Chem. Oc t 13 1995;38(21):4191- 4197. 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
90 38. Auchus RJ. Overview of dehydroepiandrosterone biosynthesis. Semin Reprod Med. Nov 
2004;22(4):281- 288. 
39. Stein MN, Goodin S, Dipaola RS. Abiraterone in prostate cancer: a new angle to an old problem. Clin Cancer Res. Apr 1 2012;18(7):1848 -1854. 
40. Reid AH, Attard G, Barrie E, de Bono JS. CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol. Nov 2008;5(11):610- 620. 
41. De Coster R, Wouters W, Bruynseels J. P450- dependent enzymes as targets for prostate 
cancer therapy. J Steroid Biochem Mol Biol. Jan 1996;56(1- 6 Spec No):133 -143. 
42. Yap TA, Carden CP, Attard G, de Bono JS. Targeting CYP17: established and novel approaches in prostate cancer. Curr Opin Pharmacol. Aug 2008;8(4):449- 457. 
43. Small EJ,  Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination 
with ketoconazole in androgen- independent prostate cancer patients: a phase III trial 
(CALGB 9583). J Clin Oncol. Mar 15 2004;22(6):1025- 1033. 
44. Attard G, Reid AH, Yap TA, et al . Phase I clinical trial of a selective inhibitor of CYP17, 
abiraterone acetate, confirms that castration -resistant prostate cancer commonly remains 
hormone driven. J Clin Oncol. Oct 1 2008;26(28):4563- 4571. 
45. Ryan CJ, Smith MR, Fong L, et al. Phase I cl inical trial of the CYP17 inhibitor 
abiraterone acetate demonstrating clinical activity in patients with castration -resistant 
prostate cancer who received prior ketoconazole therapy. J Clin Oncol. Mar 20 2010;28(9):1481- 1488.  
46. Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration -resistant prostate cancer. J Clin 
Oncol. Aug 10 2009;27(23):3742- 3748. 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
91 47. Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone 
acetate plus prednisone therapy in patients with docetaxel -treated castration -resistant 
prostate cancer. J Clin Oncol. Mar 20 2010;28(9):1496- 1501. 
48. Reid AH, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post -
docetaxel, castration -resistant prostate cancer with the CYP17 inhibitor abiraterone 
acetate. J Clin Oncol. Mar 20 2010;28(9):1489- 1495. 
49. de Bono JS, Logothetis CJ , Molina A, et al. Abiraterone and increased survival in 
metastatic prostate cancer. N Engl J Med. May 26 2011;364(21):1995- 2005. 
50. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. N Engl J Med. Dec 10 2012. 
51. O'Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17alpha -
hydroxylase/C(17,20) -lyase inhibitor abiraterone acetate (CB7630) in patients with 
prostate cancer. Br J Cancer. Jun 14 2004;90(12):2317- 2325. 
52. Clegg NJ, Wongvipat J, Joseph JD, et al.  Apal utamide : a novel antiandrogen for prostate 
cancer treatment. Cancer Res. Mar 15 2012;72(6):1494- 1503. 
53. Carver BS, Chapinski C, Wongvipat J, et al. Reciprocal feedback regulation of PI3K and androgen receptor signa ling in PTEN -deficient prostate cancer. Cancer Cell. May 17 
2011;19(5):575- 586. 
54. Kucuk O, Fisher E, Moinpour CM, et al. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). Urology. Jul 2001;58(1):53- 58. 
55. Kassouf W, Tanguay S, Aprikian AG. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J Urol. May 2003;169(5):1742- 1744. 
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
92 56. Tran C, Ouk S, Clegg N J, et al. Development of a second- generation antiandrogen for 
treatment of advanced prostate cancer. Science. May 8 2009;324(5928):787 -790. 
57. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer 
after chemotherapy. N Engl J Med. Sep 27 2012;367(13):1187- 1197.  
58. Barnett CM, Heinrich MC, Nelson DA, et al. Genomic analysis of prostate cancer. ASCO Meeting Abstracts. February 20, 2013 2013;31(6_suppl):80. 
59. Berger MF, Lawrence MS, Demichelis F, et al. The genomic comp lexity of primary 
human prostate cancer. Nature. Feb 10 2011;470(7333):214- 220. 
60. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early - 
and late- stage human malignancies. Sci Transl Med. Feb 19 2014;6(224):224ra224.  
61. Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor 
metastatic breast cancer. N Engl J Med. Mar 28 2013;368(13):1199- 1209.  
62. Galsky MD, Xie W, Nakabayashi M, et al. Analysis of the correlation between endorectal 
MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer. Prostate Cancer Prostatic Dis. Sep 2013;16(3):266-
270. 
 
 
      
Neoadjuvant abiraterone acetate plus leuprolide with or without apalutamide  
 
CONFIDENT IAL 
This document is confidential. Do not disclose or use except as authorized.  
93 17. APPENDICES  
17.1 APPENDIX A: Performance Status Criteria  
17.2 APPENDIX B : Required Forms at R egistration  
17.3 APPENDIX C : Patient’s Pill D iary 
17.4 APPENDIX D : Representative Medications that May Predispose to Seizures  
17.5 APPENDIX E : Intra-operative and Peri -operative RP Complications Q uestionnaire s  
17.6 APPENDIX F : Post -Operative Complications (Clavian Classification)   
17.7 APPE NDIX G: The Expanded Prostate Cancer Index Composite Questionnaire (EPIC -
26 +)  
17.8 APPENDIX H: Family History Questionnaire  
17.9 APPENDIX I: Multi- Center Data and Safety Monitoring Plan  
 
   
 
   
 
Neoadjuvant abiraterone plus leuprolide with or without  apalutamide  
  
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
 
94 APPENDIX A: Performance Status Criteria  
 
 
ECOG Performance Status Scale 
  
Karnofsky Performance Scale  
Grade  Description  Percent  Description  
0 Normal activity. Fully active, able 
to carry on all pre -disease 
performance without restriction.  100 Normal, no complaints, no 
evidence of disease.  
90 Able to carry on normal activity; 
minor signs or symptoms of 
disease.  
1 Symptoms, but ambulatory. 
Restricted in physically strenuous 
activity, but ambulatory and able to carry out work of a light or sedentary nature (e.g., light 
housework, office work).  80 Normal activity with effort; 
some signs or symptoms of 
disease.  
70 Cares for self, unable to carry on 
normal activity or to do active 
work.  
2 In bed < 50% of the time. 
Ambulatory and capable of all self -
care, but unable to carry out any work activities. Up and about more 
than 50% of waking hours.  60 Requires occasional assistance, 
but is able to care for most of 
his/her needs.  
50 Requires considerable assistance 
and frequent medical care.  
3 In bed >50% of the time. Capable 
of only limited self-care, confined 
to bed or chair more than 50% of waking hours.  40 Disabled, requires special care 
and assistance.  
30 Severely disabled, 
hospitalization indicated. Death 
not imminent.  
4 100% bedridden. Completely 
disabled. Cannot carry on any self-
care. Totally confined to bed or chair.  20 Very sick, hospitalization 
indicated. Death not imminent.  
10 Moribund, fatal processes 
progressing rapidly.  
5 Dead.  0 Dead.  
 
Neoadjuvant abiraterone acetate plus leuprolide with or without apaluta mide 
 
 95 APPENDIX B:  
 
Please notify the lead clinical research coordinator at the time a participant is identified or 
consented to the study.  The DFCI coordinator will register the participant once the below 
documentation is finalized using the DFCI OnCore registration system.   Non- DF/HCC 
participating sites will send the documents to the DFCI research coordinator to complete 
registration.  Please allow a one -week turn -a-round time for the DFCI research team to determine 
participant eligibility. The following documentation is r equired prior to participant registration:  
 
• Current IRB approved consent form signed by participant and Investigator (MD 
only)  
• HIPAA authorization form (if separate from the informed consent document)  
•  Signed and dated DFCI eligibility checklist (signed b y MD and  RN)  
• The following source documentation is typically required:   
• Please note: Additional documentation may be  required by the lead institution.  
o Labs for PSA values used to determine eligibility (lab values used to 
determine eligibility, including sc reening PSA)  
o Documentation of prior treatments/procedures performed to treat  
prostate cancer (e.g. Chemotherapy, Cryotherapy, Hormone Therapy,  
Radiation therapy with start and stop dates and dosing information if  
applicable)  
o Reports documenting disease sta tus 
 CT abdomen 
 MRI prostate including p elvis  
 Bone Scan  
o Pathology Report  
o Concomitant medication list  
o Progress note or equivalent documentation of consenting visit  
o Progress note documenting medical history and oncologic history  
o All screening l abs 
o Screening  visit note, with BP, vital signs, ECOG Performance status  
o Screening ECG  
o MUGA Scan or ECHO  
Neoadjuvant abiraterone acetate plus leuprolide with or without apaluta mide 
 
 96   
APPENDIX C: PATIENT’S PILL DIARY  
 
Today’s Date:    ____________________________ 
Patient Name:   ____________________________  
Patie nt Study ID: ____________________________ 
Cycle Number:  ____________________________ 
  PART 1:  
ARM 1 A:  Apalutamide  + Abiraterone Acetate + Prednisone + Leuprolide  
ARM 1B : Abiraterone Acetate + Prednisone + Leuprolide  
 PART 2:  
ARM 2A:   Apalutamide  + Abiraterone Acetate + Prednisone + L euprolide  
 
 
INSTRUCTIONS TO THE PATIENT:  
1.  Study Drug A: Apalutamide  Dose: ________________ (enter N /A if not in Arm 1A)  
Study Drug B: Abiraterone Acetate Dose: ________________  
Study Drug C: Pre dnisone Dose: ________________  
2. You should take  your full dose of  abiraterone acetate at the same time once  daily. For abiraterone acetate 
administration, no food should be consumed for at least two hours before the dose is taken and for at 
least one hour after the dose is taken. If a dose is skipped, missed or vomited, it should not be taken (or 
retaken if vomited) on the day of the missed dose but dosing should be resumed the following day. Doses 
should be taken no later than 12 hours after the scheduled time for dosing.  Abiraterone acetate should not  
be taken at the same time as apalutamide  or prednisone.  
3. You should take prednisone at the same time daily. Prednisone should be taken with food.  
4. For ARM 1 A or 2A  participants: You should take your full dose of apalutamide  at the same time  once  
daily with or without food.  Apalutamide  may be taken with prednisone (and food).  If a dose is skipped, 
missed or vomited, it should not be taken (or retaken if vomited) on the day of the missed dose but 
dosing should be resumed the following day. Doses should be taken no later than 12 hours after the 
scheduled time for dosing.  
5. Your study medications should not be crushed, chewed, or dissolved in water.  
6. You may not consume grapefruit or grapefruit -containing products while taking the study medications.  
7. Record the date, time  and the number of tablets you took.  
8. If you have any comments or notice any side effects, please record them in the comments column.  
9. Please bring your pill bottle and this form to your physician when you go to your next appointment.  
 
 
 
         
Neoadjuvant abiraterone acetate plus leuprolide with or without apaluta mide 
 
 97  
APPENDIX C: PATIENT’S PILL DIARY (Part 1)  
Today’s Date:    ____________________________  Cycle Number: ______________________ 
Patient Name:   ____________________________  Patient Study ID: ____________________ 
 
Date  Day Number of Tablets  or Capsules/Time of Day   
Comments  Abiraterone 
Acetate  Apalutamide  Prednisone  
(AM)  Prednisone  
(PM)  
 1  
     
 2  
     
 3  
     
 4  
     
 5  
     
 6  
     
 7  
     
 8  
     
 
 9  
     
 
 
 10  
     
 
 
 11  
     
 
 
 12  
 
     
 
 13  
     
 
 14  
     
 15      
 16      
 17      
 18      
 19      
 20      
 21      
 22      
 23      
 24      
 25      
 26      
 27      
 28      
 29      
 30      
 Patient’s Signature: ____________________________________________ Date: ___________________________  
Neoadjuvant abiraterone acetate plus leuprolide with or without apaluta mide 
 
 98  
APPENDIX C: PATIENT’S PILL DIARY (Part 2 A) 
Today’s Date:    ____________________________  Cycle Number: ______________________ 
Patient Name:   ____________________________  Patient Study ID: ___________________ 
 
Date  Day Number  of Tablets  or Capsules/Time of Day   
Comments  Abiraterone 
Acetate  Apalutamide  Prednisone  
(AM)  Prednisone  
(PM)  
 1  
     
 2  
     
 3  
     
 4  
     
 5  
     
 6  
     
 7  
     
 8  
     
 
 9  
     
 
 
 10  
     
 
 
 11  
     
 
 
 12  
 
     
 
 13  
     
 
 14  
     
 15      
 16      
 17      
 18      
 19      
 20      
 21      
 22      
 23      
 24      
 25      
 26      
 27      
 28      
 29      
 30      
 Patient’s Signature: ____________________________________________ Date: ___________________________  
Neoadjuvant abiraterone acetate plus leuprolide with or without apaluta mide 
 
 99 APPENDIX D : Representative Medications that May Predispose to Seizure  
Generic Name  Brand Name*  
aminophylline  Aminocont; Aminomal; Diaphyllin; Filotempo; Neophyllin; Norphyl ; 
Phyllocontin; Syntophyllin; Tefamin; Truphylline ; Xing You Shan;  
aminophylline in 
combination  Asmeton; Cha Xin Na Min; Emergent -Ez; Fufang Dan An Pian; Ke Zhi  
 
amitriptyline  
Amirol; Amitrip; Amixide; Deprelio; Diapatol; Elatrol; cElatrolet; Elavil; 
Endep; Enovil; Emitrip; Klotriptyl; Laroxyl; Levate; Limbitrol; Limbitryl; Mutabase; Mutabon; Nobritol; Novo- Triptyn; Pertriptyl; Redomex; 
Saroten; Sarotex; Sedans; Syneudon; Teperin; Triptizol; Triptyl; Tryptizol  
amitriptyline in 
combination  PMS- Levazine  
 
bupropion  
 Aplenzin; Buproban; Co ntrave; Elontril; Forfivo; Fortivo XL; Le Fu Ting; 
Prexaton; Quomem; Voxra; Wellbutrin; Wellbutrin XL; Wellbutrin SR; 
Yue Ting; Zyban  
chlorpromazine  Aminazin; Chlorazin; Hibernal; Klorproman; Largactil; Megaphen; 
Ormazine; Plegomazin; Solidon; Taroctyl;Thorazine; Vegetamin; 
Wintermin; Zuledin  
Note: in Ireland  also called “Clonazine” – very easy to confuse with 
clozapine.  
clozapine  Azaleptin; Clopine; Closastene; Clozaril; CloZAPine; Denzapine; Elcrit; 
Fazacio ODT; Klozapol; Lanolept; Leponex; Lozapine; Nemea; Ozapim; 
Synthon, Versacloz; Zaponex  
desipramine  Deprexan; Norpramin; Nortimil; Pertofrane  
doxepin  Adapin; Anten; Aponal; Deptran; Gilex; Li Ke Ning; Quitaxon; Silenor; 
Sinepin; Sinequan; Zonalon  
imipramine  Impril; Melipramin; Mipralin;  Norfranil,; Novo -Pramine; Persamine; 
Pertofram; Pryleugan; Talendep; Tofranil; Tolerade  
lithium  Arthriselect; Camcolit; Carbolith; Carbolithium; Eskolith; Hypnorex; Li -
Liquid; Licarbium; Limas; Liskonum; Litarex; Lithane; Lithicarb; 
Lithioderm; Lithionit ; Lithobid; Liticarb; Litiomal; Lito; Maniprex; 
Neurolepsin; Plenur; Priadel; Quilonorm; Quilonum; Saniquiet; Sedalit; 
Teralithe  
lithium in combination  Boripharm No 23; Emser Salz; Girheulit HOM; Helidonium -Plus; 
Heweurat N; rheuma -loges; Rhus Toxicodendr on Compose; Rhus -Plus; 
Ricinus Compose  
maprotiline  Cronmolin; Deprilept; Ludiomil; Mapromil; Melodil; Neuomil; Psymion  
meperidine/pethidine  Alodan ; Atropine and Demerol; Centralgine ; Demerol ; Dolantin ; 
Dolantina,; Dolantine ; Dolargan,; Dolcontral,; Dolestine ; Dolosal ; Dolsin; 
Fada; Hospira; Liba; Mepergan ; Meprozine,; Mialgin,; Opystan; Pethidine 
; Petigan Miro ; Psyquil compositum  
meperidine/pethidine  
in combination  Pamergan P100  
 
mesoridazine  Serentil, Mesorin  
mirtazapine  
 Arintapin; Avanza;  Axit; Combar; Esprital; Mi Er Ning; Miro; Mirta TAD; 
Mirtabene; Mirtachem; Mirtadepi; Mirtagamma; Mirtalan; MirtaLich; 
Mirtamylan; Mirtaron; Mirtaz; Mirtazelon; Mirtazon; Mirtazonal; Mirtel; 
Neoadjuvant abiraterone acetate plus leuprolide with or without apaluta mide 
 
 100 Mirtin; Mirtor; Mirzaten; Norset; Noxibel; Paidisheng; Psidep; R emergil; 
Remergon; Remeron; Remirta; Rexer; Yarocen; Zispin  
olanzapine  Anzorin, Arenbil; Arkolamyl; Atyzyo; Bloonis; Clingozan; Egolanza; 
Lansyn; Lanzek; Lazapix; Nolian; Nykob; Olafid; Olanzaran; Olanzep; 
Olanzin; Olanzine; Olapin; Olasyn; Olazax; Olpinat; Olzapin; Olzin; Ou 
Lan Ning; Ozilormar; Parnassan; Ranofren; Sanza; S tygapon; Synza; 
Ximin; Zalasta; Zamil; Zappa; Zapris; Zerpi; Zolafren; Zolaxa; Zonapir; 
Zopridoxin; Zylap; Zypadhera; Zypine; Zyprexa; Zyprexa Relprew; Zydis  
olanzapine in 
combination  Symbyax  
 
risperidone  Aleptan; Apo -Risperid; Arketin; Calmapride; Diaforin; Doresol; 
Hunperdal; Jing Ping; Ke Tong; Leptinorm; Lergitec; Orizon; Ozidal; 
Perdox; Ranperidon; Resdone; Ridal; Ridonex; Rileptid; Ripedon; Risepro; 
Rispa; Rispaksole; Rispefar; Rispemylan; Rispen; Rispera; Risperanne; 
Risperdal; Risperdalconsta ; Risperdaloro; Risperigamma; Risperon; 
Rispolept; Rispolux; Rispond; Rispons; Risset; Rixadone; Rorendo; Ryspolit; Si Li Shu; Sizodon; Speridan; Suo Le; Torendo; Zhuo Fei; Zhuo 
Fu; Ziperid; Zoridal  
theophylline  Aerolate; Afonilum; Aminomal; An Fei Lin; A pnecut; Apo -Theo; Asmalix; 
Asmalon; Bi Chuan; Bronchoparat; Bronchoretard; Cylmin; Diffumal; Elixifilin; Elixophyllin; Etipramid; Euphyllin; Euphyllina; Euphylline; 
Euphylong; Frivent; Gan Fei Lin; Nuelin; Protheo; Pulmophylline; 
Quelesu; ratio -Theo- Bronc;  Respicur; Retafyllin; Shi Er Ping; Slo -Bid; Slo -
Phyllin; Telbans; Teotard; Terdan; Teromol; Theo -24; Theo- Dur; Theo; 
Theochron; Theodur; Theofol; Theolair; Theoplus; Theospirex; Theostat ;  
Theotard; Theotrim; Theovent; Tromphyllin; Unicon; Unicontin; Uni fyl; 
Uniphyl; Uniphyllin Continus; Uniphyllin; UniXan; Xanthium; Xi Fu Li; 
Yan Er  
theophylline in 
combination  Antong; Baladex; Bi Chuan; Binfolipase; Broncho -Euphyllin; Broncomar; 
Do-Do ChestEze; Elixophyllin- GG; Elixophyllin -KI; Insanovin; Marax ; 
Neoasm a; Theofol Comp; Theophedrinum -N; Xu Hong; Yi Xi Qing  
thioridazine  Detril; Elperil; Melleril; Ridazin; Ridazine; Thiodazine; Thioril; Sonapa  
ziprasidone  Geodon; Li Fu Jun An; Pramaxima; Si Bei Ge; Ypsila; Zeldox; Zipwell; 
Zypsila; Zypsilan  
** Note:  thi s document is intended as an aid in identifying prohibited meds, but due to the global 
scope of the apalutamide studies may not be all inclusive.  
 
 
 
Neoadjuvant abiraterone acetate plus leuprolide with or without apaluta mide 
 
 101 APPENDIX E: Intra -operative and Post -operative RP Complications Q uestionnaire s 
 
Intraoperative Surgical Questionnaire  
                        Date ___/___/___ 
          
I. Patient Data  
 
A. Patient’s First Name __________________ B. Patient’s Last Name __________________  C. ID# __________________  
II. Operative Information  
 A. Age at Surgery: ___________ yr s 
 B. Date of Surgery: ___/___/___  C. Surgical Approach: Retropubic____, Perineal____, Laparoscopic____, Robotic_____  D. Neurovascular Bundle Preserved: Two_____, One_____, None_____  
 E. Ease of Neurovascular Bundle Preservation: Easy____, Moderate____, Difficult_____ 
 F. Lymph Node Dissection: Yes____, No____  
 G. Technical Modifications: ______________________________________________  H. Estimated Blood Loss (cc) _______________  
 I. Blood Transfusion Required: Yes____, No____; if yes,  
 Intraoperative Autologous Units_____, Postoperative Autologous Units_____  Intraoperative Nonautologous Units_____, Postoperative Nonautologous Units_____  J. Hemodiluted: Yes____, No_____   
K. Intraoperative Complication: Yes____, No_____; if yes, type of intraoperative   
 complication:___________________________________________       
 
Neoadjuvant abiraterone acetate plus leuprolide with or without apaluta mide 
 
 102 In Hospital Complications Surgical Questionnaire  
(to be completed after surgery)  
                        Date ___/___/___ 
 
 I. Patient Data  
  A. Patient’s First Name __________________ B. Patient’s Last  Name ________________ 
 
  C. ID# __________________ 
 
 II. Patient Data  
   A. Post-operative days admitted_______ 
   
  B. In Hospital Complication: Yes ____, No _____. If yes, circle all appropriate. 
   General:  
   1. Fever  
   2. Paralytic ileus  
   3. Deep vein thrombosis  
    4. Pulmonary embolism  
    5. Myocardial infarction  
    6. Cerebrovascular stroke  
   Specific:  
   1. Prolonged tube drainage  
   2. Foley Catheter Fell Out 
   3. Wound infection  
   4. Wound dehiscence  
   5. Hematuria with clots  
   6. Obstructed catheter  
   Other (not listed above) : ________________________________________________ 
   
  C. Tr ansfusion Yes ____, No _____. If yes , # of units : ________  
  
 
 
 
     
       
Neoadjuvant abiraterone acetate plus leuprolide with or without apaluta mide 
 
 103 APPENDIX F: Post -Operative Complications (Clavian Classification)  
Note: For any question answered “Yes”, please grade and attribute in the patient note. 
 Cardiac  
• Arrhythmia (Y____N____)  
• Myocardial Infarction (Y____N____)  
• Not otherwise specified (Y____N____)  
Lymphovascular  
• Lymphocele (Y____N____)  
• Infected lymphocele (Y____N____)  
• Lymphedema (Y____N____)  
• Postop bleeding (Y____N____)  
Gastrointestinal  
• Diarrhea (Y____N____)  
• Ileus (Y____N____)  
• Enterotomy (Y____N____)  
• Rectal laceration (Y____N____)  
• Rectal Bleeding (Y____N____)  
• SBO (Y____N____)  
• Not otherwise specif ied (Y____N____)  
Infectious  
• C. Difficile (Y____N____)  
• Pneumonia (Y____N____)  
• UTI (Y____N____)  
• Abscess (Y____N____)  
• Epididymitis/orchitis (Y____N____)  
Neurologic  
• Neuropraxia (Y____N____)  
• Transient Ischemic Attack – Stroke (Y____N____)  
• Syncope (Y____N____)  
• Psychiatric event (Y____N____)  
• Pain not otherwise specified (Y____N____)  
Pulmonary  
• Respiratory distress/failure (Y____N____)  
• Pulmonary Embolus (Y____N____)  
• Deep Vein Thrombosis (Y____N____)  
Renal  
• Acute renal failure (Y____N____)  
Urologic  
• Ureteral trauma (Y ____N____)  
• Intractable bladder spasms (Y____N____)  
• Clot retention (Y____N____)  
• Disrupted anastomosis (Y____N____)  
• Gross hematuria (Y____N____)  
• Retention (Y____N____)  
Neoadjuvant abiraterone acetate plus leuprolide with or without apaluta mide 
 
 104 • Foley malfunction (Y____N____)  
• Urine leak / urinoma (Y____N____)  
Wound  
• Dehiscence (Y____N____)  
• Infection (Y____N____)  
• Hernia (Y____N____)  
Opht halmologic  
• Xerophthalmia (Y____N____)  
Other 
• Dehydration (Y____N____)  
• Allergic reaction (Y____N____)  
• Unplanned Admission (Y____N____)  
• Unplanned Emergency Room Visit (Y____N____)  
 
      Provider Sig nature: _________________________________ Date: __________________ 
    
   
 
                
  
Neoadjuvant abiraterone acetate plus leuprolide with or without apaluta mide 
 
 105 APPENDIX G : The Expanded Prostate Cancer Index Composite (EPIC -26 +)  
 
This questionnaire is designed to measure Quality of Life issues in patients with Prostate Cancer. To help us get the most accurate measurement, it is important that you answer all questions honestly and completely.  Remember, as with all medical records, information contained within this survey will remain strictly confidential.  
 Name: ________________________ ID: __________________________ Cycle: ______________________ Today’s Date: ___/____/____   1. Over the past 4 weeks , how often have you leaked urine? (Circle one number)  
 
More than once a day...........................  1 
About once a  day..................................  2 
More than once a week.........................  3    
About once a week...............................  4 
Rarely or never.....................................  5 
 
2. Which of the following best describes your urinary c ontrol during the last 4 weeks ? 
(Circle one number)  
 
No urinary control whatsoever.............  1 
Frequent dribbling................................  2 
Occasional dribbling............................  3 
Total control.........................................  4 
 
3. How many pads or adult diapers per day  did you usually use to control leakage during 
the last 4 weeks ? (Circle one number)  
 
None..........................................  0 
1 pad per day.............................  2 
2 pads per day............................  3 
3 or more pads per day..............  4 
 
4. How big a problem, if any, has each of the following been for you during the last 4 weeks ? (Circle one number on each line)  
 
 
No 
Problem  Very 
Small 
Problem  Small 
Problem  Moderate 
Problem  Big 
Problem  
a. Dripping or leaking 
urine........................  0 1 2 3 4 
b. Pain or burning on 
urination..................  0 1 2 3 4 
Neoadjuvant abiraterone acetate plus leuprolide with or without apaluta mide 
 
 106 c. Bleeding 
urination..................   
0  
1  
2  
3  
4 
d. Weak urine stream 
or incomplete 
emptying..................  0 1 2 3 4 
e. Need to urinate 
frequently during 
the day.....................  0 1 2 3 4 
 
5. Overall, how big a problem has your urinary function been for you during the last 4 
weeks ? (Circle one number)  
 
No problem.......................................................  1 
Very small problem..........................................  2 
Small problem..................................................  3 
Moderate problem........................................... . 4 
Big problem......................................................  5 
 
6. How big a problem, if any, has each of the following been for you? (Circle one number on each line)  
 No 
Problem  Very 
Small 
Problem  Small 
Problem  Moderate 
Problem  Big 
Problem  
a. Urgency to have a 
bowel 
movement...........  0 1 2 3 4 
b. Increased frequency of 
bowel movements.......  0 1 2 3 4 
c. Losing control of your 
stools...........................  0 1 2 3 4 
d. Bloody stools..............  0 1 2 3 4 
e. Abdominal/Pelvic/Rec
tal Pain........................  0 1 2 3 4 
 
7. Overall, how big a problem have your bowel habits been for you during the last 4 weeks ? (Circle one number)  
 
No problem.......................................  1 
Very small problem...........................  2 
Small problem..................................  3 
Moderate problem............................  4 
Big problem......................................  5 
 
8. How would you rate each of the following during the last 4 weeks ? (Circle one number 
on each line)  
Neoadjuvant abiraterone acetate plus leuprolide with or without apaluta mide 
 
 107  Very 
Poor to 
None  Poor  Fair Good  Very 
Good  
a. Your ability to have an erection?..  1 2 3 4 5 
b. Your ability to reach orgasm 
(climax)?........................................  1 2 3 4 5 
 
9. How would you describe the usual QUALITY of your erections during the last  4 
weeks ? (Circle one number)  
 
None at 
all..................................................................................  1 
Not firm enough for sexual 
activity...........................................  2 
Firm enough for masturbation and foreplay 
only......................  3 
Firm enough for 
intercourse.......................................................  4 
 
10. How would you describe the FREQUENCY of your erections during the last 4 weeks ? 
(Circle one number)  
 
I NEVER had an erection when I wanted 
one...........................  1 
I had an erection LESS THAN HALF the time I wanted 
one...  2 
I had an erection ABOUT HALF the time I wanted 
one...........  3 
I had an erection MORE THAN HALF the time I wanted 
one. 4 
I had an erection WHENEVER I wanted 
one............................  5 
 
11. Overall, how would you rate your ability to function sexually during the last 4 weeks ? 
(Circle one number)  
 
Very poor...........................................   
1 
Poor....................................................  2 
Fair.....................................................  3 
Good..................................................  4 
Very good..........................................  5 
 
12. Overall, how big a problem has your sexual function or lack of sexual function been for you during the last 4 weeks ? (Circle one number)  
 
No problem.......................................  1 
Very small problem..........................  2 
Neoadjuvant abiraterone acetate plus leuprolide with or without apaluta mide 
 
 108 Small problem...................................  3 
Moderate problem.............................  4 
Big problem......................................  5 
 
13. How big a problem during the last 4 weeks , if any, has each of the following been for 
you? (Circle one number on each line)  
  
No 
Problem  Very 
Small 
Problem   
Small  
Problem   
Moderate 
Problem   
Big 
Problem  
a. Hot Flashes....................  0 1 2 3 4 
b. Breast 
tenderness/enlargement..   
0  
1  
2  
3  
4 
c. Feeling depressed..........  0 1 2 3 4 
d. Lack of energy...............  0 1 2 3 4 
e. Change in body weight..  0 1 2 3 4 
 
Supplemental Questions  
 1. Are you currently using any of the following medications, treatment, or devices for urinary incontinence?  Check all that apply:  
___A. Oral Medications (Ditropan, Detrol, Sancture, etc.)  
___B. Surgical Sling ___C. Artificial Sphincter  
___D. None of the above  
 
2. Are you currently using any of the following medications, treatment, or devices for erectile dysfunction?  Check all that apply:  
 ___A. Oral Medications (Viagr a, Levitra, Cialis)  
___B. MUSE (intra -urethral alprostadil suppository)  
___C. Vacuum erection device (such as Erect -Aid) 
___D. Penile prosthesis  
___E. No treatment (none of the above)  
  
 
       
     
Neoadjuvant abiraterone acetate plus leuprolide with or without apaluta mide 
 
 109  
 
APPENDIX H: Family History Questionnaire  
 
Name:                                                                       Date of Birth   
Please complete this form by listing all family members ( blood relatives ) known to you with a cancer diagnosis.  
Please identify your relatives using their first name, and first  letter of their  last name only.   
 
 
Relative   
Cancer(s) – What Type(s)?  Approximate Age 
at Diagnosis  
Mother    
Father    
Children  
   
Grandchildren  
   
Mother’s Mother (grandmother)  
   
Mother’s Father (grandfather)  
   
Father’s mother (grandmother)  
   
Father’s father (grandfather)  
   
Brothers  
Example :  John C . 
 
 
  
Prostate Cancer   
58 
Sisters  
 
 
   
Nieces (children of brothers/sisters)  
 
   
Nephews (children of 
brothers/sisters)  
 
   
Neoadjuvant abiraterone acetate plus leuprolide with or without apaluta mide 
 
 110 Other Relatives on Mother’s side  
Describe how related:  
Example: Mary S.   Maternal aunt  
 
 
 
  
 
Ovarian Cancer   
 
67 
Other Relatives on Father’s side  
Describe how related:  
 
 
   
 
 
 
                        
        
Neoadjuvant abiraterone acetate plus leuprolide with or without apaluta mide 
 
 111  
       
APPENDIX I  
Dana -Farber/Harvard Cancer Center  
Multi -Center Data and Safety Monitoring Plan  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
  
Neoadjuvant abiraterone acetate plus leuprolide with or without apaluta mide 
 
 112  
TABLE OF CONTENTS  
1. INTRODUCTION  
 
1.1 Purpose  
1.2 Multi- Center Data and Safety Monitoring Plan Definitions  
 
2. GENERAL ROLES AND RESPONSIBILITIES  
 
2.1 DF/HCC Sponsor  
2.2 Coordinating Center  
2.3 Participating Institution  
 
3. DF/HCC REQUIREMENTS FOR MULTI -CENTER PROTOCOLS  
 
3.1 Protocol Distribution  
3.2 Protocol Revisions and Closures  
3.3 Informed Consent Requirements  
3.4 IRB Documentation  
3.5 IRB Re -Approval  
3.6 Participant Confidentiality and Authorization Statement  
3.7 DF/HCC Multi- Center Protocol Registration Policy  
3.8 DF/HCC Protocol Case Number  
3.9 Safety Assessments and Toxicity Monitoring  
3.10 Data Management  
 
4. REQUISITIONING INVESTIGATIONAL DRUG  
  
5. MONITORING: QUALITY CONTROL  
 
5.1 Ongoing Monitoring of Protocol Compliance  
5.2 Monitoring Reports  
5.3 Accrual Monitoring  
 
6. AUDITING: QUALITY ASSURANCE  
 
6.1 DF/HCC Internal Audits  
6.2 Audit Notifications  
6.3 Audit Reports  
6.4 Participating Institution Performance  
 
  
Neoadjuvant abiraterone acetate plus leuprolide with or without apaluta mide 
 
 113 1.0 INTRODUCTION 
 
The Dana- Farber/Harvard Cancer Center Multi -Center Data and Safety Monitoring Plan 
(DF/HCC DSMP) outlines the procedures for conducting a DF/HCC Multi -Center research 
protocol. The DF/HCC DSMP should serve as a reference for any sites external to DF/HCC 
that will be participating in the research protocol.  
 
1.1 Purpose  
 
To establish standards that will ensure that a Dana -Farber/Harvard Cancer Center Multi -
Center protocol will comply with Federal Regu lations, Health Insurance Portability and 
Accountability Act (HIPAA) requirements and applicable DF/HCC Standard Operating Procedures  
 
1.2 Multi -Center Data and Safety Monitoring Plan  Definitions  
 
DF/HCC Multi -center Protocol :  A research protocol in which one  or more outside 
institutions are collaborating with Dana -Farber/Harvard Cancer Center where  a DF/HCC 
investigator is the sponsor. DF/HCC includes Dana- Farber/Partners Cancer Care (DF/PCC) 
Network Clinical Trial Affilia tes.  
 Lead Institution:  One of the  Dana- Farber/Harvard Cancer Center consortium members 
(Dana -Farber Cancer Institute (DFCI), Massachusetts General Hospital (MGH), Beth Israel 
Deaconess Medical Center (BIDMC), Children’s Hospital Boston (CHB), Brigham and Women’s Hospital (BWH) responsible for the coordination, development, submission, and approval of a protocol as well as its subsequent amendments per the DFCI IRB and 
applicable regulatory guidelines (Food and Drug Administration (FDA)).  The Lead Institution is typically the home of the DF/HCC Sponsor. The Lead Institution also typically serves as the Coordinating Center for the DF/HCC Multi -Center Protocol.   
 DF/HCC Sponsor:  The  person sponsoring the submitted Multi -Center protocol.  Within 
DF/HCC, th is person is the Overall Sponsor  Investigator who takes responsibility for 
initiation, management and conduct of the protocol at all research locations. In applicable protocols, the DF/HCC Sponsor will serve as the single liaison with any regulatory agencies (i.e. FDA). The DF/HCC Sponsor  has ultimate authority over the protocol and is responsible 
for the conduct of the study at DF/HCC and all Participating Institutions. In most cases the DF/HCC Sponsor is the same person as the DF/HCC Principal Investigator; however, both roles can be fil led by two different people.  
 
Participating Institution:  An institution that is outside the DF/HCC and DF/PCC consortium that is collaborating with DF/HCC on a protocol where the sponsor is a DF/HCC Investigator.  The Participating Institution acknowledges the DF/HCC Sponsor as having the ultimate authority and responsibility for the overall conduct of the study.    
 Coordinating Center:  The entity (i.e. Lead Institution) that provides administrative support 
to the DF/HCC Sponsor in order that he/she may fulfill the responsibilities outlined in the 
protocol document and DSMP, and as specified in applicable regulatory guidelines. In 
Neoadjuvant abiraterone acetate plus leuprolide with or without apaluta mide 
 
 114 general, the Lead Institution is the Coordinating Center for the DF/HCC Multi -Center 
Protocol.  
 DF/HCC Office of Data Quality  (ODQ): A group within DF/HCC responsible ensuring 
high-quality standards are used for data collection and the ongoing management of clinical 
trials, auditing, and data and safety monitoring. ODQ also coordinates quality assurance efforts related to multi- center clinical research.  
 DF/HCC Clinical Trials Research Informatics Office (CTRIO): A group within DF/HCC responsible for providing a comprehensive data management platform for managing clinical trial data.  
 
2.0 GENERAL ROLES AND RESPONSIBILITIES  
For DF/HCC Multi- Center Protocols, the DF/HCC Sponsor, the Coordinating Center, and 
the Participating Institutions are expected to adhere to the following general responsibilities:  
 
2.1 DF/HCC Sponsor  
 The DF/HCC Sponsor, Dr. Mary -Ellen Taplin will accept res ponsibility for all aspects of 
conducting a DF/HCC Multi -Center protocol which includes but is not limited to:  
• Oversee the coordination, development, submission, and approval of the protocol as well as subsequent amendments.  
• Ensure that the investigators , study team members, and Participating Institutions 
are qualified and appropriately resourced to conduct the protocol.   
• Submit the Multi- Center Data and Safety Monitoring Plan as an appendix to the 
protocol. 
• Assure all Participating Institutions are usin g the correct version of the protocol. 
• Ensure that each participating investigator and study team receives adequate 
protocol training and/or a Site Initiation Visit prior to enrolling participants and 
throughout trial’s conduct as needed.  
• Ensure the protoc ol will be provided to each participating site in a language 
understandable to all site personnel when English is not the primary language.  
• Monitor progress and overall conduct of the study at all Participating Institutions.  
• Ensure all DFCI Institutional Review Board (IRB), DF/HCC and other applicable (i.e. FDA) reporting requirements are met.  
• Review data and maintain timely submission of data for study analysis.  
• Act as the single liaison with FDA (investigator -held IND trials).  
• Ensure compliance with all requirements as set forth in the Code of Federal 
Regulations, applicable DF/HCC requirements, HIPAA requirements, and the 
approved protocol. 
• Commit to the provision that the protocol will not be rewritten or modified by anyone other than the DF/HCC Sponsor.  
• Identify and qualify Participating Institutions and obtain accrual commitments prior to extending the protocol to that site.  
• Monitor accrual and address Participating Institutions that are not meeting their accrual requirements.  
 
Neoadjuvant abiraterone acetate plus leuprolide with or without apaluta mide 
 
 115  
2.2 Coordinating Cent er  
 
The Coordinating Center will assume the following general responsibilities: 
• Assist in protocol development  
• Maintain copies of Federal Wide Assurance and Institutional Review Board (IRB) approvals from all Participating Institutions.  
• Maintain FDA corr espondence, as applicable.  
• Maintain updated roster of participants.  
• Verify eligibility.  
• Verify response.  
• Oversee the data collection process from Participating Institutions.  
• Maintain documentation of Serious Adverse Event (SAE) reports submitted by Participating Institutions and submit to DF/HCC Sponsor for timely review.   
• Distribute adverse events reported to the DF/HCC Sponsor that fall under the DFCI IRB Adverse Event Repo rting Policy to all participating investigators.  
• Provide Participating Institutions with information regarding DF/HCC requirements 
that they will be expected to comply with.    
• Monitor Participating Institutions either by on -site or virtual monitoring.  
• Maintain Regulatory documents of all Participating Institutions.  
• Conduct regular communications with all Participating Institutions (conference 
calls, emails, etc).  
• Maintain documentation of all communications. 
• Ensure that each Participating Institution has  the appropriate assurance on file with 
the Office of Human Research Protection (OHRP).     
 
2.3 DF/HCC Office for Data Quality ( ODQ ) 
 In addition to the Coordinating Center, the DF/HCC ODQ provides the following support 
services to assist the DF/HCC Sponsor:  
• Develop protocol specific case report forms (CRF/eCRFS). 
• QA/QC data of protocol specific CRFs.  
• Provide a central participant registration, which includes review of consent and eligibility.  
• Provide auditing services (funding and ODQ approval required).  
 
2.4 Participating Institution  
 Each Participating Institution is expected to comply with all applicable Federal Regulations and DF/HCC requirements, the protocol and HIPAA requirements. All Participating Institutions will provide a list of personnel assigned to the role for oversight of data management at their site to the Coordinating Center.  
 
The general responsibilities for each Participating Institution are as follows: 
• Document the delegation of research specific activities to study personnel.  
• Commit to th e accrual of participants to the protocol. 
Neoadjuvant abiraterone acetate plus leuprolide with or without apaluta mide 
 
 116 • Submit protocol and/or amendments to their local IRB.  
• Maintain a regulatory binder in accordance with DF/HCC requirements.  
• Provide the Coordinating Center with regulatory documents as requested.  
• Participate in pro tocol training prior to enrolling participants and throughout the trial 
as needed (i.e. teleconferences).  
• Update Coordinating Center with research staff changes on a timely basis.  
• Register participants through the Coordinating Center.  
• Submit source documents, research records, and CRFs per protocol specific 
submission guidelines to the Coordinating Center.  
• Submit Serious Adverse Event (SAE) reports to local IRB per local requirements and to the Coordinating Center, in accordance with DF/HCC requireme nts.  
• Submit protocol deviations and violations to local IRB per local requirements and to the DF/HCC Sponsor in accordance with DF/HCC requirements. 
• Order, store and dispense investigational agents and/or other protocol mandated 
drugs per federal guidelin es and protocol requirements. 
• Have office space, office equipment, and internet access that meet HIPAA standards.  
• Participate in any quality assurance activities and meet with monitors or auditors at 
the conclusion of a visit to review findings.  
Promptly provide follow -up and/or corrective action plans for any monitoring queries or audit 
findings.  
3.0 DF/HCC REQUIREMENTS FOR MULTI -CENTER PROTOCOLS  
The following section will clarify DF/HCC Requirements and further detail the expectations for participating in a DF/HCC Multi- Center protocol.  
 
3.1 Protocol Distri bution  
 The Coordinating Center will distribute the final DFCI IRB approved protocol and any subsequent amended protocols to all Participating Institutions.    
 
3.2 Protocol Revisions and Closures  
 The Participating Institutions will receive notification of protocol r evisions and closures 
from the Coordinating Center .  It is the individual Participating Institution’s responsibility 
to notify its IRB of these revisions. 
 
• Non life -threatening revisions:  Participating Institutions will receive written 
notification of prot ocol revisions regarding non life -threatening events from the 
Coordinating Center. Non- life-threatening protocol revisions must be IRB approved 
and implemented within 90 days from receipt of the notification. Approval memo 
and documents must be submitted t o the Coordinating Center.  
 
• Revisions for life -threatening causes:  Participating Institutions will receive 
immediate notification from the Coordinating Center concerning protocol revisions 
required to protect lives with follow -up by fax, mail, e -mail, etc .  Life -threatening 
protocol revisions will be implemented immediately followed by IRB request for approval.  
 
Neoadjuvant abiraterone acetate plus leuprolide with or without apaluta mide 
 
 117 • Protocol closures and temporary holds:  Participating Institutions will receive 
notification of protocol closures and temporary holds from the Coor dinating Center. 
Closures and holds will be effective immediately.  In addition, the Coordinating 
Center, will update the Participating Institutions on an ongoing basis about protocol accrual data so that they will be aware of imminent protocol closures.  
 
3.3 Informed Consent Requirements  
 The DF/HCC approved informed consent document will serve as a template for the informed consent for Participating Institutions. The Participating Institution consent form must follow the consent template as closely as possibl e and should adhere to specifications 
outlined in the DF/HCC Guidance Document on Model Consent Language for PI -Initiated 
Multi- Center Protocols.  This document will be provided separately to each Participating 
Institution.  
 Participating Institutions are to send their version of the informed consent document and HIPAA authorization, if a separate document, to the Coordinating Center for review and approval prior to submission to their local IRB. The approved consent form must also be submitted to the Coordinating Center after approval by the local IRB.  
 The Principal Investigator (PI) at each Participating Institution will identify the physician members of the study team who will be obtaining consent and signing the consent form for therapeutic protocols. P articipating institutions must follow the DF/HCC requirement that 
only attending physicians obtain informed consent and re -consent to interventional trials 
(i.e. drug and/or device trials).   
 
3.4 IRB Documentation  
 The following must be on file with the Coordinating Center: 
• Initial approval letter of the Participating Institution's IRB.  
• Copy of the Informed Consent Form(s) approved by the Participating Institution’s IRB.  
• Participating Institution’s IRB approval for all amendments.  
• Annual approval letters by the Participating Institution's IRB.  
 
 
3.5 IRB Re -Approval  
 Verification of IRB re -approval from the Participating Institutions is required in order to 
continue research activities.  There is no grace period for continuing approvals. 
 
The Coordinating Center will not register participants if a re -approval letter is not received  
from the Participating Institution on or before the anniversary of the previous approval date.   
 
3.6 Participant Confidentiality and Authorization Statement  
 
Neoadjuvant abiraterone acetate plus leuprolide with or without apaluta mide 
 
 118 In 1996, congress passed the f irst federal law covering the privacy of health information 
known as the Health Insurance Portability and Accountability Act ( HIPAA). Any 
information, related to the physical or mental health of an individual is called Protected 
Health Information (PHI). H IPAA outlines how and under what circumstances PHI can be 
used or disclosed.  
 
In order for covered entities to use or disclose protected health information during the course of a study, the study participant must sign an Authorization.  This Authorization may or 
may not be separate from the informed consent document.  The Coordinating Center, with the approval from the DFCI IRB will provide a consent template, which covered entities (Participating Institutions) must use.   The DF/HCC Sponsor will use all efforts to limit its use of protected health information in its trials.  However, because of the nature of these trials, certain protected health information must be collected per NCI requirements. These are the primary reasons why DF/HCC has chosen to use  Authorizations, signed by the participant in the trial, rather than limited data 
sets with data use agreements.  
 3.6.1  DF/HCC Multi -Center Protocol Confidentiality  
 All documents, investigative reports, or information relating to the participant are strictly confidential. Whenever reasonably feasible, any participant specific reports (i.e. Pathology 
Reports, MRI Reports, Operative Reports, etc.) submitted to the Coordinating Center must have the participant’s full name & social security number “blacked out” and the assigned 
DF/HCC ODQ case number (as described below) and DF/HCC protocol number written in (with the exception of the signed informed consent document). Participant initials may only be included or retained for cross verification of identification 
 
3.7 DF/HCC Multi -Center Protocol Registration  Policy  
 
3.7.1 Participant Registration and Randomization  
To register a participant, the following documents should be completed by the 
Participating Institution and faxed  to the Coordinating Center at Dana -Farber Cancer 
Institute at (617) 632- 6220  or e-mailed to the DFCI Clinical Research Manager and 
Clinical Research Coordinator.  
Please notify the DFCI team in advance that a registration packet is to be expected with 
the following items:  
• Current IRB approved informed consent document signed by participant and investigator .  Participant name and MRN must be redacted. Please ensure the 
participant’s initials are written on each page of the informed consent document. 
•  HIPAA authorization form (if separate from the informed consent document)  
•  Signed and dated DFCI eligibility checklist  
•  The following source documentation is typically required. Please note additional 
documentation may be required by the lead institution : 
– Labs for PSA values used to determine eligibility (lab values used to 
determine eligibility, including screening PSA)  
Neoadjuvant abiraterone acetate plus leuprolide with or without apaluta mide 
 
 119 – Reports documenting disease status : CT or MRI Abdomen and Pelvis . 
Bone Scan  
– Pathology Report  
– Concomitant medication list  
– Progress note or equivalent documentation of consenting visit  
– Progress note documenting medical history and oncologic history  
– All screening labs  
– Screening visit note, with BP, vital signs, ECOG Performance status  
– Screening ECG  
– MUGA Scan or ECHO  
 
The Coordinating Center will review the submitted documents in order to verify 
eligibility and consent. To complete the registration process, the Coordinating Center 
will:  
• Register the participant on the study with the DF/HCC ODQ 
• Upon receiving confirmation of registration by the ODQ, the Coordinating Center 
will inform the Participating Institution and provide the study specific participant case number, and if applicable the dose treatment level.  
 Treatment may not begin without confirmation from the Coordinating Center 
that the participant has been registered.   Randomization can only occur during ODQ’s normal business hours, Monday through 
Friday from 8:00 AM to 5:00 PM Eastern Time.  3.7.2 Initiation of Therapy  
 
Participants must be registered with the DF/HCC ODQ before receiving treatment.  
Treatment may not be initiated until the Participating Institution receives a faxed or e -mailed 
copy of the participant’s registration confirmation memo from the Coordinating Center. Therapy must be initiated per protocol guidelines.  The DF/HCC Sponsor and DFCI IRB must be notified of any exceptions to this policy.  
 3.7.3 Eligibility Exceptions  
 The DF/HCC ODQ will make no exceptions to the eligibility requirements for a protocol 
without DFCI IRB approval. The DF/HCC ODQ requires each institution to fully comply 
with this requirement.  
 
3.7.4 Verification of Registration, Dose Levels, and Arm Designation  
 A registration confirmation memo for participants registered to DF/HCC Multi- Center 
Protocol will be faxed or emailed to the registering institution within one business day of the registration.  Treatment may not be initiated until the site receives a faxed or e -mailed 
copy of the registration confirmation memo.  
 
3.8 DF/HCC Protocol Case Number  
Neoadjuvant abiraterone acetate plus leuprolide with or without apaluta mide 
 
 120  
Once eligibility has been established and the participant successfully registered, the 
participant is assigned a five digit protocol case number.  This number is unique t o the 
participant on this trial and must be used for ODQ CRF/eCRF completion and 
correspondence, and correspondence with the Coordinating Center.   
 
3.9 Protocol Deviations, Exceptions and Violations  
Federal Regulations require an IRB to review proposed change s in a research activity to 
ensure that researchers do not initiate changes in approved research without IRB review and approval, except when necessary to eliminate apparent immediate hazards to the participant. DF/HCC requires all departures from the defi ned procedures set forth in the 
IRB approved protocol to be reported to the DF/HCC Sponsor, who in turn is responsible for reporting to the DFCI IRB.  
  
For reporting purposes, DF/HCC uses the terms “violation”, “deviation” and “exception” to describe deriv ations from a protocol. All Participating Institutions must adhere to these 
requirements for reporting to the DF/HCC Sponsor and will follow their institutional policy for reporting to their local IRB.  
 
3.9.1 Definitions  
 
Protocol Deviation: Any departure from t he defined procedures set forth in the IRB -
approved protocol which is prospectively approved prior to its implementation.  
 
Protocol Exception:  Any protocol deviation that relates to the eligibility criteria, e.g.  
enrollment of a participant who does not meet all inclusion/exclusion criteria.  
   
Protocol Violation : Any protocol deviation that was not prospectively approved  by the IRB 
prior to its initiation or implementation.   
 
3.9.2  Reporting Procedures  
 
DF/HCC Sponsor:  is responsible for ensuring that clear documentation is available in the 
medical record and/or regulatory documents to describe all protocol exceptions, deviations and violations. The DF/HCC Sponsor will also be responsible for ensuring that all protocol violations/deviations are promptly repor ted per DFCI IRB guidelines.  
 
Participating Institutions : Protocol deviations require prospective approval from the DFCI 
IRB. The Participating Institution must submit the deviation request to the Coordinating Center who will then submit the deviation req uest to the DFCI IRB. Upon DFCI IRB 
approval the deviation is submitted to the Participating Institution IRB, per institutional policy. A copy of the Participating Institution’s IRB report and determination will be forwarded to the Coordinating Center within 10 business days after the original submission.  
 All protocol violations must be sent to the Coordinating Center in a timely manner.  
 
Neoadjuvant abiraterone acetate plus leuprolide with or without apaluta mide 
 
 121 Coordinating Center:   Upon receipt of the violation/deviation report from the Participating 
Institution, the Coordina ting Center will submit the report to the DF/HCC Sponsor for 
review. Subsequently, the Participating Institution’s IRB violation/deviation report will be 
submitted to the DFCI IRB for review per DFCI IRB reporting guidelines.  
 
3.10 Safety Assessments and Toxic ity Monitoring 
 The study teams at all participating institutions are responsible for protecting the safety, rights and well -being of study participants. Recording and reporting of adverse events that 
occur during the course of a study help ensure the cont inuing safety of study participants.  
 All participants receiving investigational agents and/or other protocol mandated treatment will be evaluated for safety. The safety parameters include all laboratory tests and hematological abnormalities, physical exa mination findings, and spontaneous reports of 
adverse events reported by participants.  All toxicities encountered during the study will be evaluated according to the NCI criteria specified in the protocol. Life -threatening toxicities 
must be reported imme diately to the DF/HCC Sponsor via the Coordinating Center.  
 
Additional safety assessments and toxicity monitoring will be outlined in the protocol.  
 
3.10.1 Guidelines for Reporting Serious Adverse Events  
 
Guidelines for reporting Adverse Events (AEs) and Serious Adverse Events (SAEs) are detailed in protocol section 11.     
 Participating Institutions must report the AEs to the DF/HCC Sponsor and the Coordinating Center following the DFCI IRB SAE Reporting Requirements.  
 The Coordinating Center will maintain documentation of all Participating Institution Adverse Event reports and be responsible for communicating to all participating 
investigators, any observations reportable under the DFCI IRB Reporting Requirements.  Participating Investigators will revie w any distributed AE reports, send a copy to their IRB 
according to their local IRB’s policies and procedures, and file a copy with their regulatory documents. 
 
3.10.2 Guidelines for Processing IND Safety Reports  
 
 The DF/HCC Sponsor will review all IND Safety Reports and ensure that all IND Safety Reports are distributed to the Participating Institutions.  Participating Institutions will 
review /submit to their IRB according to their institutional policies and procedures.     
3.11 Data Management  
 DF/HCC CTRIO  develops  case report forms (CRF/eCRF s), for use with the protocol.These 
forms are designed to collect data for each study. DF/HCC CTRIO  provides a web based 
training for  all eCRF users.    
3.11.1 Data Forms Review  
 
Neoadjuvant abiraterone acetate plus leuprolide with or without apaluta mide 
 
 122 Data submissions are monitored for timeliness and completeness of submission. If study 
forms are received with missing or questionable data, the submitting institution will receive a written or electronic query from the DF/HCC Office of Data Quality, Coord inating Center,  
or designee.  
 Responses to all queries should be completed and submitted within 14 calendar days.   
 Responses may be returned on the written query or on an amended paper case report form, or in the case of electronic queries, within the electronic data capture (eDC) system. In the 
case of a written query for data submitted on a paper case report form,  the query must be 
attached to the specific data being re -submitted in response.   
 
If study forms are not submitted on schedule, the Participating Institution will periodically receive a Missing Form Report from the Coordinating Center noting the missing for ms.  
4.0    REQUISITIONING INVESTIGATONAL DRUG
  
The ordering of investigational a gent is specified in the protocol  sections 7.1.8, and 7.2.7. 
 Participating Institutions should order their own agent regardless of the supplier (pharmaceutical company , commercia l supply, etc .)   
 If the agent is commercially available, check with the local Director of Pharmacy and/or the Research Pharmacy to ensure that the agent is in stock. If the agent is not stocked, ensure that the agent can be ordered once the protocol is a pproved by the local IRB.  
 If the agent is investigational, ensure that the pharmacy will be able to receive and store the agent according to state and federal requirements. The local IRB should be kept informed of who will supply the agent (i.e., NCI or a pharmaceutical company) so that any regulatory responsibilities can be met in a timely fashion.  
 
5.0 MONITORING: QUALITY CONTROL  
 
The quality control process for a clinical trial requires verification of protocol compliance and data accuracy. The Coordinating Center, with the aid of the ODQ provides quality 
control oversight for the protocol. 
 
5.1 Ongoing Monitoring of Protocol Complianc e 
Source documents confirming eligibility are to be sent to DFCI by the participating institutions and reviewed by DFCI study staff including a clinician prior to external site participant registration.   
The DF/HCC Lead Institution will implement monitoring activities ongoing to ensure that Participating Institutions are complying with regulatory and protocol requirements, data quality, and subject safety. Additional monitoring practices may include but are not limited to; source verification, review and a nalysis of the 
following: eligibility requirements of all participants , informed consent procedures, adverse events and all associated documentation, study drug administration / 
Neoadjuvant abiraterone acetate plus leuprolide with or without apaluta mide 
 
 123 treatment, regulatory records and site trial master files, protocol deviation s, pharmacy 
records, response assessments, and data management.  
 Site visits will generally occur once a year for sites that are actively enrolling participants and have participants in treatment.  Additional monitoring activities may occur if incidences of non -compliance are discovered or at the request of the DF/HCC 
Sponsor.   Virtual monitoring (source documents are sent to DFCI for review) may be 
performed in lieu of a site visit if the study sta ff and PI determine that virtual 
monitoring is appropriate for the site. The decision to perform virtual monitoring in lieu of a site visit will be based upon the site’s enrollment, study compliance history, history collaborating with DFCI on other multi -center studies, and number of 
participants in active treatment.  
 Monitoring will occur before the clinical phase of the protocol begins and will continue during protocol performance through study completion.  
 
Teleconferences between DFCI and the participat ing sites will be conducted on 
approximately a monthly basis. Meeting minutes for teleconferences will be issued to all participating sites. Site initiation visits will be conducted via teleconference. Ongoing training will also be conducted via teleconfer ence as needed. The 
Coordinating Center, Dana Farber Cancer Institute will be available to all participating sites for resolving questions, concerns and facilitating compliance.  
 
5.2 Evaluation of Participating Institution Performance
 
 All data submitted to the DF/HCC ODQ will be monitored for timeliness of submission, completeness, and adherence to protocol requirements. The Lead Institution or designee and if applicable ODQ Data Analysts assigned to the Protocol will perform the ongoin g protocol data compliance monitoring with the support of 
the Participating Institution’s Coordinators, the Principal Investigators, and the Protocol Chair. 
 
5.2.1 Monitoring Reports  
 
The DF/HCC Sponsor will review all monitoring reports for on- site and virtual monitoring 
of Participating Institutions to ensure protocol compliance and ability to fulfill responsibilities of participating in the study. The DF/HCC Sponsor may increase the monitoring activities at Participating Institutions that are unable to comply with the protocol, DF/HCC Sponsor requirements or federal and local regulations. Participating Institutions may also be subject to an audit as determined by the DF/HCC Sponsor. 
 
6.0 AUDITING: QUALITY ASSURANCE  
 
Auditing is a method of Quality Assurance. Its ma in focus is to measure whether standards 
and procedures were followed. Auditing is the systematic and independent examination of all trial related activities and documents.  Audits determine if evaluated activities were appropriately conducted and whether data was generated, recorded and analyzed, and 
Neoadjuvant abiraterone acetate plus leuprolide with or without apaluta mide 
 
 124 accurately reported per the protocol, Standard Operating Procedures (SOPs), and the Code 
of Federal Regulations (CFR).  
 
6.1 DF/HCC Sponsored Trials  
 
This study may be audit ed by the  DF/HCC Office of Data Quality  (ODQ)  if the Sponsor -
Investigator determines that an audit of the participating site is necessary.  
 
6.2 DF/HCC Internal Audits  
 
All Participating Institutions are subject to audit by the  DF/HCC Office of Data Quality 
(ODQ). Typically, a pproximately 3 -4 participants would be audited at the site over a 2 day 
period. If violations which impact participant safety or the integrity of the study are found, more participant records may be audited.  
 
6.3 Audit Notification  
 
 It is the Participating I nstitution’s responsibility to notify the Coordinating Center of all 
scheduled audit dates (internal or NCI) and re -audit dates (if applicable), which involve this 
protocol. All institutions will forward a copy of final audit and/or re -audit reports and 
corrective action plans (if applicable) to the Coordinating Center, within 12 weeks after the 
audit date.  
 
6.4 Audit Reports  
 
 The DF/HCC Sponsor will review all final audit reports and corrective action plans , if 
applicable. The Coordinating Center, must forwa rd any reports to the DF/HCC ODQ per 
DF/HCC policy for review by the DF/HCC Audit Committee. For unacceptable audits, the DF/HCC Audit Committee would forward the final audit report and corrective action plan to the DFCI IRB as applicable.  
 
6.4.1 Corrective Actions  
 
The DF/HCC Sponsor and DFCI IRB  are charged with considering the totality of an 
institution’s performance in considering institutional participation in the protocol. 
 
Participating Institutions that fail to meet the performance goals of accrual, s ubmission of 
timely  and accurate data, adherence to protocol requirements, and compliance with state 
and federal regulations, may  be recommended for a six -month probation period. Such 
institutions must respond with a corrective action plan and must demonst rate during the 
probation period that deficiencies have been corrected, as evidenced by the improved performance measures. Participating Institutions that fail to demonstrate significant improvement will be considered by the DF/HCC Sponsor for revocation of participation.  A 
DF/HCC Sponsor and/or the DFCI IRB may terminate a site’s participation if it is determined that a site is not fulfilling its responsibilities as described above.  
 
  
Protocol #16-223: Drafted (09/14/16)(JEP)/Approved (9/14/16)(AFP) 
 DANA-FARBER CANCER INSTITUTE 
Nursing Protocol Education Sheet 
Protocol Number: 16-223 
Protocol Name: Phase II randomized study of neoadjuvan t and adjuvant abiraterone acetate + ARN-509 for 
intermediate-high risk prostate cancer undergoing prostatectomy 
DFCI Site PI: Mary-Ellen Taplin MD 
DFCI Research Nurse: Judy Prisby, Meghara Walsh, Amanda Pace , Ralph Eugene 
Page the DFCI research nurse or DFCI site PI if there are any questions/concerns about the protocol.   
Please also refer to ONC 15 : Oncology Nursing Protocol Education Policy 
*** Remember to check the ALERT PAGE*** 
              SPECIAL NURSING CONSIDERATIONS UNIQUE TO THIS PROTOCOL Study Design 
  Study Drugs: Section 2.3. – Abiraterone CYP17 inhi bitor, second generation antiandrogen (Section 2.3.2) 
 ARN-509 (Aptilutamide)- novel second generation antiandr ogen that binds directly to the ligand binding domain 
of the androgen receptor impairing nuclear tr anslocation and DNA bindi ng (Section 2.3.4) 
 Leuprolide – GNRH agonist – lowers testosterone (Lexicomp) 
 Study Design – Section 1.1 
 Study Rationale – Section 2.2 
 A cycle is defined as 28 days – Section 5, Table 4, Study Calendar, Section 9 
 Dose Calc.  All drugs are in fixed doses, dosing Section 5 
 Leuprolide Section 5.3.4 
 Pre-Prostatectomy 
o Arm 1A – Abiraterone +Prednisone + ARN-509 + Leuprolide X 6 cycles (Section 1.1; Study 
schema) 
o Arm 1B – Abiraterone + Prednisone + Leuproli de X 6 cycles (Section 1.1; Study schema) 
 Post prostatectomy 
o Arm 2A – Abiraterone + Prednisone + ARN-509 + Leuprolide X 12 cycles (Section 1.1; Study 
schema) 
o Arm 2B - Observation (S ection 1.1; Study schema) Study Drug  
Administration Agent Administration  Guidelines are found in Section 5 
 Abiraterone is taken orally, daily, on an empty stomach (nothing to eat 2 hours pre and 1 hour post) – Section 
5.3.1 
 Prednisone is taken orally, daily, with food – Section 5.3.3, Table 4 
 ARN-509 is taken orally, daily, with or without food,  may be taken with prednisone – Section 5.3.2, Table 4 
 Leuprolide – given IM for 6 cycles pre prostatectomy ( both arms) and 12 cycles post prostatectomy (if in Arm 
2A) – Section 5.3.4 
 
 Criteria to treat – Section 5.2 and Section 6 
 Oral Agents cannot be crushed, chewed, or di ssolved, must be taken whole. – Section 5.3 
 Missed doses should be taken no later than 12 hours after the scheduled time for dosing. – Section 5.3 
 Vomited doses should not be made up. – Section 5.3 
  Dose  
Mods & 
Toxicit
yDose Modifications/Dosing Delay for Toxicity  are outlined in Section 6 
 This protocol uses NCI CTCAE criteria, version 4.0 
 Con 
Med
s Concomitant Therapy  Guidelines are in Section 5.4 and Appendix D 
 Required  
Data  Study Calendar and Assessment Required data  are outlined in Section 9 
 The study calendar is in Section 9 
 Vital signs:  Study Calendar 
 ECGs :  Study Calendar & Section 3 –Fridericia correction formula 
 Correlative studies :  Section 8, 8.2, Study Calendar and Lab Manual 
 
Protocol #16-223: Drafted (09/14/16)(JEP)/Approved (9/14/16)(AFP) 
 Charting 
Tips All study drugs require documentat ion of exact administration time. 
Abiraterone, Prednisone, and ARN-509 are under Oncol ogy Research Plan, Leuprolide under Oncology 
Supplemental Plan in EPIC. 
Please be sure to also DOCUMENT routes of administrati on, injection sites, and exact time of any correlative 
sample collection 
 
 